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MoDE of DENDRiTiC CEll ACTiVATioN: THE DECisiVE HAND iN TH2/TH17 CEll 
DiffERENTiATioN. iMPliCATioN iN AsTHMA sEVERiTy?
Asthma is a heterogeneous chronic inflammatory disease of the airways, which is initiated by ex-
posure to environmental factors (1). Phenotypically, asthma can be classified as mild, moderate 
or severe according to National Asthma Education and Prevention Program, Global Initiative for 
Asthma (GINA), or American Thoracic Society (ATS) guidelines (2,3). Mild to moderate asthma is 
initiated by an allergic response to allergens and often referred to as allergic asthma. It is defined 
by airway hyper responsiveness (AHR) of the bronchioles to aspecific stimuli, increased mucus 
production and airway remodelling. T helper (Th) 2 cells initiate allergic immune responses in 
mild to moderate asthma. Th2 cytokines are produced by both Th2 cells (IL-4, IL-5, and IL-13) 
and type 2 innate lymphoid cells (ILCs) (IL-5 and IL-13). These cytokines facilitate the classical 
allergic responses, such as IgE class switching by B cells (IL-4), eosinophilic infiltration (IL-5), and 
goblet cell hyperplasia (IL-13) (4,5). In contrast, severe asthmatic patients display an aggravated 
asthmatic phenotype, with severe and increased number of exacerbations and patients are less 
responsive to corticosteroid treatment (6). Severe asthma patients are often non-allergic, but 
display asthmatic symptoms in response to other stimuli such as diesel exhaust particles (DEP), 
viruses, and cigarette smoke (7,8). Inflammation in severe asthma patients is generally defined by 
a neutrophilic or mixed eosinophilic/neutrophilic infiltration. The neutrophilic influx is thought to 
be mediated by Th17 cells, however Th1 cells are also associated with severe asthma. Moderate 
and severe asthma patients display elevated levels of IL-17A in both bronchoalveolar lavage (BAL) 
fluid and lung biopsies (9,10). Th17 cytokines mediate an increased infiltration of neutrophils by 
activating the epithelium to secrete the neutrophil chemo-attractant CXCL8 (11). Additionally, 
Th17 cytokines will mediate increased mucus production (IL-17) and severe airway remodelling 
(IL-17/IL-22) leading to recurrent exacerbations (12). Dendritic cells (DCs) are potent antigen 
presenting cells (APCs), which are essential for inducing and priming of proper Th responses 
(13,14). DCs are crucial for both the initiation as well as the maintenance of the inflammatory 
asthmatic response (15,16). In this introduction, we will discuss a potential role for DC activation 
as initiator for Th2, Th1 or Th17-driven asthma.
iMMuNology of HousE DusT MiTE DRiVEN AsTHMA
Sensitization to house dust mite is pivotal for the development of most acute childhood 
asthma, since up to 85% of patients with recurrent asthma are allergic to HDM during hos-
pitalization (17,18). HDM contains at least 22 different allergen groups, recently reviewed by 
Jacquet et al (19). Besides HDM allergens, microbial pattern associated molecular patterns 
(PAMPs) such as lipopolysaccharide (LPS), chitin and β-glucans are frequently found in mite 
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excretes. Several allergen groups within HDM, like Derp1 and Derp3 display protease activity 
which can damage the airway epithelial layer and allow entrance to the lungs (19). Airway 
DCs are exposed to HDM, take up the allergen, become activated, and undergo maturation. 
During activation, CCR7 will be upregulated, necessary for DC migration towards the draining 
mediastinal lymph node (MLN) (20). In the MLN, fully matured DCs activate naïve T cells to 
proliferate and differentiate into effector T helper cells (21) (figure 1).
luNg DC subsETs
Lungs can be divided into the large conducting airways and the interstitium containing alveolar 
septa and capillaries. It has become clear that at least four CD11c+MHCII+ DC subsets can be 
found in the lungs of mice. During steady state, three different DC subsets can be found. These 
three DC subsets contain conventional DCs (cDCs), consisting of 2 subsets: CD103+ cDC1s and 
CD11b+ cDC2s, and plasmacytoid DCs (pDCs) (22). cDC1s underline the epithelium of the large 
conducting airways and have the potential to protrude their dendrites into the lumen of the 
airways in an active search for antigens. cDC2s can be found in the lamina propria underneath 
the epithelium (21). For optimal Th2 cell priming after HDM exposure, this cDC2 subset is 
fundamental (23). During an inflammatory response, a fourth DC subset arises in the lung, the 
inflammatory monocyte-derived DC (moDC), which will amplify the secondary local inflamma-
tory response. Lung DC subsets are reviewed in more detail by Lambrecht et al (21,23).
HousE DusT MiTE MEDiATED RECogNiTioN, uPTAkE AND ACTiVATioN of DCs
HDM can be recognized by specific pattern recognition receptors (PPRs) that are expressed by 
both immune cells as well by epithelial cells. PPRs can be subdivided into C-type lectin recep-
tors (CLRs), Toll-like receptors (TLRs), nucleotide oligomerization domain (NOD)-like receptors 
(NLRs) and retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) (19,24). PPRs recognize 
PAMPs as well as damage-associated molecular patterns (DAMPs). Beside containing several 
PAMPs, HDM can also lead to DAMP release in a TLR4 dependent manner by airway epithelial 
cells, such as heat shock proteins, ATP, and uric acid and enhance Th2 immunity (13,25). For 
instance, uric acid is released after allergen exposure in mice and asthmatic patients and is 
critical for Th2 sensitization and the secondary inflammatory response (13).
HDM recognition and uptake by DCs is mediated through binding with specific CLRs. The 
mannose receptor (MR) mediates recognition and uptake of Derp1 (26), whereas both Derp1 
and Derp2 are recognized and taken up by DC-specific intracellular adhesion molecule 3-grab-
bing non-integrin (DC-SIGN) (27-29). DCs of HDM-allergic patients show a higher MR expres-
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sion and are more effi  cient in the uptake of HDM in comparison to DCs of non-allergic pati ents 
(26). Allergen uptake by MR also promotes Th2 immunity, whereas MR-defi cient DCs promote 
Th1 responses and in turn protect from Th2 driven allergic responses (30). This is opposite for 
DC-SIGN; uptake of Derp1 by DC-SIGN induces Th1 diff erenti ati on, while DC-SIGN-defi cient DCs 
induce Th2 diff erenti ati on (27). Using its enzymati c acti vity, Derp1 is able to cleave DC-SIGN 
and thereby promote Th2 cell diff erenti ati on conditi ons (31,32). Low expression of DC-SIGN 
is also observed on DCs of HDM allergic asthma pati ents (31), suggesti ng that DCs of allergic 
asthma pati ents are intrinsically biased to induce Th2 cell diff erenti ati on.
Migration of activated 
DCs towards the MLN
DC
HDM
Eosinophil
Th2 
Th17
Neutrophil
Mucus
Epithelial cells
Th0
IL-17
IL-22
CXCL8
IL-3, IL-5
GM-CSF
IL-13
Goblet cell
Asthma Initiation Moderate/Severe AsthmaMild Asthma
CCL2/CCL20
IL-33
IL-25
TSLP
IL-4
low IL-12
OX-40L
IL-1β, TGF-β, IL-6, IL-23
CCL17
CCL22
CCL20
Smooth muscle 
cells
Collagen
Virus
Cigarette
 smoke
DEP
1.
2.
3.
4.
5. 6.
MLN
figure 1: Asthma pathogenesis in both mild as moderate to severe asthma. Upon primary exposure with HDM, 
with or without viruses, cigarett e smoke and DEP, the airway epithelium and underlying DCs are acti vated. (1) 
Acti vated airway epithelial cells will secrete CCL2 and CCL20, necessary for the att racti on of immature DCs to 
the lungs. IL-33, IL-25, and TSLP secreted by airway epithelial cells will acti vate DCs. (2) Acti vated DCs upregulate 
CCR7 and migrate to the MLN. (3) In mild asthma, acti vated DCs will prime naïve T cells to diff erenti ate into Th2 
cells through expression of OX-40L, and a cytokine milieu consisti ng of high levels of IL-4 and absence of IL-12. 
(4) In moderate to severe asthma, Th17 diff erenti ati on will be initi ated by IL-1β, TGF-β, IL-6. IL-23 producti on will 
enhance Th17 cell functi on. (5) Th2 cells migrate towards the lungs in response to CCL17 and CCL22 expression. 
Th2 cytokines induces eosinophilia (IL-3, IL-5, GM-CSF), goblet cell hyperplasia (IL-13) and airway hyperrespon-
siveness (IL-13). (6) Primed Th17 cells will migrate towards the lung in response to CCL20, produced by DCs. Th17 
cytokine secreti on acti vates airway epithelial cells (IL-17) to secrete CXCL8, a chemoatt ractant for neutrophils. 
Furthermore, IL-17 and IL-22 will induce airway remodelling by increasing smooth muscle cell hyperplasia and 
collagen depositi on.
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Derp2 has been shown to signal via TLR2 (33) and TLR4 (34). Due to its homology with my-
eloid differentiation 2 (MD2), which participates in the recognition of LPS by TLR4, Derp2 forms 
a complex with TLR4 that signals similarly to the MD2/TLR4 complex and activates the innate 
immune system. Recent reports reveal the importance of TLR4 signalling in the development 
of allergic asthma. TLR4-deficient mice were not capable of mounting HDM-driven Th2 medi-
ated allergic asthma (35,36). This was mediated by reduced expression of the Th2 promoting 
co-stimulatory molecule OX-40L on cDCs (36). However, Hammad et al (35) showed that TLR4 
expression was dispensable on DCs but crucial on airway epithelium cells for the development 
of HDM-driven allergic asthma (35). Ligation of TLR2 and TLR4 will trigger a downstream signal-
ling cascade leading to NF-κB activation. NF-κB activation will promote transcription of both 
pro-inflammatory cytokines as well as co-stimulatory molecules imperative for DC maturation.
T HElPER CEll PRiMiNg CoNDiTioNs by DCs
Fully activated mature DCs express high levels of MHCII molecules that present allergen (Ag)-
derived peptides. These MHC-II-Ag complexes will engage with T-cell receptors (TCR) on naïve 
Ag-specific CD4+ Th cells. This activation together with expression of co-stimulatory molecules 
and cytokines will determine Th cell differentiation. At this moment, at least five different Th 
cell subsets have been described (Th1, Th2, Th17, follicular T helper cells (Tfh) and regulatory T 
cells (Tregs)). Each Th cell subset expresses a unique set of transcription factors and cytokines. 
Th cell differentiation requires the expression of a master transcription factor together with 
particular signal transducer and activator of transcription (STAT) proteins. Th2 cells are as-
sociated with GATA-binding protein 3 (GATA-3)/STAT5, Th1 cells with T-box transcription factor 
expressed in T cells (T-bet)/STAT4, Th17 cells with retinoid orphan receptor γt (RORγt)/STAT3, 
Tfh cells with B-cell lymphoma (Bcl-6)/STAT3 and finally Tregs with forkhead box protein 3 
(Foxp3)/STAT5 (37).
Th2 cell priming conditions mediated by DCs
Th2 cells play an important role in the defence against helminth infections, but are also 
implicated in allergic diseases, such as atopy and asthma. Th2 cell differentiation is induced 
upon TCR stimulation in combination with Th2 cell favoring co-stimulatory molecules and 
cytokines expressed by DCs. Low dose antigen has been reported to favor specific Th2 cell 
differentiation (38,39). Besides low antigen dose, co-stimulatory molecules such as OX-40L and 
Jagged expression on DCs are required for optimal Th2 cell priming(40-43). OX-40L is induced 
after CD40L-CD40 interaction (41). CD40 expression itself is important for Th2 induction, as 
CD40-deficient DCs were incapable of inducing Th2 cell responses to helminth antigens (44). 
Additionally, differentiation of Th2 cells depends on a high IL-4 and low IL-12 environment. 
Introduction I
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IL-4 is not produced by DCs, but is produced by other cells, such as mast cells and basophils 
(45). The master transcription factor for Th2 cells GATA-3 is induced upon low antigen dose 
stimulation in naïve T cells. GATA-3 activation will induce IL-2 production. IL-2 expression in 
turn activates STAT5 in differentiating Th2 cells. STAT5 in combination with GATA-3 induces TCR 
dependent, IL-4 transcription. This endogenous produced IL-4 will continue STAT5 activation 
and determine Th2 cell fate (46). Furthermore, IL-21-producing Tfh cells can enhance Th2 cell 
function, as eosinophilia is reduced in mice lacking the IL-21 receptor (47). Moreover, evidence 
was provided supporting that Th2 cells can originate from IL-4-producing Tfh cells that upon 
secondary exposure to HDM further differentiate into IL-4 and IL-13-producing Th2 cells (48).
Th1 cell priming conditions by DCs
Th1 cells play an important role in fighting intracellular microbial and viral infections, but are 
also implicated in asthma. In contrast to Th2 cells, Th1 cells require a high antigen dose for 
their differentiation (38,39) and the expression of the co-stimulatory molecule Delta (43,49). 
DCs activated through CD40 or high dose antigens produce increased amounts of IL-12 and 
type I interferons which drive Th1 cell differentiation (50,51). IL-12 and type I interferon will 
activate STAT4 in naïve Th cells, whereas strong TCR signalling directly activates STAT1. STAT1 
will induce T-bet expression, whereas STAT4 will activate IFNγ production. Induction of T-bet 
increases the expression of IL-12R, providing a positive feedback loop for further Th1 cell dif-
ferentiation (52).
Th17 cell priming conditions by DCs
Th17 cells play an important role in protection against bacterial and fungal infections, and in 
the development of autoimmune diseases. Recent evidence has shown that Th17 cells are also 
implicated in moderate to severe asthma (11). In contrast to both Th1 and Th2 development, 
Th17 generation requires an even higher antigen concentration (53). High antigen concentra-
tion increases CD40L expression on naïve T cells (53). CD40 signalling also appears to be crucial 
in the Th17 cell induction since CD40-deficient DCs were incapable to induce Th17 differentia-
tion (54). Also CD86 expression is crucial as blocking CD86 downregulates DC-dependent Th17 
differentiation in vitro (54). Differentiation of Th17 cells from naïve T cells is also determined 
by the cytokine milieu. IL-1β, IL-6, and TGF-β in combination with TCR stimulation will program 
Th17 cell differentiation. These cytokines will induce IL-23R and RORγt expression in naïve Th 
cells (54,55). IL-23 will support maintenance and function of Th17 cells (56).
Regulatory T cell priming conditions by DCs
Regulatory T cells (Tregs) can be classified into naturally occurring Tregs (nTregs) and induc-
ible Tregs (iTregs), which both dampen inflammatory immune responses and are essential to 
maintain self-tolerance (57,58). nTregs develop in the thymus as a distinct Th cell population, 
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whereas iTregs differentiate in the periphery from CD4+ T cells (59), and can differentiate into 
ICOS-expressing Tregs. Thymic Tregs are induced by intermediate TCR stimulation and IL-2 and 
TGF-b signalling, leading to FoxP3 expression. In the periphery, multiple inducible Treg sub-
populations are found, such as inducible/adapter Tregs (iTregs), IL-10-producing type 1 Tregs 
(Tr1 cells), IL-17-producing Tregs, and CD8+ Tregs. Induced Tregs, IL-17-producing and CD8+ 
Tregs share the expression of FoxP3, and all iTreg subsets secrete IL-10 with or without TGF-b 
(60). Inducible Treg differentiation from naïve CD4+ T cells is initiated by weak TCR signals and 
absence of pro-inflammatory cytokines. TGF-b induces Smad binding to the FoxP3 locus and 
promotes transcription in iTregs (61-63). Furthermore, also retinoic acid and PPARg are also 
implicated in the differentiation of HDM-induced Treg differentiation (64,65). Interestingly, it 
was shown in mice that recent thymic emigrants are the preferential precursors of regulatory 
T cells that differentiate in the periphery (66).
TH2-iNsTRuCTiVE sigNAls foR DC ACTiVATioN
It is well described that HDM-driven activation or damage of the airway epithelium is crucial 
for DC activation in priming efficient Th2 cell immune responses. β-glucan structures in HDM 
activate dectin-1 on airway epithelial cells, initiating CCL2 and CCL20 secretion (67,68). These 
chemokines attract immature DCs and DC precursors from the bone marrow towards the lungs 
(67,68). HDM exposure will trigger cytokine production by airway epithelial cells, such as IL-1α, 
IL-33, thymic stromal lymphopoietin (TSLP), IL-25, and granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) that contribute to DC activation and provide Th2-instructive signals to 
the DCs (14,69,70). IL-33 and IL-1RL1 (which encodes ST2/IL-33R) are also identified by Genome 
Wide Association Studies (GWAS) as asthma susceptibility loci (71), indicating the importance 
of IL-33 and IL-33R for the development of Th2-driven asthma. IL-33 signalling through IL-33R/
ST-2 on DCs leads to the production of Th2-skewing co-stimulatory molecules and cytokines/
chemokines, such as OX-40L, CD40 and IL-6, IL-1β, TNFα, and CCL17 (72-74). Importantly, no 
IL-12 and/or IL-23 are induced (75), and in neonatal mice, IL-33 even suppresses IL-12p35 
expression in cDC2s (74). Thus, IL-33-stimulated DCs particularly induce Th2 differentiation 
from naïve Th cells (73). DCs can also produce IL-33 themselves, which can act in an autocrine 
manner to further amplify the Th2 driving capacity (76). DCs stimulated with Th2 promoting 
stimuli, such as low dose HDM induce interferon regulatory factor-4 (IRF4) signalling (77). 
IRF4 signalling in DCs induces IL-33 and IL-10 secretion contributing to Th2 cell differentiation. 
Moreover, IRF4 is crucial for Th2-driven allergic asthma, since mice deficient of IRF4 in DCs 
fail to develop allergic asthma (77). Classically IRF4 and IRF8 are thought to be involved in 
the development of different DC subsets. Current evidence shows that IRF molecules are also 
Introduction I
15
1
implication in directing Th differentiation by DCs (77,78), as IRF4 drives DCs to promote Th2 
immune responses (77,79) (figure 2A).
Next to IL-33, TSLP is an additional Th2 instructing cytokine for DC activation. Inhaled al-
lergen exposure increased the expression of TSLP receptor on bone marrow derived cDCs of 
asthmatic subjects (80). TSLP stimulates Th2 differentiation by inducing OX-40L expression on 
DCs in the absence of IL-12 (81-83). TSLP-activated DCs will also produce CCL17 and CCL22, 
necessary for effector Th2 cell migration towards the lungs (81,84,85). TSLP signalling induces 
activation of STAT6, which programs DCs to secrete these chemokines. In addition, TSLP sig-
nalling limits activation of STAT4 and IRF-8, essential factors for the production of the Th1 
polarizing cytokine IL-12 (78). Next to IL-33, TSLP also induces IRF4 expression through STAT5 
activation in human DCs (82,86). TSLP can also directly influence T cells, since it is a potent 
growth and survival factor for Th2 cells (87,88).
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figure 2: T helper cell differentiation mediated by DCs in asthma. DC activation is crucial for efficient Th cell dif-
ferentiation. (A) Th2 cell differentiation is induced upon low antigen dose, OX-40L expression and IL-4 presence 
in the absence of IL-12. Activation of DCs in a Th2 promoting manner is initiated by cytokines secreted by the air-
way epithelium, like TSLP and IL-33. TSLP signalling specifically suppresses IL-12 secretion while inducing CCL17 
expression. TLR4 signalling initiated by HDM induces increased OX-40L and IL-33 expression. IL-33 can signal in 
an autocrine manner, increasing the Th2 promoting activation of DCs. (B) Th17 cell differentiation is induced by 
high antigen dose, CD40 and CD86 expression in addition with IL-6 and TGF-β. Expression of IL-6 and TGF-β are 
induced upon strong NF-κB signalling. Increased NF-κB signalling can be initiated by combined signalling of e.g. 
TLR3/TSLP, C3aR, TLR2 and TLR4. Subsequent expression of IL-23 will maintain Th17 cell function.
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The third Th2-instructive cytokine IL-25 can be produced by basophils and epithelial cells 
in response to allergens (89,90). Inhaled allergen exposure increased the expression of IL-
17RB (IL-25 receptor) on both myeloid and pDCs of mild atopic asthma patients (91). Mice 
overexpressing IL-25 in lung epithelial cells show increased allergic inflammation (89). IL-25 
increases both OX-40L and Jagged1 expression by DCs, which contributes to Th2 differentiation 
(75,90,92). IL-25 expression is also associated with increased levels of CD80 and CD86 on DCs, 
indicating that IL-25 activates DCs (93). However, Jagged1 and Jagged2 expression on DCs was 
dispensable for HDM-induced Th2-mediated eosinophilic inflammation (94). IL-25 treatment 
of DCs induces CCL17 expression, attracting Th9 cells towards the lung (95).
Along this line, also GM-CSF can be produced by airway epithelium cells (96,97). DCs 
cultured in the presence of GM-CSF are very potent inducers of Th2 cell differentiation (16). 
HDM-mediated Th2 sensitization in the airways is partially mediated through GM-CSF (98) as 
GM-CSF neutralization showed reduced Th2 cell responses (99,100).
Recent research has provided better insight in Th2 cell promoting cytokines secreted by 
the airway epithelium and DCs. However, much remains unknown about underlying signalling 
pathways initiating the expression of these cytokines and co-stimulatory molecules and their 
interactions. Research exploring these mechanisms will provide more insight and possible new 
therapeutic targets.
TH1 MEDiATED iMMuNE REsPoNsEs iN AsTHMA by ACTiVATED DCs
Neutrophilic inflammation observed in moderate and severe asthmatic patients has long been 
associated with a Th1 cell immune response. T-bet-deficient mice develop spontaneous T cell 
dependent lung inflammation and AHR indicating that Th1 cells are dispensable for allergic 
asthma (101). However, Th1 cells are increased in severe asthma patients and during asthma 
exacerbations. Severe asthma patients with mixed granulocytic inflammation display increased 
levels of IFNγ, TNFα and IL-17 (102-104). These increased levels of IFNγ and TNFα generated 
the idea that Th1 cells mediate neutrophil inflammation (105). More recent evidence has 
shown that neutrophil inflammation is mediated by IL-17. IL-17 activates airway epithelium 
and initiates secretion of CXCL8, the chemo attractant for neutrophils (12). Therefore, neutro-
phil inflammation observed in moderate to severe asthmatics is now thought to be dependent 
on a Th17 immune response.
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TH17 iNsTRuCTiVE sigNAls foR DC ACTiVATioN iN AsTHMA
The role of Th17 cells in severe asthma is a relative new concept. Both exposure to HDM 
and environmental triggers, such as DEP and cigarette smoke have been shown to activate 
the airway epithelium and DCs in a Th17 promoting state. Severe Th17 cell or mixed Th2/
Th17 cell-mediated asthma is associated with exposure to DEP. DEP exposure decreases lung 
function and increases neutrophil biomarkers (106). Exposure of young and adult mice to a 
combination of DEP and HDM has been shown to provoke an exaggerated Th2 and mixed 
Th2/Th17 cell mediated inflammatory response in the airways (107,108). Strikingly, collagen 
content is increased in the lungs of DEP/HDM exposed adult mice, indicative of lung remodel-
ling. Children with allergic asthma show increased IL-17A serum levels upon DEP exposure 
(109). The underlying mechanism how DEP/HDM exposure results in a mixed Th2/Th17 or a 
more Th17 immune response remains poorly understood. Induction of Th2 and Th17 cytokines 
upon combined exposure of OVA and ultrafine particles was Jagged 1 dependent, as Jagged 
1 blockage restores this increase in IL-4, IL-13, IFNg and IL-17A (110). DEP exposure induces 
DC maturation(111,112) through activation of airway epithelium (111). Airway epithelial cell 
exposure to DEP increases secretion of CCL2 and CCL20 necessary for DC recruitment, and 
TSLP that is Th2 instructive (107,112,113). In addition, DEP exposure enhances DC migration 
towards the MLN in a CCR7 dependent manner (112), whereas moDC accumulation upon DEP 
exposure was dependent on CCR2 and CCR6 (114). Acute infiltration of monocytes and moDCs 
upon DEP exposure was dependent on G-coupled receptor chemR23 (115). Whether DEP 
exposure also induces secretion of Th17 promoting cytokines by DCs, such as IL-1β, IL-6 and 
IL-23 needs further investigation.
In addition to DEP also cigarette smoking is associated with asthma development in non-
atopic asthma patients (116). Cigarette smoking asthmatic patients develop more severe asth-
matic symptoms, such as corticosteroid resistance, increased neutrophil counts, decreased 
FEV1 and severe lung remodelling (7,117). Acrolein, one of the chemicals present in main-
stream cigarette smoke has been shown to reduce neutrophil apoptosis when administered 
in combination with LPS. Acrolein induces epithelial barrier dysfunction, thereby promoting 
neutrophil migration (118). Combined exposure of acrolein and ovalbumin increases neutro-
philic airway inflammation (119). Furthermore, acrolein promotes the production of reactive 
oxygen species (ROS), implicated in degranulation in mast cells (120). Cigarette smoke also 
increases TLR3 expression in lungs of mice. TLR3 stimulation with Poly I:C (dsRNA) results in 
exacerbated neutrophil infiltration and AHR (121). Indicating that cigarette smoke enhances 
susceptibility for viral infections that could attenuate severe asthma exacerbations. Further-
more, cigarette smoking COPD patients show increased levels of IL-22 in serum and IL-17 and 
IL-22 in sputum. This implies that cigarette smoke specifically leads to increased expression of 
Th17 cell cytokines (122,123).
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Besides environmental factors as DEP and cigarette smoke also other factors are recently 
associated with severe asthma. Recent evidence suggests a role for NLRP3 inflammasome 
in severe asthma associated Th17 cell differentiation. NLRP3 is activated by serum amyloid 
A (SAA), acute phase protein. SAA is produced by airway epithelial cells upon exposure to 
microbes or microbial particles, such as LPS and pro-inflammatory cytokines. SAA is increased 
in BAL fluid of asthma patients with a Th2/Th17-predominant phenotype (124). SAA induces 
production of IL-1α, IL-1β, IL-6, PGE2, and IL-23 by DCs, which are instructive for Th17 cell 
differentiation (125). Th17-driven severe asthma is associated with corticosteroid resistance 
and strikingly SAA-stimulated DCs are capable of stimulating Th17 cell responses even after 
treatment with corticosteroids (126). Moreover, severe asthma patients display higher SAA 
serum concentrations (127,128), suggestive of a prominent role for SAA and NLRP3 activation 
in Th17 cell-driven severe asthma. Recently, innate cells producing IL-17, such as ILC3, and 
the NLRP3 inflammasome have been implicated in obesity-associated airway hyperreactivity 
(129).
In addition to NLRP3 activation, high dose LPS exposure is also associated with Th1/Th17 
mediated severe asthma (130). High dose LPS exposure specifically induces VEGF secretion by 
the airway epithelium. VEGF induces DC maturation and secretion of Th17 promoting cytokines 
like IL-6 (131). Up to 50% of asthma exacerbations are associated with viral infections (132). 
Binding of viruses has been shown to specifically induce CXCL8 secretion by airway epithelium 
cells, thereby inducing neutrophil inflammation (133). Implicating that viral infection could be 
a potential driver of neutrophil-associated severe asthma. Administration of Poly I:C (dsRNA, 
TLR3 ligand) in combination with OVA also increases VEGF secretion, leading to subsequent 
IL-6 expression and Th17 cell-driven asthma (134). Stimulation of human DCs with TSLP/PolyI:C 
induces IL-23 production and increases Th17 differentiation (135).
Polymorphisms in complement (C) 3 and C3aR are positively associated with severe asthma, 
whereas polymorphisms in C5 are negatively associated (136,137). Asthmatic patients show 
increased C3a and C5a levels after allergen challenge in BAL fluid (138). Asthma patients with a 
Th2/Th17 high phenotype have increased C3a levels in BAL fluid (138). Thereby, recent interest 
is arising in role of complement in allergic asthma. Complement signalling has also been shown 
to promote Th cell effector responses (139,140). Several well-known triggers for asthma, such 
as HDM activate C3(141). Lajoie et al (142) have nicely shown that C3aR signalling induces 
IL-23 secretion through NF-κB activation, indicating that C3aR signalling promotes Th17 cell 
function. IL-17 expression by Th17 cells enhances C3 secretion by airway epithelial cells. This 
provides a positive feedback loop that will further enhance IL-23 production by DCs. In con-
trast, C5aR signalling induced IL-10 expression via activation of JNK signalling. IL-10 activates 
AP-1 expression. AP-1 blocks accessibility of the IL-23a promotor region and inhibits Th17 cell 
function by DCs and maintains homeostasis (142) (figure 2b).
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As mentioned above, NF-κB signalling in DCs is crucial for TLR and cytokine driven DC activa-
tion and subsequent cytokine expression. Recently single nucleotide polymorphisms (SNPs) 
in tumor necrosis factor alpha interacting protein 3 (TNFAIP3) interacting protein 1 (TNIP1) 
were found to be associated with severe asthma (143). TNFAIP3 is a deubiquinating enzyme 
and deubiquinates signalling molecules downstream of TLR and TNFαR activation, abrogating 
NF-κB signalling (144) (See box 1). This further indicates the essential role of cell activation in 
the potential pathogenesis of severe asthma.
TREg iNsTRuCTiVE sigNAls foR DC ACTiVATioN iN AsTHMA
As immunosuppressive cells, Tregs are essential for maintaining immunological tolerance to 
airborne allergens such as HDM. Depletion of Tregs only at the initiation phase of an HDM-
induced allergic asthma model is sufficient to increase airway hyperresponsiveness. Treg 
depletion increased the frequency and activation status of pulmonary DCs, indicating Tregs 
not only directly suppress Th2 immune responses through the consumption of IL-2 and secre-
tion of IL-10, but also indirectly by hampering the Th2 differentiating capacity of pulmonary 
DCs (145). Furthermore, in an ovalbumin-induced asthma model, transfer of Tregs during 
the peak of airway inflammation was even able to reverse already established airway inflam-
mation and remodelling, whereas no effects were observed on airway hyperresponsiveness 
(146). The numbers of IL-10-expressing cells are decreased in atopic allergic patients compared 
to healthy controls (147). Tregs of atopic individuals were also less capable of suppressing 
allergen-stimulated T cells (148).
Der p 1 treatment on DCs isolated from HDM-sensitive patients decreased indoleamine 
2,3-dioxygenase (IDO) expression, an immunoregulatory enzyme involved in Treg differentia-
tion, leading to increased Th2 cell differentiation, whereas IDO expression was increased in 
Der p 1 treated DCs of non-allergic patients and induced development of IL-10-producing 
Tregs (149). Treating cultured moDCs with a combination of Der p 2 and IL-10 decreased Th2 
differentiation; instead it led to the generation type 1 regulatory T cells (150). Combining Der 
p 1 treatment with Glucuronoxylomannan, a microbial compound that can modulate immune 
responses increased TGF-β secretion in DCs and promoted the generation of antigen-specific 
Tregs (151). Inhaled antigens have also been shown to induce retinaldehyde dehydrogenase 2 
(aldh1a2), an enzyme involved in the production of retinoic acid (RA), specifically in pulmonary 
CD103+ cDC1s. RA is a cofactor for TGF-β induced FoxP3 induction and subsequent Treg devel-
opment (64). The β-subunit of CK2 in Tregs is also essential to control Th2 differentiation by 
cDC2s, as Treg-specific deletion of the β-subunit of CK2 induced proliferation of ILT3-expressing 
Treg cell subpopulation. These Tregs are unable to control IRF4 expression in cDC2s, leading 
to spontaneous development of pulmonary Th2 cell airway inflammation (152). Furthermore, 
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CD103-deficient mice develop exaggerated airway inflammation upon exposure to both HDM 
and ovalbumin-induced allergic asthma models (153). Unfortunately, the effect of CD103-
depletion on Tregs was not evaluated. However, the data implicate that CD103+ cDC1s and 
CD103-expressing T cells are essential to maintain airway tolerance.
CoNClusioN
Underlying mechanisms responsible for different immune responses observed in mild and 
moderate/severe asthma patients are only partially unraveled. However, it is well established 
that DCs prime Th cell subset differentiation. Recent evidence indicates that the mode of 
DC activation is of crucial importance for cytokine and co-stimulatory molecule expression. 
Allergens activate both airway epithelium and DCs, initiating the secretion of IL-33, TSLP, IL-
25 and GM-CSF. These Th2 cell promoting cytokines inhibit IL-12 production via IRF8, while 
inducing OX-40L and Jagged1 expression. In contrast, allergen exposure in combination with 
environmental factors and/or genetic variations further increase DC activation and induce 
secretion of IL-1β, IL-6, and IL-23 driving Th17 cell differentiation. How differentiation of Th 
cells is directed by antigen strength, co-stimulatory molecules, and cytokines expressed by DCs 
is currently well established. However, the exact molecular signalling pathways responsible 
for the production of these cytokines and co-stimulatory molecules remain largely unknown. 
Therefore, molecular signalling pathways activated by various environmental triggers need 
more investigation. Better insight in the underlying mechanisms driving Th cell differentiation 
could improve our current understanding of different asthma pathologies.
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AiMs AND ouTliNE of THE THEsis
It is becoming more and more clear that asthma is not a purely Th2-mediated inflammatory 
disease, but also other Th cell subsets, such as Tfh and Th17 cells contribute to the asth-
matic disease. Therefore, in this thesis, we will investigate the importance of DCs as underlying 
mechanism controlling asthmatic Th2-mediated eosinophilic, Th17-mediated neutrophilic 
inflammation, or suppress allergic airway inflammation.
Recently it has been shown that Tfh cells can enhance Th2 cell function (47) and that IL-4-
expressing Tfh cells have the capacity to differentiate into IL-4 and IL-13 double-expressing 
Th2 cells upon secondary HDM exposure (48). However, both these studies used acute HDM-
mediated allergic asthma models that consist of a sensitization and a challenge phase, which 
does not correspond to the continuous allergen exposure as occurs in patients. Furthermore, 
acute HDM-mediated asthma models do not strongly induce airway remodelling as observed in 
asthma patients. Therefore, we examined in Chapter 2, whether Tfh cells and germinal center 
reactions are also essential for the development of Th2-mediated eosinophilic inflammation in 
a chronic HDM-driven asthma model in which animals are continuously treated with allergens, 
resembling the natural exposure of asthma patients. In Chapter 2, we observed that follicular T 
helper (Tfh) cells and B cells are not required for the development of eosinophilic inflammation 
in the airways in a chronic HDM-driven asthma model. This indicates that the experimental 
model and antigen dose make an essential difference in how Th2-mediated eosinophilic airway 
inflammation develops.
As described above, not all asthmatic patients display with a Th2-mediated eosinophilic in-
flammation. Especially, severe asthma patients can display mixed eosinophilic/neutrophilic or 
neutrophilic inflammation or even without detectable granulocytic inflammation. Neutrophils 
observed in severe asthma patients are most likely attracted to the lung due to Th17 cell activa-
tion. Patients with severe asthma display elevated levels of IL-17A in both bronchoalveolar 
lavage (BAL) fluid and lung biopsies (9). Underlying mechanisms that control the development 
of these two asthma phenotypes are currently unknown. DCs as antigen-presenting cells are 
unique in their capacities to induce Th cell differentiation and are therefore likely to control 
the differentiation of either Th2 and/or Th17 cell differentiation in these two different asthma 
subtypes. The mode of DC activation is of crucial importance for cytokine and co-stimulatory 
molecule expression, and as described above, Th17 cell differentiation in general requires a 
higher state of DC activation than Th2 cell differentiation.
In Chapter 4, we investigated whether the activation status of DCs affects Th2 and Th17-
mediated asthmatic airway inflammation. To investigate this, we used a mouse model in which 
TNFAIP3, one of the negative regulators of NF-kB, was removed from DCs, leading to increased 
DC activation (Box 1), and exposed the mice to both acute and chronic HDM-driven asthma 
models.
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As we found in chapter IV that TNFAIP3 levels in lung DCs controlled development of eosino-
philic and neutrophilic airway inflammation, we investigated in Chapter 5, whether the ob-
served severe neutrophilic asthma phenotype as observed in mice harboring Tnfaip3-deficient 
DCs was dependent on IL-17R signalling by depleting IL-17RA.
cDC1s were recently described to dampen Th2 immune responses in the case of helminth 
infections through IL-12 expression (158). Furthermore, cDC1s have also been shown to 
specifically induce Treg differentiation upon HDM exposure (64), and CD103-deficient mice 
box 1: Canonical NF-κB activation is essential for proper DC activation, which is triggered by TLR activa-
tion by for instance HDM. NF-κB signalling is regulated by ubiquitination. K48-linked polyubiquitin chains 
targets proteins for proteasomal degradation, whereas K63-linked polyubiquitin chains can induce the re-
cruitment of downstream signalling molecules. To ensure proper regulation of NF-κB signalling, special 
enzymes are involved in the synthesis, recognition and degradation of various types of ubiquitin chains. 
The ubiquitin-modifying enzyme TNFAIP3 restricts NF-κB signalling downstream of TLR, NOD-like receptors 
(NLRs), different cytokine-receptors, and CD40 signalling, of which some are implicated in the recognition 
of HDM (figure 3) (144). Specific deletion of TNFAIP3 in DCs, using Tnfaip3fl/fl mice crossed to Cd11c-cre 
mice has shown to increase DC activation(154). TNFAIP3 levels in different cell types has been shown to 
influence the Th2 cell response as TNFAIP3 levels in epithelial cells protect against development of Th2 
immune responses upon HDM activation (155), whereas absence of TNFAIP3 in myeloid cells induces de-
velopment of Th17 cells and arthritis (156). Lack of TNFAIP3 in mast cells controls the activation state, 
causing increased plasma extravasation and features of eosinophilic asthma upon allergen challenge (157).
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figure 3: Negative regulation of Nf-kb signalling by TNfAiP3. Upon TLR activation, a signalling cascade 
will be activated inducing K63 ubiquitination of TRAF6. TRAF6 K63 ubiquitination will induce K48 ubiqui-
tination of IKKβ, leading to proteasomal degradation of IKKβ. Upon degradation of IKKβ, NF-kB translocates 
to the nucleus and start transcription of pro-inflammatory genes but also negative regulators as TNFAIP3/
A20 (A). The deubiquitinating enzyme TNFAIP3 deubiquitinates the ubiquitin proteins on TRAF6, IKKβ and 
IKKγ and thereby abrogates NF-kB signalling (B).
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develop exaggerated Th2-mediated eosinophilic inflammation upon HDM exposure, indicating 
the Th2-suppressive capacity of pulmonary cDC1s (153). Therefore, we investigated in Chapter 
6 whether increasing the activation status of specifically cDC1s in the lung would increase their 
Th2 suppressive capacity in a HDM-driven asthma mouse model.
Finally, in Chapter 7, we wondered what the immunological differences in circulating im-
mune cells would be between healthy controls, steroid controlled, partially controlled and 
uncontrolled asthma patients. These differences were determined based on an automated 
clustering method, FlowSOM, enabling cluster different cell populations with similar marker 
expressions.
The implications of our studies and potential directions for future research are presented in 
the general discussion in Chapter 8.
mo-DCs
* Tnfaip3CD11c mice ~ 90%
* Tnfaip3LysM mice ~ 45%
* Tnfaip3Langerin mice < 5%
Figure 4: Tnfaip3 deletion in lung DC subsets in various transgene mouse strains used in 
this thesis 
cDC1s
* Tnfaip3CD11c mice ~ 95%
* Tnfaip3LysM mice ~ 45%
* Tnfaip3Langerin mice ~ 20%
cDC2s
* Tnfaip3CD11c mice ~ 90%
* Tnfaip3LysM mice ~ 35%
* Tnfaip3Langerin mice < 5%
pDCs
* Tnfaip3CD11c mice ~ 35%
* Tnfaip3LysM mice ~ 0%
* Tnfaip3Langerin mice < 5%
Eosinophils
* Tnfaip3CD11c mice < 10%
* Tnfaip3LysM mice ~ 60%
* Tnfaip3Langerin mice < 5%
Neutrophils
* Tnfaip3CD11c mice < 10%
* Tnfaip3LysM mice ~ 90%
* Tnfaip3Langerin mice < 5%
Alveolar macrophages
* Tnfaip3CD11c mice ~ 95%
* Tnfaip3LysM mice ~ 100%
* Tnfaip3Langerin mice < 5%
Monocytes
* Tnfaip3CD11c mice ~ 10%
* Tnfaip3LysM mice ~ 50%
* Tnfaip3Langerin mice < 5%
figure 4: Activation of different DC subsets by targeting TNfAiP3. Graphical representation of the percentage 
Tnfaip3-deficient DC subsets and other myeloid populations in the lung, using either Lyz2CRE (Tnfaip3LysM mice), 
Cd11cCRE (Tnfaip3CD11c mice), or LangerinCRE (Tnfaip3Langerin).
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In this thesis, we made use of different transgene mouse lines that target TNFAIP3 to activate 
different DC subsets in the lungs and thereby determine the effect on Th cell differentiation 
upon HDM exposure (figure 4). The function of these different DC subsets is summarized in 
Chapter iii.
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AbsTRACT
background: Chronic exposure to environmental triggers, such as house dust mite (HDM), 
drives T helper 2 (Th2) cell-mediated asthma. Recent evidence has shown that B-T cell interac-
tion, and in particular germinal centre reactions and follicular T helper (Tfh) cells are required 
for the development of eosinophilic airway inflammation in HDM-driven models containing a 
sensitization and challenge phase. Whether B-T cell interactions are essential for pulmonary 
eosinophilic inflammation following chronic allergen provocation remains unknown.
Aims: In this study, we investigated the importance of B-T cell interaction in the development 
of eosinophilic airway inflammation and pulmonary remodelling in a chronic HDM-driven 
asthma model.
Methods: We exposed C57BL/6, Cd40l-/-, and Mb1-/- mice to HDM three times a week for five 
consecutive weeks.
Results: Chronic HDM exposure induced a pronounced eosinophilic allergic airway inflamma-
tion in broncho-alveolar lavage fluid (BALf) and lung tissue, associated with the formation of 
immunologically active inducible bronchus-associated lymphoid tissue (iBALT) in the lungs. 
The absence of B cells, or lack of CD40L signalling did not hamper eosinophilic inflammation in 
the airways, although the number of Tfh and Th2 cells was substantially reduced in the lungs. 
Importantly, type 2 innate lymphoid cells (ILC2) numbers in BALf and lung were not affected by 
the absence of B cells or B-T cell interaction. Furthermore, eosinophilic airway inflammation is 
not sufficient to induce pulmonary remodelling and airway hyperresponsiveness.
Conclusion and Clinical Relevance: From these findings, we conclude that B-T cell interac-
tion is required for robust Tfh and Th2 cell induction, but not essential for eosinophilic airway 
inflammation during a chronic HDM-driven asthma model.
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iNTRoDuCTioN
Asthma is a chronic inflammatory disease of the airways, which is initiated by exposure to 
environmental factors in susceptible individuals (1). Asthma is defined by airway hyper respon-
siveness (AHR) of the bronchioles to various stimuli, such as house dust mite (HDM), leading to 
increased mucus production and airway remodelling. T helper (Th) 2 cell cytokines produced 
by both Th2 cells (IL-4, IL5, and IL-13) and type 2 innate lymphoid cells (ILC2s) (IL-5 and IL-13) 
are critically involved in allergic airway inflammation (2), whereas in non-allergic asthma also 
Th17 cells are implicated. Th2 cytokines facilitate classical allergic responses, such as IgE class 
switching by B cells (IL-4), eosinophilic infiltration (IL-5), and goblet cell hyperplasia (IL-13) 
(2,3). Th17 cytokines can also contribute to asthma symptoms as they increase smooth muscle 
cell proliferation (IL-17A/IL-22) and collagen deposition (IL-17A) (4). Tregs on the contrary will 
dampen these pro-inflammatory Th2 and Th17 cells (3).
In allergic asthma, B cells are well known for their allergen-specific IgE secretion, which 
exacerbates airway inflammation and induces airway narrowing through mast cell activation 
(5). However, beyond their antibody secretion capacities, B cells can also present antigens, 
produce cytokines, regulate T-cell-mediated immune responses, and induce the formation of 
tertiary lymphoid structures (6,7). The functional roles and importance of B cells in allergic 
airway inflammation have been controversial. Several studies in B-cell-deficient mice have 
shown that B cells are dispensable for eosinophilic airway inflammation (8-12). However, it was 
recently shown in a HDM-driven asthma model that B cells synergize with dendritic cells (DCs) 
to promote the differentiation of IL-4-commited follicular helper T (Tfh) cells into memory 
Th2 cells during the HDM-sensitization phase (13). Tfh cells have gained a lot of interest in 
HDM-driven asthma models that contain a sensitization and challenge phase, as they can 
either develop into effector Th2 cells (13) or promote the differentiation of effector Th2 cells 
(14). However, asthma patients are continuously exposed to allergens, whereby sensitization 
and challenge phases cannot be distinguished. Therefore, we wondered whether B cells, B-T 
cell interaction and Tfh cells are similarly important in an asthma model with chronic HDM 
provocation.
We found that exposing mice for 5 weeks with HDM induced a prominent adaptive immune 
response, characterized by B cell activation, development of Tfh cells and germinal centers 
(GC) containing inducible bronchus associated lymphoid tissue (iBALT) structures. Surprisingly, 
eosinophilic airway inflammation was normally present in HDM-exposed B cell-deficient Mb1-/- 
mice and Cd40l-/- mice, but unexpectedly had reduced pulmonary Tfh and Th2 cell numbers.
38
Chapter 2
MATERiAls AND METHoDs
Mice
Male and female C57/BL6, Cd40l-/-, and Mb1-/- mice (15,16) were bred and housed at the 
animal facility of the Erasmus MC Rotterdam. Mice were housed under specific pathogen-free 
conditions and were ~12-16 weeks at time of analysis. All experiments were approved by the 
animal ethical committee of the Erasmus MC (EMC3329).
HDM-induced allergic airway inflammations
During HDM exposures, mice were anesthetized using isoflurane and sensitized intranasally 
with 25 μg/40 μl HDM (Greer) or 40 μl PBS as a control (GIBCO Life Technologies) three times 
per week, for five consecutive weeks. Mice were sacrificed for analysis at day 37 and day 65. 
Lung function was measured following increasing doses of nebulized methacholine (0.4 mg/
ml – 25 mg/ml) using a restrained whole body plethysmograph (EMKA) under urethane seda-
tion. BALf was obtained by flushing the lungs three times with 1 mL PBS containing 0.5 mM 
EDTA (Sigma-Aldrich). Lungs were inflated with either PBS/OCT (1:1) solution, snap frozen in 
liquid nitrogen and kept at -80 °C until further processing, or placed in 4% PFA and embedded 
in paraffin, or homogenized for collagen measurements.
flow cytometry procedures
Single cell suspensions were prepared from BALf, lungs, and MLN using standard procedures. 
Single cell suspensions were obtained from lungs by digesting the lungs using DNAse and 
Liberase for 30 minutes at 37 °C (17). Upon digestion, the lungs were homogenized through a 
100 μm cell strainer (BD Biosciences). Lung red blood cells were lysed using osmotic lysis buffer 
(8.3% NH4CL, 1% KHCO3 and 0.04% NA2EDTA in Milli-Q). Flow cytometry surface and intracel-
lular staining procedures have been described previously (18). Monoclonal antibodies used for 
flow cytometric analyses are listed in Table S1. For all experiments, dead cells were excluded 
using Live-dead Aqua (Invitrogen). For cytokine production measured by flow cytometry, cells 
were stimulated at 37 °C using 10 ng/ml PMA (Sigma-Aldrich), 250 ng/ml ionomycin (Sigma-
Aldrich) and GolgiStop (BD Bioscience), for 4 hours. Data were acquired using a LSR II flow 
cytometer (BD Bioscience) and FACSDivaTM software (BD Bioscience) and analysed by FlowJo 
version 9 (Tree Star Inc software)
lung histology
5 μm-thick paraffin embedded or snap frozen lung sections were stained with heamatoxylin/
eosin or periodic acid-Schiff (PAS). For lung eosinophil staining, 5 μm-thick lung sections were 
fixed in acetone and incubated 1 hour with Siglef-F – PE (BD, Biosciences, clone E50-2240). 
After washing, slides were incubated for 30 minutes with anti-PE – PO (Rockland). Sections 
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were counterstained with hematoxylin. Peribronchial eosinophils were counted in 4 bronchi/
slide by two independent researchers.
For confocal imaging, 10 μm-thick lung sections were fixed in acetone and incubated for 1 
hour with primary antibodies (Table S1). After washing, slides were incubated for 30 minutes 
with secondary antibodies (Table S2). Where necessary, slides were incubated with 10% nor-
mal rat serum or 10% normal donkey serum to prevent unspecific binding of antibodies. Slides 
were counterstained with DAPI and analysed on a Zeiss Meta311 confocal microscope. Images 
were analysed using ImageJ software.
Hydroxyproline assay
Collagen quantification was performed on the right post-caval lobe by hydroxyproline assay as 
previously described (19). Hydroxyproline content may be converted to collagen (1 μg hydroxy-
proline corresponds to 6.94 μg collagen).
ElisA
Total and antigen-specific IgE were measured in serum and BALf (Opteia, BD Biosciences). KC 
levels were measured in BALf (DuoSet, R&D systems).
statistical analysis
Mann-Whitney U tests were used for comparison between two groups and a p-value of <0.05 
was considered statistically significant. All analyses were performed using Prism (GraphPad 
Software).
REsulTs
Chronic HDM exposure induces eosinophilic inflammation and remodelling in the 
airways
To determine the inflammatory kinetics in a clinically relevant chronic HDM-induced asthma 
model, C57BL/6 mice were treated with 25 μg HDM or PBS 3 days per week for 5 consecutive 
weeks and analysed 4 days (day 37) or 32 days (day 65) after the last HDM provocation (Figure 
1A). HDM exposure increased eosinophil numbers in broncho-alveolar lavage fluid (BALf) 
and lung tissue on day 37 compared with PBS-treated controls (Figure 1B, 1F, and Figure S1). 
Furthermore, neutrophil, B cell, Th cell, and ILC2 numbers were also increased in the BALf on 
day 37 compared to PBS-treated controls (Figure 1B-D, Figure S1 – S2). IL-4-, IL-5-, and IL-13-
secreting Th cells were enhanced upon HDM treatment, whereas no increase in IL-17-secreting 
Th cells was observed (Figure 1E).
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Remodelling of the airways is an essenti al feature of asthmati c disease and involves fi brosis, 
goblet cell hyperplasia, and smooth muscle cell hypertrophy, resulti ng in an increased AHR 
(20). Repeti ti ve HDM exposures induced long-lasti ng airway remodelling, as demonstrated by 
the presence of mucus-producing goblet cells (Figure 1H) and smooth muscle cells (Figure 
1I), AHR (Figure 1J), and increased lung collagen content (Figure 1K). On day 65, the type 2 
infl ammati on was no longer detectable in the BALf (Figure 1B, 1E).
Together, these data show that chronic HDM provocati on induces specifi cally robust but tran-
sient type 2 airway infl ammati on, as well as airway remodelling that was maintained over ti me.
Chronic HDM exposure induces development of ibAlT in the lungs
Given the evidence that iBALT areas are increased in asthmati c pati ents (21), we wondered 
whether repeti ti ve HDM provocati ons would induce iBALT formati on in our mouse model.
Lungs of HDM-treated mice showed dense cellular infi ltrates that were associated with 
bronchioles and blood vessels at day 37 (Figure 2A-B), with similariti es to iBALT structures 
observed during infl uenza infecti on (22,23). These HDM-induced structures contained large B 
cell follicles adjacent to T cell areas and CD11c+ anti gen presenti ng cells (APCs) (Figure 2C-D). In 
contrast, in HDM-driven asthma models containing a sensiti zati on and a short challenge phase, 
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figure 1. Chronic HDM exposure induces eosinophilic infl ammati on and remodelling in the airways. (A) 
Chronic HDM model. Mice were treated with PBS or HDM at indicated ti me points. Analysis was performed 
at day 37 and day 65. (B-D) Quanti fi cati on of BALf eosinophils, neutrophils, B cells, Th cells and ILC2s by fl ow 
cytometry (E-F) Flowcytometric gati ng and quanti fi cati on of IL-4+, IL-5+, IL-13+ and IL-17+ Th cells in BALf by fl ow 
cytometry. (G) Histologic analysis of Siglec-F+ eosinophils in lung ti ssue. (H) Histologic analysis and quanti fi ca-
ti on of mucus-producing cells in 3 bronchi per lung in paraffi  n-embedded lung ti ssue using a PAS staining. (I) 
Immunofl uorescent staining of αSMA (green) in lungs at day 37 and day 65. (J) Airway hyper-responsiveness 
was measured upon increasing doses of inhaled methacholine. (K) Lung collagen content was determined by hy-
droxyproline assay. Results are presented as mean ±SEM of n=5-7 per group and representati ve of two or more 
independent experiments with 5-7 mice per group. * = p<0.05, ** = p<0.01, *** = p<0.001.
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iBALTs were not observed and B cell numbers in both BALf and lungs were 10 times lower as 
compared to chronic HDM treatment (Figure S3). These findings suggest that B cells play a 
more prominent role in chronic than in acute HDM-driven asthma models.
iBALTs of chronic HDM-provoked mice contained GC B cells surrounded with plasma cells. 
IgE-expressing GC B cells and plasma cells were found in association with B cell follicles (Figure 
2E-G, and Figure S4A). Both total IgE and HDM-specific IgE were induced in BALf and serum 
(Figure 2H-I). T cells were also located in HDM-induced iBALT structures and could be detected 
inside the B cell follicles, indicative of Tfh cells (Figure 2C). An accordingly significant increase 
in differentiated CXCR5+PD1+ Tfh, GATA3+ Th2, RORγT+ Th17, and FOXP3+CD25+ Tregs was 
observed in the lungs of HDM-treated mice compared with control mice (Figure 2J, Fig S4B), 
whereas naïve CD62L+ Th cells were not increased (Figure S5).
Taken together, these data show that chronic HDM-treatment induced active iBALT struc-
tures containing both Tfh cells and GC B cells, associated with IgE plasma cell formation locally 
in the lungs.
germinal centre b cells and Tfh cells are induced in the MlN upon chronic HDM 
exposure
GC reactions and Tfh cells were shown to be important in Th2 differentiation in acute HDM-
driven asthma models (13,14), therefore we investigated whether GCs and Tfh cells were also 
induced in the MLN of chronic HDM-exposed mice. On day 37, a strong increase in total B cells 
(Figure 3A), GL7+CD95+ GC B cells (Figure 3B-C), and CD138+ plasma cell numbers (Figure 3D-E) 
was observed in the MLN of HDM-treated animals compared with PBS-treated mice. HDM 
treatment also increased the total number of Th cells (Figure 3F), Tfh cells (Figure 3G-H), Th2 
cells, Th17 cells (Figure 3I-K), and Treg cells (Figure 3L-M). B and T cell inflammation remained 
enhanced on day 65 in HDM-treated mice, but GC B cells and plasma cells were significantly 
reduced compared with day 37 of HDM-treated mice (Figure 3A-M).
Thus, chronic HDM-exposures also induce robust GC reactions in the lung-draining MLN.
Eosinophilic inflammation is not dependent on b-T cell interactions
Given that HDM provocations induced a strong GC response and iBALT formation, we wondered 
whether iBALT formation and B-T cell interactions within GCs are essential for the development 
of eosinophilic airway inflammation. Therefore, we exposed B cell-deficient mice (Mb1-/-), and 
mice deficient for CD40L signalling (Cd40l-/-) to our chronic HDM-driven asthma model. Mb1-/- 
mice are deficient in the expression of Iga/CD79a molecule, an essential transducer of B cell 
receptor signals. As a result, B cell differentiation is abrogated in the bone marrow, and mature 
B cells are lacking (15). Cd40l-/- mice lack expression of the CD40L molecule, thus CD40L-CD40 
interaction between T and B cells is hampered and as a consequence these mice fail to develop 
GCs, and class switch recombination is absent (16,24).
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figure 2. Chronic HDM exposure induces development of ibAlT in the lungs. (A) Histological overview images 
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total lungs counted double-blinded. (C) Immunofluorescent staining of CD3+ T cells (green), B220+ B cells (red), 
and CD11c+ APCs (blue) in lungs at day 37. (D) B and Th cells in lung tissue. (E) Immunofluorescent staining of 
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figure 3. germinal centre b cells and Tfh cells are induced in the MlN upon chronic HDM exposure. (A) Quan-
tification of B cells by flow cytometry. (B) Flow cytometric gating of GC B cells from CD19+B220+ B cells in MLN at 
day 37. (C) Enumeration of GC B cells by flow cytometry. (D) Flow cytometric gating of plasma cells from live cells 
at day 37. (E) Enumeration of plasma cells by flow cytometry. (F) Enumeration of Th cells by flow cytometry in 
MLN. (G) Flow cytometric gating of Tfh cells from CD4+ T cells in MLN at day 37. (H) Quantification of Tfh cells by 
flow cytometry. (I) Flow cytometric gating of RORγt+ Th17 and GATA3+ Th2 cells from CD4+ T cells in MLN at day 
37. (J-K) Enumeration of Th2 and Th17 cells in MLN by flow cytometry. (L) Flow cytometric gating of FoxP3+CD25+ 
Tregs cells from CD4+ T cells in MLN at day 37. (M) Quantification of Treg cell numbers in MLN by flow cytometry. 
Results are presented as mean ±SEM of n=5-7 per group and representative of two or more independent experi-
ments with 5-7 mice per group. * = p<0.05, ** = p<0.01.
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Surprisingly, both HDM-treated Cd40l-/- and Mb1-/- mice developed BALf eosinophilic inflam-
mation comparable to HDM-exposed WT controls as assessed at day 37 (Figure 4A). Neutrophil 
numbers in HDM-treated Cd40l-/- and Mb1-/- mice were also not different from HDM-treated 
WT mice; Mb1-/- mice even showed increased neutrophil numbers compared with Cd40l-/- mice 
(Figure 4A). B cells were reduced in HDM-exposed Cd40l-/- mice and as expected completely 
absent in Mb1-/- mice (Figure 4B). BALf Th cell and ILC2 numbers were not different in HDM-
treated Cd40l-/- and Mb1-/- mice from HDM-treated controls (Figure 4C). Strikingly, the numbers 
of BALf IL-4+, IL-5+, IL-13+, and IL-17+ Th cells and ILC2s in HDM-treated Cd40l-/- and Mb1-/- mice 
were similar to WT controls (Figure 4D and Figure S6). Eosinophilic inflammation in lung tissue 
in HDM-treated Cd40l-/- and Mb1-/- mice was also not different from HDM-treated WT mice 
(Figure 4E-4F).
These data show that eosinophilic airway inflammation and Th2 cytokine production can 
develop in the absence of B-T cell interaction upon chronic HDM exposure.
Reduced Tfh and Th2 cell numbers but normal ilC2 numbers in the absence of ibAlT 
structures in the lung
Since Th2 inflammation in the BALf was similar between WT and Cd40l-/- and Mb1-/- mice, we 
investigated whether lung inflammation was affected by the absence of B-T cell interactions or 
B cells. Total lung B cells of HDM-treated Cd40l-/- mice were reduced and completely absent in 
HDM-treated Mb1-/- mice as compared with HDM-treated controls. As expected, GC B cells and 
plasma cells were completely absent in both HDM-treated Cd40l-/- and Mb1-/- mice (Figure 5A). 
In contrast to our findings in BALf, total pulmonary Th and Tfh cells of HDM-treated Cd40l-/- and 
Mb1-/- mice were significantly reduced compared to HDM-treated controls; Th2 cell numbers 
in the lungs of Cd40l-/- mice were also reduced (Figure 5B). Lung Th17 and Treg cell numbers 
of HDM-treated Cd40l-/- and Mb1-/- mice were similar to those in HDM-treated control mice 
(Figure 5B). Surprisingly, pulmonary ILC2 numbers were similar between HDM-treated WT and 
Cd40l-/- and Mb1-/- mice (Figure 5C).
As the inflammation in the lungs is largely reduced, we wondered whether the remaining T 
cells would still cluster together in the absence of B cells and B-T cell interaction. HDM-treated 
Cd40l-/- and Mb1-/- mice exhibited no iBALT structures, although T cells were located in close 
proximity to the bronchioles in all HDM-treated mice (Figure 5D).
Therefore, these data show that as expected B-T cell interaction is essential for iBALT devel-
opment. However, ILC2 numbers are not affected by the absence of iBALT structures.
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Tfh development in MlN in the absence of CD40l signalling upon chronic HDM-
treatment
Since eosinophilic airway inflammation developed normally in the absence of B-T cell interac-
tion, we wondered whether Tfh and Th2 cell differentiation would be hampered in the MLN in 
the absence of CD40L signalling and B cells upon chronic HDM exposure.
As expected, MLN from Cd40l-/- mice had reduced B and T cell numbers, compared with 
HDM-treated WT mice (Figure 6A-B), whereas B cells were absent in Mb1-/- mice (Figure 6A). 
GC B cells and plasma cells were completely absent in HDM-treated Cd40l-/- mice, indicating 
that GC B cell formation is dependent on CD40L signalling in a chronic HDM-induced asthma 
model (Figure 6C). Surprisingly, Tfh cell numbers were not significantly reduced in Cd40l-/- 
mice; Tfh differentiation was lacking in Mb1-/- mice (Figure 6D-E). In PBS-treated Cd40l-/- mice, 
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figure 4. Eosinophilic inflammation is not dependent on b-T cell interactions. (A-C) Quantification of eosino-
phil, neutrophil, B cell, Th cell, and ILC2 cell numbers in BALf by flow cytometry. (D-E) Flow cytometric gating and 
quantification of IL-4+, IL-5+, IL-13+ and IL-17+ producing Th cells in BALf by flow cytometry. (F) Histologic analysis 
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mean ±SEM (n=4 and 7 in PBS and HDM, respectively). *, p<0.05, ** p<0.01, *** = p<0.001.
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Tfh cells were reduced compared with WT mice, as reported before (Figure S7) (25). Tfh cells 
are characterized by the expression of CXCR5, a chemokine receptor that enables the migra-
tion towards the GC (26), and PD1, a potent inhibitory receptor inhibiting excessive Th cell 
proliferation (27). PD1 expression was reduced on Tfh cells of both HDM-treated Cd40l-/- and 
Mb1-/- mice, compared with HDM-treated WT Tfh cells. Nevertheless, PD1 expression on Tfh 
cells of HDM-treated Cd40l-/- mice was still elevated, compared with PBS-treated WT Tfh cells. 
CXCR5 expression was only reduced in Tfh cells of Mb1-/- mice (Figure 6D, quantified in Figure 
6F). In contrast to Tfh cells, Th2 cells were strongly reduced in MLN of both HDM-treated 
Cd40l-/- and Mb1-/- mice, compared with HDM-treated WT mice. Tregs were reduced in both 
HDM-treated Cd40l-/- and Mb1-/- mice, and Th17 cell numbers were only significantly reduced 
in Mb1-/- mice (Figure 6G).
In summary, these data confirm that GC B cell formation in the MLN is dependent on CD40L 
signalling. Importantly, in the MLN, Tfh cell induction during chronic HDM-exposure does not 
require CD40L, but is dependent on B cells. In contrast, Th2 cell development in the MLN is 
dependent on both CD40L signalling and B cells.
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lung. (A) Quantification of B cell, GC B cell, and plasma cell numbers in lung tissue by flow cytometry. (B) Quan-
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7 in PBS and HDM, respectively). *, p<0.05, ** p<0.01, *** = p<0.001.
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b cells and b-T cell interaction are essential for pulmonary remodelling
Both cytokine production by Th2 cells, as well as IgE secretion by B cells are known to contrib-
ute to pulmonary remodelling (28), therefore we wondered whether remodelling is dependent 
on the presence of B cells or B-T cell interaction. HDM-treated Cd40l-/- and Mb1-/- mice had a 
reduced area of α-smooth muscle actin (αSMA) surrounding the bronchioles and mucus-pro-
ducing goblet cells compared to HDM-treated WT mice (Figure 7A-D). A trend towards reduced 
AHR was observed at lower methacholine concentrations in both HDM-treated Cd40l-/- and 
Mb1-/- mice, compared to HDM-treated WT mice (Figure 7C).
These data demonstrate that the presence of B cells and CD40L signalling is essential for 
airway remodelling that accompanies chronic airway inflammation.
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DisCussioN
B cells are essential for the maintenance and final differentiation of Tfh cells (29). Tfh cells 
have recently been reported to contribute to Th2-mediated inflammation in asthma, either 
by the differentiation into effector Th2 cells or by promoting Th2 cell differentiation (13,14). 
However, whether B cells and B-T cell interaction are also important for eosinophilic airway 
inflammation in a clinically relevant chronic asthma model characterized by prolonged allergen 
exposure remains unknown. Chronic HDM exposures induced transient type-2 airway inflam-
mation, whereas structural changes such as airway remodelling and airway hyperresponsive-
ness sustained over time. Our study demonstrates that in a chronic HDM-mediated asthma 
model eosinophilic inflammation in the BALf and lung tissue can develop in the absence of 
B-T cell interaction and iBALT structures. The accumulation of ILC2s in BALf and lung tissue 
was not affected by the absence of iBALT tissue. In particular, we have found that the absence 
of B cells precluded the formation of Tfh cells in the MLN upon chronic HDM exposure, but 
nevertheless eosinophilic inflammation was induced. Thus, in contrast to published findings in 
acute HDM models characterized by sensitization and challenge phases (13,14), our findings 
in a chronic HDM asthma model demonstrate that pulmonary eosinophilic inflammation is 
independent of B-T cell communication and iBALT formation. Nevertheless, our chronic HDM 
model revealed that pulmonary Th2 inflammation and airway remodelling require B cells and 
B-T cell interaction.
Although CD40L is mostly studied because of its prominent role on activated T cells in the 
context of B-T cell interaction, CD40L is also expressed on several other cell types, including 
mast cells, eosinophils, monocytes, B cells, and DCs (30). It is therefore conceivable that addi-
tional immunological responses may be hampered in Cd40l-/- mice, next to B-T cell interaction 
and communication. For instance, CD40-CD40L signalling in DCs is also involved in Th2 cell 
differentiation (31). Furthermore, upon CD40-CD40L interaction OX-40L, a Th2 cell promoting 
co-stimulatory molecule, is induced on DCs (32). However, it is not likely that decreased Th2 
differentiation in the MLN of Cd40l-/- mice is mainly a result of insufficient DC-T cell interaction, 
rather than abrogated B-T cell communication, because Mb1-/- mice – in which CD40-CD40L 
signalling between DC and T cells is still intact – also showed a similar reduction of the numbers 
of Th2 cells in MLN as Cd40l-/- mice.
Eosinophils were also reported to be important for airway remodelling in OVA-induced 
asthma models (33). In this context, however, our data indicate that a reduction in airway re-
modelling is observed, although similar eosinophilic inflammation is present in Mb1-/-, Cd40l-/- 
and WT mice. This is consistent with other reports that investigated the role of eosinophils in 
airway remodelling upon HDM-driven asthma models (34). Recently, eosinophil derived IL-4 
was also described to induce both proliferation and IL-5 and IL-13 secretion by ILC2s, suggest-
ing a positive feedback loop between ILC2s and eosinophils (35). This would complement our 
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data, as we found normal levels of both eosinophils and ILC2s in the airways of mice deficient 
of B cells or CD40L signalling.
B cells can contribute to various aspects of asthma pathology through the secretion of cyto-
kines, antigen presentation and their production of antigen-specific IgE (36). Our data demon-
strates that during chronic HDM exposure B cells are dispensable for pulmonary eosinophilic 
influx, but are essential for the development of airway remodelling. Other studies have also 
found similar numbers of eosinophilic inflammation in B cell-deficient mice (8,11,37), whereas 
especially allergen-specific IgE secretion by plasma cells was shown to be sufficient to induce 
AHR (38,39), smooth muscle cell proliferation, and collagen deposition (40,41). In contrast, 
Drake et al, found that B cells are important for Th2-mediated asthmatic inflammation, how-
ever in contrast to our study, mice were exposed to different allergens such as, ovalbumin, 
Alternaria, Aspergillus, and HDM (42).
It has been reported in a model containing a sensitization and challenge phase, that 
HDM-specific CD4+ T cells are first primed by lung-migratory DCs at the B cell follicle border 
where they proliferate and acquire a Tfh like-signature (13). IL-4-committed pre-Tfh cells 
subsequently encounter allergen-bearing B cells that acquired allergen from lung-migratory 
DCs. These allergen-presenting activated B cells, replace DCs as the primary APCs in the B cell 
follicle and provide Th cell survival and differentiation signals (13). We also found significantly 
lower numbers of Th2 and Tfh cells in the MLN and lung, whereas the numbers of Th17 and 
Tregs were similar in the absence of B cells. However similar numbers of Th cells were found 
in association with the bronchioles. This suggests that the decrease in both total Th cells as in 
Th2 cells in the lung is likely caused by the absence of iBALT structures. This is in contrast to 
the BALf, where we found normal Th2 levels in both HDM-treated Mb1-/- and Cd40l-/- mice as 
compared to WT mice, indicating that the lungs could contain two separately controlled Th2 
compartments.
It is well possible that the observed role for both B cells and Tfh cells is dependent on the 
experimental model, allergen type, and kinetics of exposure. Clearly, our data demonstrate 
that in a chronic HDM-driven asthma model normal lung eosinophilic inflammation can be 
initiated in the absence of B-T cell interactions and iBALT structures. This finding indicates 
that chronic HDM exposure elicits a very robust and/or long lasting pulmonary inflammatory 
response that overcomes the need for Tfh cells during Th2 cell differentiation that was ob-
served in acute HDM models (12,13). Unlike in acute models, chronic allergen exposure could 
result in prolonged activation of ILC2s that may support or induce eosinophilic inflammation, 
independently of Tfh cells or GC formation in the MLN and lungs.
Collectively our data shows that upon chronic allergen exposure, B-T cell interactions are re-
quired for robust Tfh and Th2 cell induction, however are not essential for eosinophilic airway 
inflammation. Eosinophilic airway inflammation alone is not sufficient to induce pulmonary 
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remodelling and airway hyperresponsiveness, which is likely dependent on the outcome of B-T 
cell interactions.
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figure s1. flow cytometric gati ng of eosinophils, neutrophils, b cells, and T cells in bAlf. Eosinophils were 
gated as Siglec F+, GR-1-, Neutrophils were gated as GR1+, Siglec Fint, T cells were gated as CD3+MHCII-, and B cells 
were gated as CD19+MHCII+. Due to the limited amount of fl uorochromes available, CD19 and CD3 were stained 
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figure s2. flow cytometric gati ng of ilCs in bAlf. ILC2s were gated as Lineage negati ve (CD3, CD5, CD8α, CD11b, 
CD11c, CD19, B220, NK1.1, GR-1, Ter-119, FcεRIα, and CD14) and CD45+, Sca-1 (Ly6A/E)+, T1ST2+, and CD127+.
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figure s3. b cell infl ammati on is less prominent in the bAl and lungs of mice exposed to an acute HDM-driven 
asthma model. (A) Scheme for acute intranasal HDM treatment of C57BL/6 mice to induce airway infl ammati on. 
Mice were sensiti zed with PBS or 1 μg HDM at day 1, and challenged with 10 μg of HDM at day 8-12. Analysis 
was performed at day 13. (B) Quanti fi cati on of eosinophil and neutrophil cell numbers in BALf by fl ow cytometry. 
(C) Quanti fi cati on of B and T cell numbers in BALf by fl ow cytometry. (D) Quanti fi cati on of B and T cell numbers 
in lung by fl ow cytometry. Results are presented as mean ±SEM (n=6 in PBS and HDM). *, p<0.05, ** p<0.01.
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Table s1: Antibodies used for flowcytometryTable S1 tibodies used for flow cytometry
Antibody Conjugate Clone Company
B220 PE RA3-6B2 eBiosciences
CD11b PE M1/70 eBiosciences
CD11c PE N418 eBiosciences
CD127 PE-Cy7 SB/14 BD Biosciences
CD138 APC 281-2 eBiosciences
CD19 APC-eFluor 780 ID3 eBiosciences
CD19 PE ID3 BD Biosciences
CD25 PerCP-Cy5.5 PC61 BD Biosciences
CD3 PE-CF594 145-2C11 BD Biosciences
CD3 APC-eF780 17A2 eBiosciences
CD3 PE 145-2C11 eBiosciences
CD4 Brilliant Violet 605 RM4-5 BD Biosciences
CD45 Pe-CF594 I3/2.3 Abcam
CD5 PE 53-7.3 eBiosciences
CD8a PE 53-6.7 eBiosciences
CD62L APC-eFluor 780 MEL-14 eBiosciences
CD95 PE-CF594 Jo2 BD Biosciences
CXCR5 Biotin 2G8 BD Biosciences
FceRIa PE MAR-1 eBiosciences
FoxP3 AF488 FJK-16s eBiosciences
GATA3 eFluor 660 TWAJ-14 eBiosciences
GL7 FITC GL7 BD Biosciences
Gr-1 PE RB6-8C5 eBiosciences
IL-13 eFluor 450 eBio13A eBiosciences
IL-4 Brilliant Violet 711 11B11 BD Biosciences
IL-5 APC TRFK-5 BD Biosciences
Ly6A/E Brilliant Violet 786 D7 BD Biosciences
Ly6C/Ly6G Pe-Cy7 RB6-8C5 eBiosciences
MHCII Alexa Fluor 700 M5/114.15.2 eBiosciences
NK1.1 PE PK136 eBiosciences
PD1 Brilliant Violet 421 J43 BD Biosciences
RORyt PE Q31-378 BD Biosciences
Siglec-F PE E50-2440 BD Biosciences
Streptavidin Brilliant Violet 786 BD Biosciences
T1ST2 FITC DJ8 mdbioproducts
Ter-119 PE TER119 eBiosciences
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Table s2: Primary and secondary antibodies used for confocal microscopyTable S2 Pri ary and secundary antibodies used for confocal icrosc y
Primary antibodies Host IgG Producer Cat#
a-SMA Mouse IgG2a R&D systems IC1420G
B220 Rat IgG2a eBioscience 56-0452-82
CD11c Armenian Hamster IgG1 eBioscience 12-0114-83
CD138 Rat IgG2a BD biosciences 553713
CD3 Armenian Hamster IgG1 BD biosciences 553062
collagen Rabbit IgG Merck Millipore ABT123
GL7 Rat IgM BD biosciences 553666
IgE Goat IgG Novus Biologicals NB7530
Secundary antibodies Fluorchrome Producer
donkey anti-goat IgG Cy-3 Jackson Immunoresearch
donkey anti-rabbit IgG Cy-3 Jackson Immunoresearch
goat anti-armenian hamster IgG Cy-3 Jackson Immunoresearch
donkey anti-rat IgG Cy-5 Jackson Immunoresearch
mouse anti-FITC AF488 Jackson Immunoresearch
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DENDRiTiC CEll subsETs iN AsTHMA
impaired tolerance or exaggerated inflammation?
Allergen-activated dendritic cells are essential for the induction of Th cell differentiation from 
naïve T cells in the lung draining lymph node, but also drive the maintenance of pulmonary 
inflammation during continuous allergen exposure (Chapter 1) (1). Lung DCs are a heteroge-
neous cell population that consists of two types of conventional DCs (cDCs), e.g. cDCs type 1 
(cDC1s) and cDC2s. Next to cDCs, the lungs also contain plasmacytoid DCs (pDCs) and under 
inflammatory conditions, monocyte derived DCs (moDCs) (2-4). DCs can become activated by 
allergens exposure and by cytokines secreted by the airway epithelium (5,6). Activation of DCs 
requires induction of the pro-inflammatory transcription factor NF-kB, which can be negatively 
regulated by the deubiquinating enzyme TNFAIP3/A20 (7). In this thesis, we have made use 
of transgene mouse strains, enabling the activation of different DC subsets and myeloid cells 
(summarized Chapter 1, figure 4). In the Introduction II, an overview of the ontogeny and 
pulmonary localization of DC subsets and their function in asthma both in mouse as in human 
will be given.
DC ontogeny
DCs originate from hematopoietic stem cells (HSCs) in the bone marrow. These HSCs differenti-
ate into the macrophage DC progenitor (MDP) (8), which give rise to both the common mono-
cyte progenitor (cMoP) and the common DC progenitor (CDP). Whether CDPs also develop 
without the intermediate MDP stage and can develop directly from HSC is currently unknown. 
CDPs give rise to pre-cDCs and pDCs (9). Recently, two studies showed that bone marrow 
pre-cDCs can be divided into pre-cDC1s and pre-cDC2s that are committed to cDC1 and cDC2 
development. This indicates that the decision to become cDC1s or cDC2s already occurs in the 
bone marrow and not in the periphery (10,11). MoDCs develop from the cMoPs (12,13).
location of pulmonary DC subsets
As the number of pulmonary DCs is low and until recently multiple markers were needed to 
specify DC subsets, the number of current studies that investigated the location of specific DC 
subsets in the lung during steady state are rather limited. It is known that cDC1s are located in 
close proximity to the airway epithelium, and as they express CD103 (alpha integrin) and beta7 
integrin, they can interact with E-cadherin expressed by epithelial cells. Compared to other DC 
subsets, cDC1s have higher expression of tight junction proteins, which facilitates the sampling 
of antigen by extending their dendrites into the airway lumen. However, cDC1s can also be 
found in the proximity of vascular endothelial cells (14). Most studies that investigated the 
localization of pulmonary DC subsets used CD11b as marker for cDC2s (14-16), however CD11b 
is not exclusively expressed by cDC2s and is also highly expressed by moDCs (1). A recent study 
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could distinguish moDCs and cDCs by crossing MacBlue mice (Csf1r-EGFPtg/+) mice to Itgax-YFP 
or Cx3cr1gfp/+ mice, in which cDCs can be distinguished by YFP expression and monocytes and 
macrophages by ECFP expression. This study indicated that cDCs are located near the large 
airways, whereas monocytes and alveolar macrophages are localized in the alveolar space 
(17). Using MacBlue mice, in situ traveling of monocytes and monocytes-derived cells could be 
investigated, and revealed that monocyte-derived cells in the lungs are located at the interface 
of blood vessels and the airways (17,18). During steady state, the majority of pulmonary pDCs 
are located in the alveolar interstitium (14,19), however pDCs are also found in pulmonary 
infiltrates upon an ovalbumin (OVA)-mediated asthma model.
Due to recent published research, investigating the localization of DC subset can now be 
performed with fewer markers, as Guilliams et al, showed that interferon regulatory factor 4 
(IRF4) and IRF8-expression is exclusive for respectively cDC2s and cDC1s across different or-
gans and species (3). Combining these markers with a universal DC marker such CD11c should 
therefore be sufficient to visualize cDC1 and cDC2 subsets and ease localization studies.
CoNVENTioNAl TyPE 1 DENDRiTiC CElls
Development of cDC1
cDC1 development is highly dependent on the transcription factor IRF8, as IRF8 drives DC 
precursor generation (11), development of pre-cDCs in the bone marrow and promotes 
survival of terminally differentiated cDC1s (20). Basic Leucine Zipper ATF-Like Transcription 
Factor 3 (BATF3) is also implicated during cDC development (21), whereas DNA-binding protein 
inhibitor (ID2) is essential for the terminal differentiation of cDC1s (22). Ontogeny of cDC1s is 
also regulated by cytokines, as Fms-like tyrosine kinase receptor 3-ligand (Flt3L)-deficient mice 
completely lack cDC1s in the lungs (1,23). Development of cDC1s is similar to CD8a cDCs in 
lymphoid organs (23,24).
function of cDC1s in airway inflammation
Conventional DC1s are well appreciated for their superior cross-presentation of antigens to 
CD8+ T cells, essential for the induction of virus-specific CD8+ T cells and anti-tumor immune 
responses (21,25,26). However, cDC1s have an inferior capacity to take up allergens compared 
to other DC subsets (27). Whether cDC1s are also implicated in Th2 skewing in response to al-
lergen exposure remains controversial, as cDC1s are reported to promote, inhibit or be redun-
dant for Th2 immune responses (27-29). These differences may be explained by the allergen 
used, amount of allergen, or the mouse strain used to deplete cDC1s. Next to promoting CD8+ 
T cell responses, cDC1s are often associated with a tolerogenic function. cDC1s can induce 
differentiation of Tregs upon HDM exposure through the induction of retinoic acid and PPARγ 
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(28,30). During OVA or HDM-mediated airway inflammation (31) and helminth infections (32). 
cDC1s can limit Th2 inflammatory responses, emphasizing their tolerogenic potential (figure 
1). Conventional DC1s are also crucial for the function of products known to dampen allergic 
airway disease, such as Helicobacter pylori treatment (33). Furthermore, CD103-deficient mice 
exposed to a OVA-mediated asthma protocol involving five OVA aerosol challenges, developed 
a more pronounced eosinophilic inflammation indicating their tolerogenic role during Th2-
mediated immune responses (31). In contrast, Fear et al, showed that CD103-/- mice that 
received only a single OVA challenge had decreased eosinophilic inflammation, arguing the 
tolerogenic properties of cDC1s. Absence of CD103 did not affect DC migration, but decreased 
the percentage of allergen-loaded migratory DCs in the lung draining lymph node (34). As 
CD103 can be expressed on both T cells as cDC1s (35) it is hard to determine which effects are 
caused by the DCs, and which by the T cells. However, it is conceivable that cDC1s are essential 
for the uptake of antigens through the epithelial barrier at low antigen concentrations. This 
could explain the decrease in allergen-loaded DCs and absence of Th2 cell immune responses 
with only a single OVA challenge. By increasing allergen concentrations or frequent allergen 
exposures this can be overcome by protease activity or passive leakage, enabling other DC 
subsets to access the allergens and migrate towards the draining lymph node.
In addition to their capabilities to suppress Th2 cell differentiation, cDC1s also control Th17 
immune responses upon Aspergillus infections through secretion of IL-2 (36), indicating that 
cDC1s are essential for maintaining homeostasis in the airways. Furthermore, cDC1s are also 
important for the removal of apoptotic cells, as resolution of airway inflammation is reduced in 
CD103-deficient mice (31), and cDC1s have been shown to remove apoptotic cells (37).
As it was described that pulmonary cDC1s express Langerin (14), some studies that investi-
gated pulmonary cDC1 function, depleted pulmonary cDC1s using Langerin- diphtheria toxin 
receptor mice (1,27). However, flow cytometric analysis showed that only a minority of the 
pulmonary cDC1s expressed Langerin (38), indicating heterogeneity within the pulmonary 
cDC1 population.
CoNVENTioNAl TyPE 2 DENDRiTiC CElls
Development of cDC2
In contrast to knowledge on cDC1 development, the transcriptional control of cDC2s is not 
well characterized. Differentiation of cDC2s from pre-cDCs is regulated by RELB (39), PU.1 
(40), RBPJ (41-43) and IRF4 (44-46). However, it is unknown during which cDC2 developmental 
stage these transcription factors are important. Also, the role of the cytokine Flt3L in cDC2 
development is controversial, as it has been shown that cDC2 development is independent 
of Flt3L (23), whereas others found a complete absence of cDC2s in Flt3L-deficient mice (1). 
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These different findings are likely caused by the dissimilar protocols to distinguish cDC2s from 
moDCs, as moDCs develop independently of Flt3L (1). The newly proposed universal gating 
strategy using IRF4 and IRF8 (3) makes the distinction between these DC subsets easier and 
will help future studies investigating the role of specific transcription factors or cytokines on 
the development of different DC subsets.
function of cDC2s in asthma
Conventional DC2s can take up allergen very efficiently (1,47), migrate well to the lung drain-
ing lymph node, and induce proper T cell proliferation (1) (figure 1). Conventional DC2s are 
essential for the induction of Th2 cell differentiation in allergen-exposed lungs (1,47,48) and 
even possess the capability to induce Th17 cell differentiation in the gut (44,49). In an HDM-
mediated asthma model, cDC2s can induce both Th2 and Th17 differentiation (50). HDM can be 
recognized by various innate receptors on the cell membrane of DCs, including C-type lectin re-
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figure 1: Dendritic Cell functions upon allergen exposure. Type 2 cDCs are essential for the migration and 
induction of differentiation of Th2 cells in the lung draining lymph node upon allergen Exposure. MoDCs are im-
portant for the chemotaxis of effector Th2 cells towards the lungs by secretion of chemokines CCL17 and CCL22. 
In asthmatic disease, plasmacytoid DCs suppress Th2-mediated inflammation via PD-L1 expression, whereas 
cDC1s induce Tregs via expression of retinoic acid (RA).
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ceptors, such as Dectin-2 (51). Both HDM-mediated Th2 and Th17 differentiation is dependent 
on Dectin-2-mediated recognition and/or allergen uptake, as T cells of Dectin-2-deficient mice 
have reduced expression of both Th2 and Th17 cytokines (50). cDC2-deficient mice through 
IRF4 deficiency have reduced Th2 immune responses in the airways upon sensitization in the 
airways (52) or in the skin (53). Similarly, no eosinophilic inflammation and Th2 differentiation 
was induced in mice in which IRF4 was depleted in mature DCs, using a different CD11cCre, 
which did not affect cDC2 cell development (54). This indicates the importance of cDC2s for 
the induction of Th2 differentiation. Dectin-1 expression on DCs appears to be important for 
migration, as Dectin-1-deficient cDC2s display lower levels of CCR7, and have lower numbers 
of migratory cDC2s in the lung draining lymph node. Furthermore, Dectin-1-/- mice did not 
develop eosinophilic inflammation and did not show induction of Th2 or Th17 cytokines in an 
HDM-mediated asthma model (55). Indicating that Dectin-1 is required for the induction of 
chemokines and chemokine receptors on cDC2s, needed to migrate towards the lung draining 
lymph node and induce T cell differentiation. cDC2s exclusively express OX-40L (56), essential 
for Th2 cell differentiation, implicating the importance of cDC2s for Th2 differentiation.
MoNoCyTE-DERiVED DENDRiTiC CElls
Development of moDCs
As their name implicates and stated above, moDCs derive from monocytes. There are two 
types of monocytes, Ly6Chi and Ly6Clow monocytes (57). Ly6Chi monocytes migrate towards 
inflammatory sites and give rise to Ly6Chi moDCs, Ly6Clow moDCs (58) and Ly6Clow monocytes 
(59). MoDCs downregulate Ly6C, upon differentiation from monocytes (1). Ly6Clow monocytes 
patrol the vasculature (57,60) and can differentiate into more long-lived Ly6Clow moDCs (58). It 
is even suggested that monocytes or moDCs can serve as a cDC precursor, in which cDC1s can 
arise from Ly6Chi CCR2hi monocytes, and cDC2s develop from Ly6Clow CCR2low monocytes (61).
function of moDCs in asthma
After a primary high dose HDM in the airways, moDCs accumulate within 48 hours in the lungs 
and peak at 72 hours in the lung draining lymph node (1). HDM and other environmental 
factors trigger the airway epithelium to secrete chemokines and cytokines (62). Secretion of 
CCL2 will drive migration of monocytes towards the lungs (63), where they will differentiate 
into moDCs under the regulation of both CCL2 (1) and CSF-1 (23). MoDCs are efficient in an-
tigen uptake, however their capacity to drive T cell proliferation is inferior to cDC2s. Instead, 
moDCs produce vast amounts of cytokines and chemokines essential for the recruitment 
and activation of Th2 cells upon HDM exposure (1) (figure 1). This indicates that moDCs are 
dispensable for Th2 differentiation but essential during the effector phase of asthma models, 
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as depletion of CD11b+ myeloid cells during allergen challenge drastically reduces eosinophilia 
(64). Nevertheless, upon high antigen dose, moDCs migrate towards the lymph nodes and 
induce Th2 differentiation in the absence of cDCs upon exposure to HDM (1) or cockroach 
extract (65). Depletion of migratory cDCs enhances Th2 cell-mediated immune responses in 
an OVA-alum model (66). Furthermore, absence of Th2 cell-mediated immunity, due to the 
absence of DCs can be reverted by adoptive transfer of monocytes, which then differentiate 
into moDCs (67). These data are in agreement with recent results indicating that systemic 
administration of CD11b+ cells from the bone marrow, likely being monocytes, are efficient 
inducers of Th2-mediated eosinophilic airway inflammation (68). This implicates that at high 
allergen concentration, moDCs can acquire migratory capacities and are capable of inducing 
Th2 differentiation and thereby drive Th2-mediated immune responses.
PlAsMACyToiD DENDRiTiC CElls
Development of pDCs
Plasmacytoid DCs differentiate directly in the bone marrow from CDPs (69). Differentiation of 
pDCs depends on Flt3L and STAT3 signalling, in combination with various transcription factors, 
such as E2-2, IRF8, Ikaros, and PU.1, of which E2-2 is highly specific for pDC development 
(70-72).
function of pDCs in asthma
Plasmacytoid DCs are essential for anti-viral immune responses as they produce large amounts 
of type I interferons (IFN-a) after toll-like receptor 7 (TLR7) activation (73,74). In comparison to 
other DC subsets, pDCs have a limited capacity to take up, and present antigens (1,19,75,76). 
pDCs are described to have a tolerogenic function in asthma, as pDCs induce Treg cell dif-
ferentiation (77,78), and depletion of pDCs in Siglec-H-DTR mice increased the proliferation 
of antigen-specific CD4+ T cells (79). Increasing pDC numbers by Flt3L treatment alleviates eo-
sinophilic inflammation, which is reversed upon pDC depletion (80). Programmed death-ligand 
1 (PD-L1) expression on pDCs is essential for their suppressive effect, as PD-L1-deficient pDCs 
could not alleviate allergic airway inflammation, whereas indoleamine-pyrrole 2,3-dioxygenase 
or inducible T cell costimulator ligand (ICOSL)-deficient pDCs could (80) (figure 1). Develop-
ment of HDM-driven allergic asthma can be inhibited by the adoptive transfer of pDCs of sen-
sitized donors (81). Different pulmonary pDC subsets are described, e.g. CD8a-b-, CD8a+b-, and 
CD8a+b+ pDCs (82). Only CD8a+b- pDCs and CD8a+b+ pDCs have tolerogenic capacities, whereas 
CD8a-b- pDCs display more pro-inflammatory functions upon TLR7 and TLR9 stimulation (82). 
Specifically, CD8a+b+ pDCs CD8a+b- pDCs have increased expression of retinal dehydrogenase 
leading to retinoic acid production resulting in increased Treg differentiation (82).
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PDCs are also essential for the beneficial effects observed in immunotherapy via the comple-
ment subunit C1q. Administration of C1q reduces airway hyperresponsiveness (AHR) and 
eosinophilia as efficiently as dexamethasone administration, and pDC depletion abrogates the 
protective effect of C1q (83).
Viral infections are often a trigger for asthma exacerbations. Viral particles activate DC sub-
sets via TLR7, and its expression was decreased in pDCs by allergic inflammation. TLR7-deficient 
mice displayed reduced IFN secretion, increased virus replication and increased eosinophilic 
inflammation and AHR, implicating that impaired TLR7 expression on pDCs by allergic inflam-
mation could exaggerate asthma exacerbations (84). Furthermore, pDCs transferred from do-
nors with respiratory tract syncytial virus (RSV) did not provide protection from Th2-mediated 
inflammation as transferred pDCs from naïve mice did (81). However, CpG maturated pDCs are 
well capable of protecting from eosinophilic inflammation (80), suggesting that the mode of 
activation of pDCs can alter their function.
CoNCluDiNg REMARks
Taken together, different DC subsets exert different functions. Next to differences in CD4+ or 
CD8+ T cell activation, it appears that in allergic airway inflammation cDC2s and moDCs are 
essential for the induction and maintenance of Th2 and/or Th17-mediated inflammation, 
whereas cDC1s and pDCs are in general suppressive. The exact function of cDC1s during Th2 in-
flammation remains controversial, as cDC1s are ideally situated to sample incoming allergens, 
however in allergic asthmatic patients, cDC1s are unable to control inflammation to these 
harmless antigens. Newly developed stainings and technologies will therefore in the future 
provide more extensive insight into the similarities and differences of DC functions in asthma.
HuMAN PulMoNARy DENDRiTiC CEll subsETs
Transcriptional development of human DCs
In human lungs, three different DC subsets have been described, human DC subset 1 (DC1) that 
expresses BDCA1 (CD1c), DC2s, that expresses BDCA3 (CD141) and pDCs, that express BDCA2 
(CD123) (3,4,85). Gene-expression profiles of human DC1 and DC2 revealed that human DC 
subsets resembled mouse cDC1s and cDC2s respectively (3,86-89). Development of human 
DCs is also highly dependent on Flt3L, as Flt3L injection drastically increases the number of 
DCs in blood of healthy volunteers (90). Similar to the differentiation of mouse DC subsets, the 
differentiation of human pDCs is mediated by E2-2 (91), whereas differentiation of cDC1s and 
cDC2s is controlled by transcription factors BATF3 (92) and IRF4 (93,94) respectively.
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location of human DC subsets in the lungs
BDCA1+ cDC2s were increased in the airway epithelium of asthma patients that display a 
Th2 phenotype, whereas this was not observed in patients without a Th2 profile (95). Strik-
ingly, DCs are increased in the outer wall of the large airways in patients that suffer from fatal 
asthma, which are likely moDCs, as they express XIIIa (96). XIIIa is a coagulation factor that 
is also expressed on macrophages in the skin (97), which are also derived from monocytes 
and points to a similar precursor cell. Unfortunately, the lack of lung material consisting of 
airway epithelium as well as airway interstitium of both healthy controls and asthma patients 
makes it hard to interpret the localization of different DC subset during steady state and in the 
asthmatic lung. Recent consensus about universal markers that can identify DC subsets will 
facilitate the visualization of DC subsets in human organs (3).
function of human DCs in asthma
Until recently most studies investigating human DC function compared pDCs to myeloid DCs 
(mDCs) that include both cDC1s and cDC2s. Allergic asthmatics have increased frequencies of 
cDC1s and cDC2s in peripheral blood (98), induced sputum and BAL upon allergen inhalation 
compared to controls (99-101). After allergen inhalation, only cDC2s migrated towards the 
bronchial tissue (101). Allergen exposure increased the expression of TSLP receptor but not IL-
33 receptor on cultured cDCs from CD34+ precursors of the bone marrow, which are implicated 
as Th2 instructive cytokine receptors (101). Inhalation of allergens induced expression of IL-25 
receptor on both cDCs and pDC (102) (figure 2). The co-stimulatory molecule OX-40L and the 
expression of the Th2 chemoattractant CCL17 was higher on cDCs of patients with mild asthma 
than on cDCs of healthy controls (103). In patients that displayed high Th2 cell numbers, a large 
number of airway mucosal cDC2s expressed FceRIa compared to Th2-cell low asthma patients 
(95). This is likely, as IgE levels are increased in patients that exhibit high Th2 cell numbers, 
indicating that IgE increases the expression of FceRIa. IgE-bound antigens are rapidly internal-
ized, processed and presented by DCs to antigen-specific CD4+ T cells (104,105). cDC2s loaded 
with Der p1 allergen-IgE immune complexes induced IL-4 and lowered IFNg-expression upon 
co-culture with naïve T cells (106), indicating that allergen-IgE immune complexes promote 
Th2 differentiation (107).
cDCs of allergic asthmatics induced increased Th2 differentiation upon stimulation with TSLP 
and Der p compared to cDCs of controls. TSLP-stimulated cDCs of allergic asthmatics and not 
of controls, induced IL-9 production and PU.1 expression. When the Th2 priming capacity of 
cDC1 and cDC2s from human blood and lungs was compared, it was found that both lung as 
blood cDC1s are superior in Th2 differentiation (109). However, in this study, live attenuated 
influenza virus was used to activate cDC1s and cDC2s, which primarily will activate cDC1 as 
they are essential for the induction of anti-viral immune responses (25). During acute asthma 
exacerbations, the expression of CD141, a marker for cDC1 is increased in blood leukocytes on 
Introducti on II: DC subsets in asthma
75
3
moDCs, but surprisingly not on cDC1s (110). This could indicate that cDC1s or CD141 expres-
sion plays an important role in the pathogenesis of asthma. CD1c+ cDC2s from allergic rhiniti s 
pati ents effi  ciently prime Th2 diff erenti ati on (111) and express lower levels of ICOSL as com-
pared to controls (figure 2). Blockade of ICOSL in cDC2s of controls increases the producti on 
of Th2 cytokines, indicati ng that decreased ICOSL expression on cDC2s could promote Th2 dif-
ferenti ati on (112). Both human cDC1s and cDC2s have been reported to induce Th2 cytokines, 
however Th2 diff erenti ati on by cDC1s was observed upon exposure to live-att enuated viral 
parti cles (111). This may implicate that during virus infecti ons, cDC1s in asthmati cs shift  from 
promoti ng Th1 immune responses or maintaining tolerance towards a more Th2-promoti ng 
phenotype.
Figure 2: DC subset alterations in asthmatic patients 
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figure 2: Dendriti c cell subset alterati ons in asthmati c pati ents. Conventi onal DCs, including both cDC1s and 
cDC2s of asthma pati ents display higher levels of IL-25R, TSLP receptor, OX-40L and secreti on of CCL17. Especially 
ICOSL expression in cDC2s of asthmati cs is reduced whereas FceRIa expression is increased in asthmati cs that 
display a Th2 high phenotype. MoDCs of asthmati cs display increased expression of HLA-DR, CD141 and PAR-2, 
and the anti -infl ammatory cytokine IL-10, whereas IL-12 producti on is reduced. Plasmacytoid DCs of asthmati cs 
show increased expression of the IL-25R, whereas IFNa secreti on was reduced.
Allergen inhalati on increased pDCs numbers in the airway lumen (99,113), however vari-
able results exist whether circulati ng pDCs diff er between asthmati cs and healthy individuals 
(114,115). In a birth cohort, numbers of circulati ng pDCs predicted respiratory tract infecti ons, 
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wheezing and asthma diagnosis by 5 years of age (116). It was also shown that pDCs of severe 
asthmatics produced less IFNa following influenza infection, than pDCs of healthy controls 
(117) (figure 2).
HDM activation of cultured monocyte-derived DCs of HDM-allergic asthma patients induced 
more T cell proliferation (118) and Th2 differentiation than control moDCs (119). This could 
be due to a higher HLA-DR expression of moDCs from allergic asthmatics compared to non-
asthmatic subjects (118) (figure 2). When examining the frequency of intermediate mono-
cytes, expressing both CD14 and CD16, conflicting results exist in severe asthmatics (120,121). 
Monocytes of allergic patients showed increased IL-10 and decreased IL-12 production upon 
HDM and Der p1 stimulation, which enhanced Th2 differentiation (122). Intermediate mono-
cytes of severe asthma patients display higher expression of Protease-Activated Receptor-2 
(PAR-2), a G-coupled receptor activated by proteases as compared to mild/moderate asthma 
patients (121). PAR-2-mediated activation of monocytes induces secretion of IL-1b, IL-6 and 
IL-8 (123), indicating that activation via PAR-2 facilitates secretion of cytokines important for 
Th17 cell differentiation and neutrophil activation and attraction, which does not occur in 
mild/moderate asthmatics.
CliNiCAl iMPliCATioNs
In conclusion, whereas in mice the function of different DC subsets in asthma pathogenesis 
is becoming more and more clear, there are no studies at present that compared the Th2 or 
Th17-priming capacity of different human DC subsets in response to allergens. The limited 
number of DCs in peripheral blood and the difficulty to obtain lung or lung-draining lymph 
nodes, hamper these studies. Current possibilities in single cell analysis will enable analysis of 
these different DC subsets, and provide insights in differences in DC characteristics in asthmat-
ics that display either Th2, mixed Th2/Th17 or Th17-mediated asthma.
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AbsTRACT
background: It is currently unknown, why allergen exposure or environmental triggers in mild 
to moderate asthma patients results in Th2-mediated eosinophilic inflammation, whereas 
severe asthma patients often present with Th17-mediated neutrophilic inflammation. The 
activation state of dendritic cells (DCs) is crucial for both Th2 and Th17-cell differentiation, 
and is mediated through NF-κB activation. Ablation of TNFAIP3, one of the crucial negative 
regulators of NF-κB activation in myeloid cells and DCs was shown to control DC activation.
objective: In this study, we investigated the precise role of TNFAIP3 in myeloid cells for the 
development of Th2 and Th17-cell mediated asthma.
Methods: We exposed mice with conditional deletion of the Tnfaip3 gene in either myeloid 
cells (using the LysM promotor) or specifically in DCs (using the Cd11c promotor) to acute and 
chronic house dust mite (HDM)-driven asthma models.
Results: We demonstrated that reduced Tnfaip3 gene expression in DCs in either Tnfaip3CD11c 
or Tnfaip3LysM mice dose-dependently controlled development of Th17-mediated neutrophilic 
severe asthma in both acute and chronic HDM-driven models, whereas wildtype mice devel-
oped a purely Th2-mediated eosinophilic inflammation. TNFAIP3-deficient DCs induced HDM-
specific Th17-cell differentiation, through increased expression of Th17-instructing cytokines, 
IL-1ß, IL-6 and IL-23, whereas HDM-specific Th2-cell differentiation was hampered by the 
increased IL-12 and IL-6 production.
Conclusions: These data show that the extent of TNFAIP3 expression in DCs controls Th2/Th17-
cell differentiation. This implies that reducing DC activation could be a new pharmacological 
intervention to treat severe asthma patients that present with a Th17-mediated neutrophilic 
inflammation.
DC activation instructs eosinophilic or neutrophilic asthma
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iNTRoDuCTioN
Asthma is a heterogeneous chronic inflammatory disorder of the airways, that can present 
with T helper 2 (Th2) cell driven eosinophilic, Th17-driven neutrophilic, or even agranulo-
cytic inflammation (1). In general, Th2-mediated asthma can be well treated by inhalation of 
corticosteroids, whereas patients that display with Th17-mediated neutrophilic asthma are 
often unresponsive to corticosteroid treatment, resulting in poor disease control and frequent 
exacerbations (2).
Myeloid cells, such as macrophages, monocytes and dendritic cells (DCs) have antigen pre-
senting functions and control naive CD4+ T cell differentiation into effector Th2 and Th17-cells 
in asthma, but also mediate tolerance to inhaled antigens (3,4). Th-cell differentiation depends 
on antigen dosing, expression of co-stimulatory molecules and the cytokine milieu. Th2-cell 
differentiation is favoured with a low antigen dose (5,6) and expression of OX40L and Jagged 
on antigen presenting cells (APCs) (7-10), in a cytokine environment high in interleukin (IL)-4 
and low in IL-12 (11). Conversely, Th17-cell differentiation is induced by a high antigen dose 
(12), expression of CD40 and CD86 (13), and an IL-1β, IL-6, and TGF-β-rich environment (14). 
IL-23 supports the maintenance and function of differentiated Th17-cells (15).
Polarization of antigen-specific naïve T-cells into Th1, Th2 or Th17-cells is a specialized func-
tion of migratory conventional DCs (cDCs) that derive from circulating pre-DCs (3,16). DCs also 
regulate effector T-cell responses, as monocyte-derived DCs (moDCs) control effector T-cell 
responses to allergens in the lungs, due to the production of chemokines that attract effector 
cells to the lungs (3,17).
DC activation is essential for proper Th-cell differentiation into either Th2 or Th17-cells (18). 
Activation of DCs in the context of asthma can occur directly by allergen exposure triggering 
pattern recognition receptors (PRRs) on DCs (19,20). In addition to direct activation, DCs are 
also activated by cytokines secreted by the airway epithelium upon Toll-like receptor 4 (TLR4) 
ligation (21). PRR triggering on DCs activates the transcription factor NF-κB, and thereby initi-
ates transcription of pro-inflammatory cytokines, such as IL-1 and IL-12 (22,23). The activation 
threshold of DCs and NF-κB levels is carefully regulated, as overt activation can lead to immune 
responses to self-antigens in addition to allergens. NF-κB activation is negatively regulated 
by TNFAIP3 (TNFa-induced protein 3, also known as A20), a ubiquitin modifying enzyme that 
deubiquitinates several key intermediate NF-κB signalling molecules, and thus acts as a brake 
on DC activation (24,25). Genetic polymorphisms in TNFAIP3 and TNFAIP3 interacting protein 
(TNIP) have been associated with risk of developing asthma and allergies (26,27). How altera-
tions in TNFAIP3 levels might control asthma development remains enigmatic, as TNFAIP3 has 
very diverse effects in many different cell types. TNFAIP3 controls the production of Th-cell 
skewing cytokines in lung epithelial cells and a high expression (induced by environmental 
exposure to farm dust) is beneficial to protect from allergic asthma development (26). Lack 
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of TNFAIP3 in mast cells controls the activation state of the cell, causing increased plasma ex-
travasation and features of eosinophilic asthma upon allergen challenge (28). The precise role 
of TNFAIP3 in myeloid cells in asthma is currently unknown, however absence of TNFAIP3 in 
myeloid cells or CD11chi DCs provokes Th17 induction (29). These studies indicate that TNFAIP3 
levels in different cell types can control Th-cell differentiation.
As the role of TNFAIP3 in myeloid cells in the development on Th2 immune responses is 
unknown at present, we addressed the precise role of TNFAIP3 in myeloid cells in asthma. To 
determine this, we used mice that lack Tnfaip3 in either myeloid cells or in DCs, and exposed 
these mice to either acute and chronic house dust mite (HDM)-driven asthma models. Our 
data shows that TNFAIP3 levels in DCs control whether HDM induces a predominantly Th2-
mediated eosinophilic or Th17-mediated neutrophilic form of the disease.
MATERiAls AND METHoDs
Mice
Tnfaip3LysM and Tnfaip3CD11c mice were bred and housed at Erasmus MC. Tnfaip3LysM mice were 
crossed to ROSA26flEGFP mice, and Tnfaip3CD11c mice were crossed to IL-23YFP mice. 1-Der mice 
were provided by B.N. Lambrecht (VIB, Ghent, Belgium). Female C57BL/6 mice were from 
Harlan. Experiments were performed on mice backcrossed into C57BL/6 genetic background 
for at least ten generations and housed under SPF conditions. Mice were analysed at 6-12 
weeks of age. All experiments were performed under approval by the animal ethics committee 
of the Erasmus MC.
HDM-induced allergic airway inflammation
During HDM exposures, mice were anesthetized using isoflurane. For the acute allergic HDM 
model, mice were sensitized intranasally with 1 μg/40 μl HDM (Greer) or 40 μl PBS (GIBCO Life 
Technologies) as control on day 1, and challenged on day 7-11 with 10 μg/40 μl HDM. Mice 
were sacrificed on day 15. In the chronic HDM-driven asthma model, mice were treated intra-
nasally with 25 μg/40 μl HDM or 40 μl PBS as control three times per week for five consecutive 
weeks (35). Mice were sacrificed for analysis at day 37. Lung function was measured using a 
whole body plethysmograph (EMKA) under urethane sedation. BAL was obtained by flush-
ing the lungs three times with 1 mL PBS containing 0.5 mM EDTA (Sigma-Aldrich). Lung were 
inflated with either PBS/OCT (1:1) solution and placed in 4% PFA and embedded in paraffin.
HDM-induced innate immune responses and Th-cell polarization
To determine the innate effect of HDM exposure on cytokine production by pulmonary DCs, 
mice were treated with 100 μg of HDM extract intratracheally. 24 hours later, single cell 
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suspensions were obtained from lungs by digesting the lungs using DNAse and Liberase for 
30 minutes at 37°C(3). Upon digesting, the lungs were homogenized through a 100 μm cell 
strainer (BD Biosciences). Red blood cells were lysed using osmotic lysis buffer (8.3% NH4CL, 
1% KHCO3 and 0.04% NA2EDTA in Milli-Q).
To examine Th-cell proliferation and differentiation in naïve HDM-specific T-cells, we adop-
tively transferred 2x106 CFSE-labelled 1-DER T-cells, specific to the Der p 1WAFSGVAAT peptide 
(35) prior to 50 μg of HDM extract. Th-cell proliferation and differentiation were determined 3 
days later by flow cytometry.
generation of bM-Derived DCs
To obtain monocyte-derived DCs, bone marrow (BM) cells were cultured for 9 days in DC 
culture medium (DC-CM, RPMI 1640 containing GlutaMAX (Invitrogen) supplemented with 
5% FCS (Hyclone), 50 μM 2-mercaptoethanol (Sigma) and 50 μg/ml gentamycin (Invitrogen) 
containing 20 ng/ml of GM-CSF, as previously described. 5 μg/mL HDM was added 18 hr prior 
to harvesting the cells.
RNA sequencing
Total RNA was extracted from monocyte-derived DCs using the miRNAeasy mini kit (Qiagen 
Sciences). Approximately 1 ug of RNA from each sample was used to generate RNA-seq cDNA 
libraries for sequencing using the TruSeq RNA sample Prep Kit v2 (Illumina). Sample prepara-
tion followed the manufacturer’s protocol. Sequencing of SR42 bp paired reads was performed 
with an Illumina HiSeq HT instrument at the Bio Informatics department of the Erasmus MC. 
Single-end reads were aligned to the mouse genome (UCSC Genome Browser mm9) using 
TopHat (Tophat version 2.0.8). Gene expression levels as fragments per kilobase of a transcript 
per million mapped reads (FPKMs) were calculated using Cufflinks.
RNA-seq Data Analysis
Differential gene expression assessment was done in the R environment (version 3.1.1) with 
edgeR (version 3.6.8) (52), as earlier described by Nota et al. (53) on TIGR multiexperiment 
viewer (MEV) software (54). MeV software was used to generate heatmaps and principal 
component analysis.
flow cytometry procedures
Single cell suspensions were prepared from BAL and MLN using standard procedures. MLNs 
were homogenized through a 100 μm cell strainer (BD Biosciences). Flow cytometry surface 
and intracellular staining procedures have been described previously (55). Monoclonal an-
tibodies used for flow cytometric analyses are listed in Table S1. For all experiments, dead 
cells were excluded using Live-dead Aqua (Invitrogen). Cytokine production was measured 
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by flow cytometry. To measure cytokine production by T-cells, cells were stimulated at 37°C 
using 10 ng/ml PMA (Sigma-Aldrich), 250 ng/ml ionomycin (Sigma-Aldrich) and GolgiStop (BD 
Bioscience), for 4 hr. To measure cytokine production by DCs, cells were stimulated at 37°C 
with GolgiPlug (BD Biosciences) for 4 hours. Data were acquired using a LSR II flow cytometer 
(Beckton Dickinson) and FACSDivaTM software (Beckton Dickinson) and analysed by FlowJo 
version 9 (Tree Star Inc software).
lung histology
5 um-thick paraffin embedded lung sections were stained with heamatoxylin/eosin.
ElisA
Antigen-specific IgE was measured in serum. Plates were coated overnight with anti-IgE cap-
ture antibody (Opteia, BD Biosciences). Serum was incubated for 2 hours at 37°C. Detection 
was performed using biotinylated-HDM, and streptavidin-HRP was used to develop the ELISA, 
according the manufacturers protocol (Opteia, BD Biosciences). IL-5 (Ready Set Go, eBiosci-
ence), IL-13, IL-17 (R&D systems), and IFNγ (Opteia, BD Biosciences) levels were measured in 
supernatant of HDM restimulated MLN cells. IL-1β (Opteia, BD Biosciences), IL-23 and IL-12p70 
(Ready Set Go, eBioscience) were measured in supernatant of DC cultures, 18 hours after 
stimulation with HDM.
statistical analysis
Mann-Whitney U tests were used for comparison between two groups and a p-value of <0.05 
was considered statistically significant. RNA sequencing analyses were performed using MEV 
software, and all other analysis were performed using Prism (GraphPad Software, USA).
REsulTs
lysM expression targets pulmonary DC subsets
As the lysozyme M promotor is active in several myeloid cell types (30), we crossed Tnfaip3LysM 
mice to Rosa26-stopflEGFP mice, to visualize TNFAIP3 deletion in various myeloid cell types. 
As described before, GFP expression was found in pulmonary macrophages, neutrophils, 
monocytes, and DCs (30) (Figure 1A). LysM-driven cre-recombinase activity in DCs has been 
reported previously (30), but is exceptional as cDCs seem to derive from a dedicated pre-cDC 
progenitor (31,32). Pulmonary DCs can be subdivided into cDCs (CD103+ cDC1s and CD11b+ 
cDC2) and CD64+ moDCs (32). Both moDCs, cDC2s and cDC1s showed similar GFP expression as 
pulmonary monocytes (Figure 1B-C). To determine whether TNFAIP3-deletion would alter the 
proportions of GFP+ cells, GFP expression was determined in Tnfaip3LysM-WT, Tnfaip3LysM-HZ and 
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Tnfaip3LysM-KO mice. The proportions of GFP-expressing cDC2s, moDCs, and monocytes was en-
hanced in Tnfaip3LysM-KOxROSA26flEGFP mice compared with Tnfaip3LysM-WTxROSA26flEGFP mice 
(Figure 1A/1C). Not only the proportions of GFP+ cells increased, also total DCs, cDC1s, and 
moDC numbers were elevated in naïve Tnfaip3LysM-KO mice compared with both Tnfaip3LysM-WT 
and Tnfaip3LysM-HZ mice (Figure 1D).
These data indicate that cre-recombinase under the Lysozyme M promotor not only deletes 
Tnfaip3 in macrophages, monocytes and neutrophils, but also targets pulmonary cDC subsets 
to a similar extent as monocytes. Absence of TNFAIP3 selectively increases the numbers of 
cDC1s and moDCs, indicating that TNFAIP3 deletion in myeloid cells increases their recruit-
ment or survival.
Myeloid specific deletion of Tnfaip3 induces Th17-mediated neutrophilic airway 
inflammation in a HDM-driven model
To address whether TNFAIP3 expression in myeloid cells controls asthma development, we 
used Tnfaip3LysM mice (29) and exposed them to an acute HDM-driven asthma model (Fig-
ure 2A). As expected, HDM-sensitized Tnfaip3LysM-WT mice had increased eosinophils in the 
broncho-alveolar lavage (BAL) compared to PBS-treated controls (Figure 2C). In contrast, 
HDM-sensitized Tnfaip3LysM-KO mice developed only a very mild eosinophilic inflammation, 
but neutrophilic inflammation was strongly increased compared to WT controls. Moreover, 
using Tnfaip3LysM-HZ mice, a gene dose effect was observed, as these mice developed a mixed 
eosinophilic/neutrophilic inflammation (Figure 2C). T-cells, B-cells, DC, and macrophages influx 
did not differ between Tnfaip3LysM-WT and Tnfaip3LysM-KO mice, yet B cells were increased in HDM-
sensitized Tnfaip3LysM-HZ mice compared to HDM-sensitized Tnfaip3LysM-WT and Tnfaip3LysM-KO mice 
(Figure 2D-E).
Eosinophilia is generally associated with a type 2 immune response, whereas neutrophilia is 
a sign of IL-17-producing cells. Whereas in BAL fluid of HDM-sensitized Tnfaip3LysM-WT mice the 
numbers of IL-13-expressing Th2-cells were increased, Tnfaip3LysM-KO mice mainly showed an 
increase in IL17-expressing Th17 and interferon γ (IFNg)-expressing Th1-cells.
IL-17/IFNg-double-expressing CD4 T-cells were not induced (data not shown). Tnfaip3LysM-HZ 
mice had elevated numbers of Th2-cells compared to Tnfaip3LysM-WT and Tnfaip3LysM-KO mice, 
and similar numbers of Th17-cells compared to Tnfaip3LysM-KO mice (Figure 2F). Effector T cells 
are typically found in the lungs, whereas central memory T cells are found in lung draining 
mediastinal lymph nodes (MLN). IL-17 and IFNγ secretion were also increased in in vitro HDM-
restimulated MLN cells of HDM-sensitized Tnfaip3LysM-KO mice compared with both Tnfaip3LysM-WT 
and Tnfaip3LysM-HZ mice. IL-13 levels were elevated in in vitro HDM-restimulated MLN cells of 
HDM-sensitized Tnfaip3LysM-HZ mice compared with HDM-sensitized Tnfaip3LysM-WT mice (Figure 
2G).
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In summary, ablation of TNFAIP3 levels in myeloid cells dose dependently induces a neutro-
philic, Th17-mediated airway inflammation rather than a Th2-mediated eosinophilic airway 
inflammation in an HDM-driven asthma model.
Tnfaip3lysM-ko mice develop severe asthma upon chronic HDM exposure
Uncontrolled severe asthma patients display increased neutrophil numbers, IL-17 levels in 
serum and BAL fluid, and increased airway remodelling (33). To more closely mimic severe 
asthma and to induce structural airway remodelling in mice, we exposed Tnfaip3LysM mice to 
HDM over period of 5 weeks (Figure 3A) (34). Upon chronic HDM exposure, eosinophilic and 
B-cell inflammation was increased in both Tnfaip3LysM-WT and Tnfaip3LysM-KO mice compared to 
PBS controls. Neutrophils and total T-cell numbers were higher in HDM-treated Tnfaip3LysM-KO 
mice compared to HDM-treated Tnfaip3LysM-WT mice (Figure 3C-D). No differences were found 
Th2-cell numbers in BAL fluid of Tnfaip3LysM-WT and Tnfaip3LysM-KO mice, whereas Th17 and 
Th1-cell numbers were strongly increased in Tnfaip3LysM-KO mice compared with HDM-treated 
Tnfaip3LysM-WT (Figure 3E). Serum levels of HDM-specific IgE were similar between HMD-treated 
Tnfaip3LysM-WT and Tnfaip3LysM-KO mice (Figure 3F). HDM-treated Tnfaip3LysM-KO mice showed 
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figure 1: lysM expression targets all pulmonary DC subsets. (A) Gating strategy for different pulmonary DC 
subsets using flow cytometry. (B) Percentage GFP positive cells within the gated population. (C) Percentage GFP 
positive cells within the gated population in Tnfaip3LysM-WT, Tnfaip3LysM-HZ and Tnfaip3LysM-KO mice. (D) Quantifica-
tion of total DCs, cDC1s, cDC2s, and moDCs by flow cytometry. Results are presented as mean ±SEM of n=4 per 
group and representative of two or more independent experiments. * = p<0.05, ** = p<0.01, *** = p<0.001.
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denser pulmonary infl ammatory sites compared to HDM-treated Tnfaip3LysM-WT mice (Figure 
3G). Despite the absence of clear diff erences in the airway hyperresponiveness (AHR) causing 
cytokine IL-13-expressing CD4+ T-cells, lung resistance was surprisingly higher in HDM-treated 
Tnfaip3LysM-KO mice compared to HDM-exposed Tnfaip3LysM-WT mice (Figure 3H).
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figure 2: Myeloid specifi c deleti on of Tnfaip3 induces Th17 neutrophilic asthma upon an acute HDM-driven 
asthma protocol. (A) Mice were sensiti zed i.n. with PBS or 1 μg HDM on day 0 and challenged i.n. with 10 μg 
HDM daily between days 7 and 11 to induce allergic asthma. Analysis was performed at day 15. (B-E) Quanti fi ca-
ti on of total BAL infl ammati on, eosinophils, neutrophils, DCs, macrophages, B-cells and T-cells by fl ow cytom-
etry. (F) Number of IL-13+, IL-17+ and IFNγ+ CD4+ T-cells in the BAL were analysed by fl ow cytometry. (G) Quanti -
fi cati on of IL-13, IL-17 and IFNγ in supernatant of HDM-resti mulated MLN cells by ELISA. Results are presented 
as mean ±SEM of n=4-7 per group and representati ve of two or more independent experiments. * = p<0.05, ** 
= p<0.01, *** = p<0.001.
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In conclusion, upon chronic HDM exposure, absence of TNFAIP3 in myeloid cells induces 
development of a severe Th2/Th17-cell-mediated eosinophilic and neutrophilic asthma phe-
notype with severe airway remodelling and increased AHR.
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figure 3: Tnfaip3lysM-ko mice develop severe corti costeroid resistant asthma upon chronic HDM exposure. (A) 
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p<0.05, ** = p<0.01, *** = p<0.001.
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DC-specific deletion of Tnfaip3 also induces Th17-mediated neutrophilic asthma
As shown before, deletion of Tnfaip3 using the LysM promotor affected many cell types, 
including neutrophils that accumulated in the airways of Tnfaip3LysM-KO mice after HDM chal-
lenge. To specify whether reduced TNFAIP3 levels only in CD11chi DCs were responsible for 
the development of Th17-mediated neutrophilic asthma phenotype, we exposed Tnfaip3CD11c 
mice to the acute HDM-driven asthma protocol. In these mice, Tnfaip3 is specifically deleted 
in all DC subsets and alveolar macrophages as previously shown by Kool et al (25). HDM-
sensitized Tnfaip3CD11c-KO mice were resistant to development of eosinophilic inflammation, yet 
a strong neutrophilic inflammation was induced compared with HDM-sensitized WT controls. 
Like the Tnfaip3LysM-HZ mice, HDM-treated Tnfaip3CD11c-HZ mice developed a mixed eosinophilic/
neutrophilic inflammation (Figure 4A-B). Numbers of T-cells and macrophages in BAL were not 
BAL
Eosinophils
0
200
400
600
800
*
*
**
p=0.057
C
el
l n
um
be
rs
 (1
03
)
BAL
Neutrophils
0
10
20
30
40
**
p=0.057
BAL
T cells
0
20
40
60
80
C
el
l n
um
be
rs
 (1
03
)
*
p=0.057
BAL
B cells
0
20
40
60
80
*
*
**
p=0.057
BAL 
Total cells
0
500
1000
1500
*
*
**
p=0.057
p=0.057
C
el
l n
um
be
rs
 (1
03
)
Figure 4: CD11c data Acute
Tnfaip3CD11c-WT  PBS
Tnfaip3CD11c-WT  HDM
Tnfaip3CD11c-HZ  PBS
Tnfaip3CD11c-HZ  HDM
Tnfaip3CD11c-KO  PBS
Tnfaip3CD11c-KO  HDM
A B
D BAL
CD4+ T cells
Th2 Th17 Th1
0
0.5
1.0
1.5
2.0
(IL-13+) (IFNγ+)(IL-17A+)
C
el
l n
um
be
rs
 (1
03
)
0.066 * *
**
0.057
*
0.066
*
E
BAL
DCs
0
2
4
6
8
10
*
*
**
p=0.057
C
el
l n
um
be
rs
 (1
03
)
BAL 
Macrophages
0
100
200
300
p=0.057
C
IL-13
0
5
10
15
*
n
g/
m
l
IL-17A
0
500
1000
1500
pg
/m
l
IFNγ
0
50
100
150
*
pg
/m
l
F
figure 4: DC specific deletion of Tnfaip3 also induces Th17 mediated neutrophilic asthma. (A-D) Quantification 
of total BAL inflammation, eosinophils, neutrophils, DCs, macrophages, B cells and T-cells by flow cytometry. (E) 
Number of IL-13+, IL-17+ and IFNγ+ CD4+ T-cells in the BAL were analysed by flow cytometry. (F) Quantification 
of IL-13, IL-17 and IFNγ in supernatant of HDM-restimulated MLN cells by ELISA. Results are presented as mean 
±SEM of n=3-7 per group and representative of two or more independent experiments. * = p<0.05, ** = p<0.01, 
*** = p<0.001.
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significantly different between HDM-sensitized Tnfaip3CD11c-WT, Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO 
mice, but B cells and DCs were reduced in HDM-sensitized Tnfaip3CD11c-KO mice compared with 
both HDM-sensitized Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice (Figure 4C-D). Th2-cell numbers in 
BAL fluid of HDM-sensitized Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice were increased compared 
to HDM-sensitized Tnfaip3CD11c-KO mice. HDM-sensitized Tnfaip3CD11c-KO mice showed increased 
Th17-cells in BAL fluid compared to HDM-sensitized Tnfaip3CD11c-WT mice (Figure 4E). MLN cells 
of both HDM-sensitized Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice produced IL-13 in response to 
HDM-restimulation in vitro, whereas no IL-13 production was found in HDM-restimulated MLN 
cells of HDM-sensitized Tnfaip3CD11c-KO mice. IL-17A levels were higher in HDM-restimulated 
MLN cells of HDM-sensitized Tnfaip3CD11c-KO mice than of HDM-sensitized Tnfaip3CD11c-WT mice 
(Figure 4F).
Therefore, we conclude that specific ablation of TNFAIP3 in CD11chi DCs (and/or alveolar 
macrophages), but not in neutrophils, induces development of Th17-mediated neutrophilic 
airway inflammation.
instruction of Th17 differentiation of HDM-specific T-cells by Tnfaip3-deficient DCs
To investigate more directly whether Tnfaip3CD11c-KO mice induced HDM-specific Th17 differ-
entiation, Tnfaip3CD11c mice received Der p1-specific TCR transgenic (Tg) CD4+ T cells obtained 
from 1-DER mouse intravenously. 1-DER CD4+ T cells transgenitically express TCRs encoding a 
Vβ4 and Vα8 chain, leading to a precursor frequency of 60-70% of Der p1-reactive CD4+ T cells 
(35).
1-DER CD4+ T-cells were transferred into Tnfaip3CD11c mice at day 0 and subsequently treated 
with 50 μg HDM intra-tracheally at day 1 (Figure 5A). At day 4, 1-DER T-cells that were trans-
ferred into Tnfaip3CD11c-KO mice showed reduced proliferation in the MLN, compared with those 
transferred into Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice (Figure 5B-5C). However, the replication 
index in the dividing 1-DER T-cells in Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO mice was increased com-
pared to dividing 1-DER T-cells in Tnfaip3CD11c-WT mice (Figure 5D). Indicating that once 1-DER 
T-cells start proliferation, the amount of proliferation cycles is higher in Tnfaip3CD11c-KO mice 
compared to Tnfaip3CD11c-WT mice.
The expression of lineage defining transcription factors like RORgT, GATA3 and T-bet were 
used to study differentiation of Th17, Th2 and Th1-cells, respectively. Strikingly, the percent-
age of RORgT+ 1-DER T-cells was increased in both undivided and divided 1-DER T-cells in 
Tnfaip3CD11c-KO mice compared to both Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice (Figure 5E-F). The 
MFI of GATA3 and T-bet was elevated in divided 1-DER T-cells compared to undivided 1-DER 
T-cells in all mice, however both undivided as divided 1-DER T-cells in Tnfaip3CD11c-KO mice had 
decreased levels of GATA3 compared with Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice (Figure 5F). 
No differences were found in the expression levels of T-bet in 1-DER T-cells in Tnfaip3CD11c-WT, 
Tnfaip3CD11c-HZ, and Tnfaip3CD11c-KO mice (Figure 5F).
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This indicates that HDM induces Th17-cell diff erenti ati on of Der p1-specifi c T-cells in 
Tnfaip3CD11c-KO mice that lack TNFAIP3 expression in DCs and alveolar macrophages, whereas in 
wild type mice it predominantly induces a Th2 response.
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figure 5: HDM specifi c diff erenti ati on of Th17-cells by Tnfaip3 defi cient DCs. (A) Scheme for intravenous trans-
fer of CFSE labelled 1-DER T-cells into Tnfaip3CD11c mice and subsequent exposure to HDM intranasal at indicated 
ti me points. Analysis was performed at day 5. (B) Flow cytometric gati ng of proliferati ng 1-DER T-cells in the 
MLN. (C) Quanti fi cati on of the % proliferati ng 1-DER T-cells in the MLN by fl ow cytometry. (D) Flow cytometric 
gati ng of RORγT+ dividing 1-DER T-cells in the MLN. (E) Percentage of RORγt+ Th17-cells within the undivided and 
divided 1-DER T-cell populati on in the MLN by fl ow cytometry. (F) Quanti fi cati on of the MFI of GATA3 and T-bet 
in undivided and divided 1-DER T-cells in the MLN by fl ow cytometry. Results are presented as mean ±SEM of 
n=4 per group. * = p<0.05, ** = p<0.01, *** = p<0.001.
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Adoptive transfer of Tnfaip3-sufficient or deficient DCs drives eosinophilic or 
neutrophilic asthma
The Cd11c promotor used to excise Tnfaip3 can also lead to excision of this gene in other cells 
like alveolar macrophages, CD8 T-cells, plasmacytoid DCs and plasmablasts, caused by Cd11c 
gene expression in these cell types (36). We therefore resorted to a model of intra-tracheal 
adoptive transfer of bone marrow (BM)-derived DCs to induce asthma (37). This would exclude 
any effects due to expression outside the DC lineage. It became clear that GM-CSF-stimulated 
BM cultures contains a mix of cDCs and macrophage-like cells, but we did not observe large 
shifts in the relative distribution of these cell subsets in cultures of mice of different genotypes 
(Figure S1) (38). GM-CSF BM-cultured Tnfaip3KO DCs lacked expression of exon 4 and 5 of the 
Tnfaip3 gene, preventing formation of functional TNFAIP3 protein, and confirming effective 
Cre-mediated recombination in vitro (Figure S2). We intra-tracheally sensitized C57BL/6 mice 
by adoptive transfer of HDM or PBS-stimulated BM-derived DCs from Tnfaip3CD11c-WT and 
Tnfaip3CD11c-KO mice, followed by 5 HDM challenges (Figure 6A). As previously reported in this 
model when mice were sensitized with ovalbumin-stimulated DCs, C57BL/6 mice sensitized 
with HDM-stimulated Tnfaip3WT DCs developed an increased eosinophilic airway inflammation 
both in absolute numbers as in percentages compared to mice sensitized with PBS-stimulated 
Tnfaip3WT DCs (Figure 6B). Eosinophilic inflammation was not induced in mice sensitized with 
HDM-stimulated Tnfaip3KO DCs. Neutrophilic inflammation was increased in absolute count 
in mice sensitized with HDM-stimulated Tnfaip3WT and Tnfaip3KO DCs, but was not different 
between mice sensitized with HDM-stimulated Tnfaip3WT or Tnfaip3KO DCs (Figure 6C). Mice 
that received HDM-stimulated Tnfaip3KO DCs had a decreased percentage of Th2-cells and 
an increased percentage of Th17-cells in BAL compared with HDM-stimulated Tnfaip3WT DC-
sensitized mice. The percentage of IFNg-expressing CD4+ T-cells was not different between all 
mice (Figure 6D).
In conclusion, HDM-stimulated Tnfaip3KO DCs specifically induce Th17-cell differentiation 
above Th2-cell differentiation, resulting in an absence of eosinophilic inflammation.
Tnfaip3ko DCs display a pro-Th17-cell signature upon HDM stimulation in vitro and in 
vivo
To gain insight into the mechanism by which Tnfaip3KO DCs induced Th17-cell differentiation, 
we performed gene expression profiling of PBS or HDM-stimulated GM-CSF BM-cultured 
Tnfaip3WT and Tnfaip3KO DCs. Both unstimulated as HDM-stimulated GM-CSF BM-cultured 
Tnfaip3WT and Tnfaip3KO DCs differed in their expression profile as observed in the Principal 
Component Analysis (PCA) (Figure 7A). In the unstimulated situation, 934 genes were differ-
entially expressed between Tnfaip3WT and Tnfaip3KO DCs (Figure S3), whereas 1290 genes were 
differentially expressed upon HDM stimulation in either Tnfaip3WT or Tnfaip3KO DCs (Figure S4). 
Of these 1290 genes, 1054 were differentially expressed in HDM versus unstimulated Tnfaip3WT 
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DCs, 174 genes in both Tnfaip3WT and Tnfaip3KO DCs, and 62 genes only in Tnfaip3KO DCs (Figure 
7B). Clustering of these 1290 genes, revealed that multi ple genes involved in Th17 diff erenti a-
ti on, such as IL-6 and IL-1β were upregulated upon HDM sti mulati on specifi cally in Tnfaip3KO 
DCs. Also CXCL3, a known chemoatt ractant for neutrophils was increased in HDM-sti mulated 
Tnfaip3KO DCs (39). Furthermore, IL-12b, a cytokine known to inhibit Th2 diff erenti ati on when 
expressed in DCs (40) was specifi cally induced in HDM-sti mulated Tnfaip3KO DCs (Figure 7C-D). 
IL-1β, IL-23 and IL-12 protein expression in culture supernatants of BM-derived DC cultures was 
also increased upon HDM sti mulati on, whereas IL-6 protein expression was already increased 
in unsti mulated GM-CSF BM-cultured Tnfaip3KO DCs compared to HDM-sti mulated GM-CSF 
BM-cultured Tnfaip3WT DCs (Figure 7E).
Since GM-CSF-cultured DCs displayed a Th17-cell-promoti ng phenotype upon HDM sti mula-
ti on in vitro, we wondered whether Th17-cell diff erenti ati on instructi ve cytokines would also 
be increased in DCs of Tnfaip3CD11c mice that received HDM in vivo. To determine this, IL-23YFP 
mice were crossed to Tnfaip3CD11c mice, generati ng IL-23YFPxTnfaip3CD11c mice.
IL-23YFPxTnfaip3CD11c mice received an intranasal administrati on of 100 mg of HDM and 
cytokine expression by diff erent pulmonary DC subsets was determined 24 hours later. The 
numbers of IL-6 and IL-23 producing moDCs in IL-23YFPxTnfaip3CD11c-KO mice was increased 
compared to IL-23YFPxTnfaip3CD11c-WT mice (Figure 8A-B). cDC2s in IL-23YFPxTnfaip3CD11c-KO mice 
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figure 6: Adopti ve transfer of Tnfaip3-suffi  cient or defi cient DCs drives eosinophilic or neutrophilic asthma. 
(A) C57bl/6 mice were sensiti zed on day 1 i.n. with 30.000 PBS/HDM sti mulated GM-CSF cultured DCs from bone 
marrow of Tnfaip3CD11c mice. All mice were challenged i.n. with 10 μg HDM daily between days 7 and 11 to induce 
allergic asthma. Analysis was performed at day 15. (B-C) Quanti fi cati on of total BAL infl ammati on, eosinophils, 
neutrophils by fl ow cytometry. (D) Number of IL-13+, IL-17+ and IFNγ+ CD4+ T-cells in the BAL were analysed by 
fl ow cytometry. Results are presented as mean ±SEM of n=4-6 per group and are representati ve of two indepen-
dent experiments. * = p<0.05, ** = p<0.01, *** = p<0.001.
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figure 7: gM-Csf cultured Tnfaip3ko DCs display a Th17-instructive signature after HDM stimulation. (A) Prin-
cipal Component Analysis of PBS/HDM stimulated GM-CSF BM-cultured Tnfaip3WT and Tnfaip3KO DCs. (B) RNA 
sequencing analysis of total mRNA from PBS/HDM stimulated GM-CSF BM-cultured DCs. EdgeR analysis identi-
fied 1290 significantly different genes. (C) MeV hierarchical clustering of a selection of the 1290 differentially 
expressed genes are represented in the heatmap. (D) FPKM values of PBS/HDM stimulated GM-CSF BM-cultured 
DCs. (E) Analysis of IL1β, IL23, IL-6 and IL12 in supernatant of PBS/HDM stimulated GM-CSF bone marrow cul-
tured DCs using ELISA. Results are presented as mean ±SEM of n=4-6 per group. * = p<0.05, ** = p<0.01, *** = 
p<0.001.
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only had significantly increased IL-23 production, whereas IL-6 and IL-23 production was not 
different between cDC1s in IL-23YFPxTnfaip3CD11c-WT and IL-23YFPxTnfaip3CD11c-KO mice (Figure 8B).
In summary, these data show that Tnfaip3-deficient moDCs and cDC2s express increased 
levels of cytokines that promote Th17 differentiation in response to HDM.
DisCussioN
Asthma is a heterogeneous disorder. Mild to moderate asthma patients often display Th2-
cell-mediated eosinophilic inflammation, whereas severe asthma patients often present 
Th17-cell-mediated neutrophilic inflammation (1). DCs are essential for both the initiation and 
maintenance of Th2-cell-mediated asthma, and can also induce pulmonary Th17-cell responses 
(41,42). However, the underlying mechanisms driving Th17-cell-driven neutrophilic asthma are 
still undetermined. We and others have previously shown that DCs activation is crucial for 
Th-cell differentiation and activation, and is mediated through NF-κB activation driving expres-
Figure 8: increased expression of Th17 polarizating cytokines in IL-23YFP x Tnfaip3CD11c-KO mice
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figure 8: MoDCs and cDC2s in il-23yfPxTNFAIP3CD11c-ko mice display a pro-Th17-signature upon HDM stimula-
tion in vivo. (A) Flow cytometric gating of IL-6 and IL-23 producing pulmonary DCs in IL-23YFPxTnfaip3CD11c mice 
24 hours after HDM exposure. (B) Quantification of total IL-6-producing and IL-23-producing pulmonary DCs. 
Results are presented as mean ±SEM of n=2-4 mice per group. Similar results were found in Tnfaip3LysM mice. * 
= p<0.05, ** = p<0.01, *** = p<0.001.
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sion of key cytokine pathways. Ablating the negative feedback regulator of NF-κB signalling, 
TNFAIP3, in myeloid cells and DCs was shown to be essential for Th17 differentiation (25,29).
Our results demonstrate that TNFAIP3 levels in DCs control development of Th17-cell-
mediated neutrophilic asthma in an acute HMD-driven asthma model, and a mixed Th2/
Th17-mediated severe eosinophilic/neutrophilic asthma upon a chronic HDM-driven asthma 
model. TNFAIP3-deficient DCs induced HDM-specific Th17-cell differentiation and hampered 
HDM-specific Th2-cell differentiation. TNFAIP3-deficiency in specifically cDC2s and moDCs 
increased their potential to produce cytokines implicated in Th17-cell differentiation, such as 
IL-1ß, IL-6 and IL-23, whereas IL-12 is known to inhibit Th2 differentiation (43). IL-6 secretion by 
DCs is also known to hamper Th2 differentiation (44), either directly through inhibiting GATA3 
expression, or indirectly by restricting IL-4 expression by follicular Th-cells (45). This indicates 
that both IL-12 as IL-6 could explain why development of Th2 immunity was hampered.
Ablating TNFAIP3 expression in DCs increased AHR upon chronic exposure to HDM, whereas 
the AHR-inducing cytokine IL-13 was similar between KO and WT mice, however IL-17 levels 
are specifically increased in mice lacking TNFAIP3 in DCs. Transfer of both Th2 as Th17-cells 
has been shown to elicit AHR (46), suggesting that combined expression of Th2 and Th17-cell 
cytokines can further enhance AHR. Furthermore, suppression of IL-13 and IL-17 simultane-
ously decreases AHR more efficiently (47).
Sensitization of C57BL/6 mice by TNFAIP3-deficient DCs also induced Th17-cell differentia-
tion, suggesting that our observed phenotype was indeed due to genetic alterations selectively 
in DCs, and not in neutrophils.
Our data indicate that TNFAIP3 levels directly control secretion of Th17-polarizing cytokines 
in moDCs and cDC2s, whereas these cytokines are not increased in cDC1s. This together with 
the fact cDC2s and moDCs are essential for Th2 differentiation and maintenance in asthma 
(41), shows that these DC subsets are crucial for the balance of Th2/Th17-cell differentiation 
in asthmatic lungs.
Ablation of TNFAIP3 in DCs results in constitutive NF-κB activation (25,48). NF-κB directly 
promotes transcription of pro-inflammatory Th17 differentiation target genes IL-1β and IL-6 
(49), which indicates that TNFAIP3 deletion in DCs directly enables the transcription of Th17-
promoting cytokines through increased NF-κB signalling.
Now that we have established that intrinsic levels of TNFAIP3 in DCs can determine the 
type of allergen-induced inflammation, it will be important to understand how this pathway 
is regulated in DCs, and can be manipulated in the future. First, SNPs in the TNFAIP3 gene 
as well as its binding partner TNIP1 are associated with asthma and allergy development in 
at least 2 genetic association studies, suggesting that an important aspect of this pathway 
might be genetically regulated (26,27). It is conceivable that, environmental triggers might 
also alter Tnfaip3 expression in DCs, as combined exposure with allergens and environmental 
factors (such as diesel exhaust particles, cigarette smoke and viral infections) are essential for 
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DC-induced Th17-mediated severe asthma, by induction of Th17-cell differentiating cytokines 
(18,50). It will thus be very important to study if any of these environmental co-regulators 
might suppress TNFAIP3 gene and/or protein expression in DCs. There is already evidence for 
such environmental regulation of TNFAIP3 in lung epithelial cells in vivo (26). TNFAIP3 seems 
to be strongly regulated by microRNAs (mir125 family and mir221) (51), and microRNA levels 
can vary greatly in response to chronic environmental stimulation.
In conclusion, our data demonstrate that loss of TNFAIP3 specifically in pulmonary cDC2s 
and moDCs, amplifies NF-κB-controlled gene expression of IL-6 and IL-23 in response to 
allergen exposure. Increase in these Th17-cell-polarizing cytokines promotes Th17-cell dif-
ferentiation and Th17-cell-mediated severe neutrophilic asthma phenotype, accompanied 
by increased lung resistance. As a result, our data imply that increasing TNFAIP3 levels and 
thereby decreasing DC activation could be a new pharmacological intervention to treat severe 
Th17-cell-mediated neutrophilic asthma.
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Supplementary Figure 1: Composition of moDCs and cDCs in GM-CSF cultured BM-DCs
supplementary figure 1: Composition of moDCs and cDCs in gM-Csf cultured bM-DCs. Flow cytometric analy-
sis of the composition of moDCs and cDCs in GM-CSF cultured BM-DCs.
Tnfaip3WT DCs
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Figure S2: Exon 4 and 5 are deleted in Tnfaip3KO DCs 
supplementary figure 2: Deletion of exon 4 and 5 in TNfAiP3-deficient gM-Csf cultured bM DCs. Reads of 
RNA sequencing of total mRNA from GM-CSF BM-cultured Tnfaip3WT and Tnfaip3KO DCs mapped to Tnfaip3 gene, 
visualized with IGV.
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supplementary figure 3: Heatmap of differentially expressed genes between unstimulated TNfAiP3-sufficient 
and TNfAiP3-deficient gM-Csf cultured bM DCs. RNA sequencing analysis of total mRNA from unstimulated 
GM-CSF BM-cultured DCs. EdgeR analysis identified 934 significantly different genes. Gene expression differ-
ences are represented in the heatmap based on MeV hierarchical clustering.
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supplementary figure 4: Heatmap of differentially expressed genes between house dust mite and unstimu-
lated TNfAiP3-sufficient and TNfAiP3-deficient gM-Csf cultured bM-DCs. RNA sequencing analysis of total 
mRNA from PBS/HDM stimulated GM-CSF BM-cultured DCs. EdgeR analysis identified 1290 significantly differ-
ent genes. Gene expression differences are represented in the heatmap based on MeV hierarchical clustering.
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Table s1: Antibodies used for flowcytometryTable	S1	 ntibodies	used	f r	flow	cytometry
Antibody Conjugate Clone Company
CD103 eF450 2E7 eBioscience
CD11b PerCP-Cy5.5 M1/70 BD	Biosciences
CD11c PE-TxR N418 eBiosciences
CD19 APC-eFluor	780 ID3 eBiosciences
CD3 PE-CF594 145-2C11 BD	Biosciences
CD3 APC-eF780 17A2 eBiosciences
CD4 BV711 RM4-5 BD	Biosciences
CD4 BV605 L3T4 BD	Biosciences
CD45.1 APC-Cy7 A20 BD	Biosciences
CD45.2 BV711 104 BD	Biosciences
CD64 BV711 X54-5/7.1 Biolegend
CD8 PE-Cy7 53-6.7 eBioscience
FoxP3 PE-Cy7 FJK-16s eBioscience
GATA3 APC TWAJ-14 eBioscience
GR-1 Pe-Cy7 RB6-8C5 eBiosciences
IFNy EF450 XMG1.2 eBioscience
IL-13 EF660 eBio13A eBioscience
IL-17A AF700 TC11-18H10.1 BD	Biosciences
IL-5 PE TRFK-5 BD	Biosciences
IL-6 PE MP5-20F3 BD	Biosciences
MHCII Alexa	Fluor	700 M5/114.15.2 eBiosciences
RoRgt PE Q31-378 BD	Biosciences
Siglec	F PE E50-2440 BD	Biosciences
T-bet eF450 O4-46 BD	Biosciences
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AbsTRACT
background: Asthma is a heterogeneous disease of the airways that involves several types of 
granulocytic inflammation. Recently, we have shown that the activation status of myeloid cells 
regulated by the enzyme TNFAIP3/A20 is a crucial determinant of eosinophilic or neutrophilic 
airway inflammation. However, whether neutrophilic inflammation is dependent on IL-17 
remains unknown.
objective: In this study, we investigated the importance of IL-17RA-signalling in the develop-
ment of eosinophilic or neutrophilic inflammation in house dust mite (HDM)-driven airway 
inflammation.
Methods: Tnfaip3fl/flxLyz2+/cre (Tnfaip3LysM-KO) mice were crossed to Il17raKO mice, generating 
Tnfaip3LysMIl17raKO mice and exposed to an HDM-driven airway inflammation model.
Results: Both eosinophilic and neutrophilic inflammation observed in HDM-exposed WT and 
Tnfaip3LysM-KO mice respectively, was reduced but not abrogated in the absence of IL-17RA. 
Mucus-producing cells in Tnfaip3LysM-KOIl17raKO mice were reduced compared to their controls. 
Production of IL-5, IL-13 and IFNg by CD4+ T cells was similar between WT and Il17raKO mice, 
whereas IFNg-expressing CD4+ T cells increased in Tnfaip3LysM-KOIl17raKO mice. Strikingly, a spon-
taneous accumulation of pulmonary Th17 and γδ-17 T cells was observed in Tnfaip3LysM-KOIl-
17raKO mice compared to all other genotypes. This coincided with increased IL-23 expression 
in the lungs of HDM-exposed Tnfaip3LysM-KOIl17raKO mice.
Conclusion/Discussion: IL-17RA-signalling is dispensable for the development of HDM-
induced eosinophilic or neutrophilic airway inflammation, however not for mucus production. 
Strikingly, defective IL-17RA-signalling combined with activated Tnfaip3-deficient myeloid cells 
leads to spontaneous accumulation of pulmonary Th17 and γδ-17 T cells, probably due to high 
local IL-23 production. This model could be exploited to study spontaneous differentiation and 
accumulation of pulmonary Th17 and γδ-17 T cells.
Neutrophilic airway inflammation is IL-17-independent
115
5
iNTRoDuCTioN
Asthma is characterized by reversible airway obstruction, airway remodelling and mucus 
production, together with increased pulmonary inflammation (1). Granulocytic cells observed 
in pulmonary inflammation of asthmatic patients can comprise eosinophils, neutrophils, or a 
mixture of both cell types (2). Eosinophilic inflammation is induced by interleukin (IL)-5, a type 
2 cytokine produced by both Th2 cells and innate lymphoid cells type 2 (ILC2s) (3). Neutrophilic 
inflammation is triggered by IL-8 produced by airway epithelial cells after activation by IL-17 
(4). IL-17 furthermore contributes to asthma symptoms as it induces airway remodelling by 
promoting fibroblast proliferation, reduces apoptosis of smooth muscle cells, and increases 
the expression of mucin genes in airway epithelial cells (5-7). Th17 cells primarily produce 
IL-17 and Th17-mediated neutrophilic inflammation is particularly found in late-onset asthma 
patients with a severe phenotype (8,9). Unfortunately, severe asthma patients are often un-
responsive to corticosteroid treatment, leading to frequent asthma exacerbations and higher 
morbidity (10). Neutrophils and Th17 cells are likely contributing to this phenotype, as both 
cell types are corticosteroid insensitive (11-13). Therefore, it is imperative to investigate the 
contribution of IL-17-signalling to the development of asthma.
Dendritic cell (DC) activation is essential for Th cell differentiation as antigen load, expres-
sion of costimulatory molecules, and DC-derived cytokines determine whether Th2 or Th17 
cell differentiation is induced (14). Recently, we found that increasing the activation status of 
DCs by ablation of the Tnfaip3/A20 gene in myeloid cells induced a neutrophilic inflammation 
in house dust mite (HDM)-mediated asthma protocols (Chapter 4). TNFAIP3 (TNFa-induced 
protein 3, also known as A20) is a ubiquitin modifying enzyme that deubiquitinates several key 
intermediate NF-κB signalling molecules, and thereby controls NF-κB-mediated cell activation 
(15). TNFAIP3 expression in myeloid cells controls development of rheumatoid arthritis (RA), as 
TNFAIP3 depletion in myeloid cells induces spontaneous development of RA (16).
To gain better insight into the role of IL-17 in HDM-driven neutrophilic airway inflammation, 
we crossed myeloid-specific Tnfaip3 knockout mice (Tnfaip3LysM mice) (16) to Il17raKO mice, 
generating Tnfaip3LysMIl17raKO mice, in which IL-17A, IL-17E and IL-17F-signalling is disabled 
(17). We found that the absence of IL-17RA-signalling does not significantly affect eosinophilic 
or neutrophilic inflammation, whereas it does hamper hyperplasia of mucus-producing goblet 
cells. Strikingly defective IL-17RA-signalling in combination with increased activation of my-
eloid cells by TNFAIP3/A20 depletion induces a spontaneous accumulation of Th17 cells and 
γδ-17 T cells in the airways.
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MATERiAls AND METHoDs
Mice
Male and female C57BL/6 mice harbouring a conditional Tnfaip3 allele between LoxP-flanked 
sites (18) were crossed to transgenic mice expressing the Cre recombinase under the LysM 
promotor (19), generating Tnfaip3fl/flxLyz2+/cre mice16 (Tnfaip3LysM-KO mice). Tnfaip3fl/flLyz2+/+ 
littermates (wild type (WT) mice) were used as controls. Tnfaip3LysM mice were crossed with 
Il17raKO mice (4), creating Tnfaip3fl/flxLyz2+/crexIl17ra-/- (Tnfaip3LysM-KOIl17raKO mice) and Tn-
faip3fl/flxLyz2+/+xIl17ra-/- mice (Il17raKO mice). Mice were housed under specific pathogen-free 
conditions and were analysed at ~8 weeks (naïve and house dust mite (HDM) experiments) 
or at ~18 weeks (arthritis experiments). All experiments were approved by the animal ethical 
committee of the Erasmus MC, Rotterdam, The Netherlands.
HDM-induced allergic airway inflammation
During intranasal (i.n.) exposures, mice were anesthetized using isofluorane. On day 0, mice 
were sensitized with 1 μg/40 μL HDM (Greer Laboratories Inc, Lenoir, NC, USA) i.n. or with 40 
μL PBS (GIBCO Life Technologies, Carlsbad, CA, USA) as a control and challenged with 10 μg/40 
μl HDM on days 7-11. Four days after the last challenge, bronchoalveolar lavage (BAL), lung, 
and mediastinal lymph node (MLN) were collected.
Cell suspension preparation
BAL was obtained by flushing the lungs three times with 1 mL PBS containing 0.5 mm EDTA 
(Sigma-Aldrich, St. Louis, MO, USA). The right lung was inflated with either 1:1 PBS/Tissue-TEK 
O.C.T. (VWR International, Darmstadt, Germany) solution, or snap-frozen in liquid nitrogen, and 
kept at −80°C until further processing for histology. The left lung was used for flow cytometry. 
Single-cell suspensions of the left lung were obtained by digesting using DNase (Sigma-Aldrich) 
and Liberase (Roche, Basel, Switzerland) for 30 min at 37°C. After digestion, the lungs were 
homogenized using a 100-μm cell strainer (Fischer Scientific, Waltham, MA, USA) and red 
blood cells were lysed using osmotic lysis buffer (8.3% NH4CL, 1% KHCO3, and 0.04% NA2EDTA 
in Milli-Q). MLN and spleen were isolated for confocal analysis and flow cytometry, for which 
they were homogenized through a 100-μm cell strainer.
flow cytometry procedures
Flow cytometry surface and intracellular staining procedures have been described previously 
(20). Monoclonal antibodies used for flow cytometric analyses are listed in Supplementary 
table 1. For all experiments, dead cells were excluded using fixable viability dye (eBioscience, 
San diego, CA, USA). For measuring cytokine production, cells were stimulated with 10 ng/mL 
PMA (Sigma-Aldrich), 250 ng/mL ionomycin (Sigma-Aldrich), and GolgiStop (BD Biosciences, 
Neutrophilic airway inflammation is IL-17-independent
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San Jose, CA, USA) for 4 h at 37°C. Data were acquired using a LSR II flow cytometer (BD Biosci-
ences) with FACS DivaTM software and analysed by FlowJo version 9 (Tree Star Inc software, 
Ashland, OR, USA).
lung histology
Six-μm-thick paraffin embedded lung sections were stained with periodic acid-Schiff (PAS) to 
visualize goblet cell hyperplasia. For confocal imaging, 10-μm-thick cryo-sections were fixed in 
acetone and incubated for 1 h with primary antibodies anti-CD3 (Clone KT3, Bioceros, Utrecht, 
The Netherlands), anti-TCRγδ (FITC, Clone GL3, BioLegend, San Diego, CA, USA) and anti-Ki67 
(FITC, Clone SolA15, Ebioscience). After washing, slides were incubated for 30 min with second-
ary antibodies anti-Rat Cy-5 (Jackson Immunoresearch, West Grove, PA, USA), anti-Hamster 
Cy3 (Jackson Immunoresearch) and anti-FITC Alexa Fluor 488 (Jackson Immunoresearch). To 
prevent unspecific binding of antibodies, an intermediate blocking step with 10% normal rat 
serum was performed. Lastly, slides were counterstained with DAPI and images were acquired 
on a Zeiss Meta311 confocal microscope. Images were analysed using ImageJ software21.
Cytokine mRNA assessment by Quantitative Real-Time PCR
Homogenized left lower lung lobe was used to isolate and purify total RNA using the GeneElute 
mammalian total RNA miniprep system (Sigma-Aldrich) and RNA quantity was determined us-
ing a NanoDrop 1000 (VWR International). Up to 0.5 μg of total RNA was reverse-transcribed 
with SuperScript II reverse transcriptase (Invitrogen). Gene expression was analysed for Gapdh, 
Il1b, Il6, Il22, Il23, Csf2 and Muc5a in SYBR Green Master Mixes (Qiagen, Hilden, Germany) us-
ing an ABI Prism 7300 Sequence Detector and ABI Prism Sequence Detection Software version 
1.4 (Applied Biosystems, Foster City, CA, USA). Forward and reverse primers for each gene are 
listed in Supplementary table 2. Samples were analysed simultaneously for Gapdh mRNA as 
internal control. Each sample was assayed in duplicate and normalized to the internal control, 
and data were determined as copies of mRNA/GAPDH.
statistical analysis
All data was presented as means ± SEM. Mann–Whitney U-tests were used for comparison be-
tween two groups, and a P-value of <0.05 was considered statistically significant. All analyses 
were performed using Prism (Version 5, GraphPad Software, La Jolla, CA, USA).
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REsulTs
loss of il-17RA-signalling combined with myeloid TNfAiP3 deficiency increases splenic 
monocytes, neutrophils and γδ-17 T cells with progressing age
To investigate the role of IL-17R-signalling in HDM-driven neutrophilic airway inflammation re-
sponses, we crossed Tnfaip3LysM mice (16) with Il17raKO mice (4). It has been demonstrated that 
aged Tnfaip3LysM-KO mice develop arthritis (16) and that Il17raKO mice have altered monocyte 
homeostasis (22). We therefore first examined whether abrogation of IL-17RA-signalling in 
Tnfaip3LysM-KO mice induces additional alterations in the immune system. We assessed spleens 
of 8 and 18-week-old mice, as a representation of the systemic immune state. Both 8 and 
18-week-old Tnfaip3LysM-KO and Tnfaip3LysM-KOIl17raKO mice showed splenomegaly comparison 
to WT and Il17raKO control mice (Figure 1A), which did not correlate with splenic cell counts 
(Figure 1B). Monocytes and neutrophils (gated as shown in Figure S1) were significantly 
increased in 8-week-old Tnfaip3LysM-KO mice comparison to WT mice (Figure 1C-D), however 
only neutrophils were significantly increased in 18-week-old Tnfaip3LysM-KO mice compared to 
WT mice (Figure 1D) confirming previous findings (16). Interestingly, both neutrophils and 
monocytes were significantly increased in 18-week-old Tnfaip3LysM-KOIl17raKO mice compared 
to Tnfaip3LysM-KO mice (Figure 1C-D). Despite increased monocyte and neutrophil numbers in 
Tnfaip3LysM-KOIl17raKO mice, the macroscopic and microscopic arthritis phenotype was similar 
between Tnfaip3LysM-KO mice and Tnfaip3LysM-KOIl17raKO mice (Figure S2).
As IL-17 controls its own expression, and regulates IL-17 expression in both CD4+ as 
γδ T cells (23), we assessed conventional TCRαβ T cells and γδ T cell in the spleen (gating 
shown in Figure 1E). Total CD4+ T helper (Th) cells were not altered between each mouse 
genotype in 8-week old mice, but were significantly increased in 18-week old IL17raKO mice 
compared to WT mice (Figure 1F). Splenic RORγt+ Th17 cells were increased in 8-week old 
Tnfaip3LysM-KOIl17raKO mice compared to Tnfaip3LysM-KO mice, but were not significantly altered 
between 18-week old Tnfaip3LysM-KOIl17raKO and Tnfaip3LysM-KO mice (Figure 1G). No significant 
differences were observed in splenic γδ T cell numbers at 8 weeks, while 18-week old IL17raKO 
mice had increased splenic γδ T cell numbers compared to WT mice. Splenic γδ T cell numbers 
further enhanced in Tnfaip3LysM-KOIl17raKO mice compared to both Tnfaip3LysM-KO and IL17raKO 
mice (Figure 1H). RORγt+ γδ (γδ-17) T cells were increased in spleens of Il17raKO mice and 
Tnfaip3LysM-KOIl17raKO mice at both ages, compared to WT and Tnfaip3LysM-KO mice respectively 
(Figure 1I). At 18 weeks, splenic γδ-17 T cells further amplified in Tnfaip3LysM-KOIl17raKO mice 
compared to IL17raKO littermates (Figure 1I).
Taken together, these data show that loss of IL-17RA-signalling in combination with TNFAIP3 
deficiency in myeloid cells induces accumulation of monocytes and neutrophils upon aging. In 
contrast, splenic Th17 cells and γδ-17 T cells were already increased in young Tnfaip3LysM-KOIl-
17raKO mice, and their numbers were amplified at older age.
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House dust mite-induced eosinophilic and neutrophilic airway inflammation are 
unaltered in the absence of il-17RA-signalling
We have previously shown that Tnfaip3LysM-KO mice develop Th17-associated neutrophilia upon 
HDM-treatment, whereas WT mice develop Th2-mediated eosinophilic inflammation (Chapter 
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figure 1: loss of il-17RA-signalling in combination with myeloid TNfAiP3 deficiency increases splenic mono-
cytes, neutrophils and γδ-17 T cells with progressing age. Tnfaip3LysMIL17ra mice were analysed at 8 weeks 
and 18 weeks of age. (A-B) Quantification of spleen weight (A) and total cell numbers (B). (C-D) Enumeration of 
monocytes (C) and neutrophils (C) analysed in spleen cell suspensions by flow cytometry. (E) Flow cytometric 
gating strategy of T cells and γδ T cells. Example is shown from a spleen obtained from a WT mouse. (F-H) Cell 
numbers are depicted of Th cells (F), Th17 cells (G), γδ T cells (H)and γδ-17 T cells (I) in spleen cell suspensions by 
flow cytometry. Results are presented as mean ± SEM of n = 4-10 per group. *P < 0.05, **P < 0.01, ***P < 0.001.
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4). As neutrophil numbers were not affected by the loss of IL-17RA-signalling in Tnfaip3LysM-KO 
mice at young age, we exposed young Tnfaip3LysMIl17ra mice to an HDM-driven allergic airway 
inflammation model (Figure 2A), to investigate the role of IL-17RA-signalling on neutrophilic 
airway inflammation. As previously shown (Chapter 4), HDM-sensitization and challenge 
induced a predominant eosinophilic inflammation in WT mice, whereas Tnfaip3LysM-KO mice 
developed a neutrophilic inflammation in the bronchoalveolar lavage (BAL) compared to PBS-
sensitized WT littermates (Figure 2B). Absence of IL-17RA-signalling lowered eosinophilic or 
neutrophilic inflammation, but this did not reach statistical significance (Figure 2B). BAL DCs 
were increased in both HDM-sensitized WT mice and Il17raKO mice compared to their respec-
tive PBS-sensitized littermates (Figure 2B). However, in HDM-sensitized Tnfaip3LysM-KO mice, DC 
numbers were reduced compared to HDM-sensitized WT mice and were strikingly increased 
in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized Tnfaip3LysM-KO mice 
(Figure 2B). The absence of IL-17RA did not significantly alter the number of BAL macrophages 
in comparison to IL-17RA sufficient controls (Figure 2B).
HDM-sensitized WT and Il17raKO mice exhibited increased mucus-producing goblet cells 
and inflammatory cells compared to their PBS-sensitized controls (Figure 2C). HDM-sensitized 
Tnfaip3LysM-KO mice had similar numbers of mucus-positive cells compared to HDM-sensitized 
WT mice (Figure 2C). Remarkably, with additional loss of IL-17RA-signalling, the amount of 
goblet cells and Muc5a mRNA levels were severely reduced in the airways of HDM-sensitized 
Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized Il17raKO mice (Figure 2C-D).
In HDM-sensitized WT mice, total BAL T cells and CD4+ T cells increased compared to PBS-
sensitized WT mice (Figure 2E). All BAL T cell subsets and γδ T cells were prominently increased 
in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized Il17raKO mice (Figure 
2E). Total BAL T cells, CD4+ T cells and γδ T cells were prominently increased in HDM-sensitized 
Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized Tnfaip3LysM-KO mice (Figure 2E). Also, 
HDM-sensitized Il17raKO mice had a slight increase in γδ T cells compared to HDM-sensitized 
WT mice (Figure 2E). Differences in total T cells and γδ T cells were not observed in the MLN 
(Figure S3).
Briefly, absence of IL-17RA-signalling did not significantly alter eosinophilic or neutrophilic 
airway inflammation in respectively HDM-treated Il17raKO and Tnfaip3LysM-KOIl17raKO mice. In 
contrast, abrogated IL-17RA-signalling in combination with Tnfaip3-deficient myeloid cells 
hampered goblet cell hyperplasia. Surprisingly, a distinct increase of γδ T cells was observed 
specifically in the airways in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice.
loss of il-17RA-signalling does not affect lung Th2 cytokines in an HDM-sensitized 
model, but increases il-17 production
The effects of IL-17 on Th2 differentiation in allergic asthma models depend on the allergen 
used and the timing of IL-17 exposure (24-26). As eosinophilia and neutrophilia were not signif-
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icantly affected by the loss of IL-17RA-signalling in HDM-sensitized WT and Tnfaip3LysM-KO mice, 
we determined the effects of IL-17RA-signalling on cytokine secretion by T cells upon HDM-
provoked airway inflammation. As expected, IL-13 and IL-5-expressing Th cells were increased 
within the BAL of HDM-sensitized WT mice compared to PBS-sensitized WT mice (Figure 3A-B). 
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figure 2: House dust mite induced eosinophilic and neutrophilic airway inflammation are unaltered in the 
absence of il-17RA-signalling. (A) Mice were sensitized with PBS or HDM (1 μg) on day 0 and challenged with 
10 μg HDM from day 7-11. Analysis was performed at day 15. (B) Quantification of bronchoalveolar lavage (BAL) 
fluid eosinophils, neutrophils, dendritic cells and macrophages by flow cytometry. (C) Periodic Acid Schiff (PAS) 
stained lung small airway and large airway histology of Tnfaip3LysMIL17ra mice after HDM exposure. Scale bar in-
dicates 200μM. (D) Muc5a mRNA levels within lung homogenates of PBS and HDM challenged Tnfaip3LysMIl17ra 
mice. (E) Enumeration of total CD3+ T cells, CD4+ T cells, CD8+ T cells and γδ T cells in BAL by flow cytometry. 
Results are presented as mean ± SEM of n = 6 per group. *P < 0.05, **P < 0.01.
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HDM-sensitized Tnfaip3LysM-KO mice did not show significant differences in IL-13+ or IL-5+ Th cells 
compared to WT HDM-sensitized controls (Figure 3B). Also, IL-13+ and IL-5+ Th cells were un-
altered in HDM-sensitized Il17raKO and Tnfaip3LysM-KOIl17raKO mice compared to their respective 
controls with functional IL-17RA-signalling (Figure 3B). HDM-sensitized Tnfaip3LysM-KOIl17raKO 
mice had reduced IL-13+ and IL-5+ Th cells compared to HDM-sensitized Il17raKO mice (Fig-
ure 3B). As previously shown in Chapter 4, BAL IL-17+ Th cells increased in HDM-sensitized 
Tnfaip3LysM-KO mice compared to HDM-sensitized WT controls. Already in PBS-sensitized Il17raKO 
mice, an increase of BAL IL-17+ Th cells was observed compared to PBS-sensitized WT mice, 
which was even more enhanced in HDM-sensitized Tnfaip3LysM-KOIL17raKO mice (Figure 3B). 
BAL IFNγ-producing Th cells were only increased in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice 
compared to either HDM-sensitized Il17raKO or Tnfaip3LysM-KO mice (Figure 3B).
Since IL-17 can also be produced by γδ-17 T cells (27), we evaluated the cytokine expres-
sion from γδ T cells upon HDM antigen exposure (Figure 3C). HDM-sensitized Tnfaip3LysM-KO 
mice had increased IL-17+ γδ T cells in BAL in comparison to HDM-sensitized WT mice (Figure 
3D). Further loss of IL-17RA-signalling in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice resulted in 
remarkably elevated IL-17+ γδ T cells in BAL (Figure 3D). In the MLN, IL-17-producing Th cells 
and γδ T cells were increased in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice compared to their 
controls, although not as prominent as in the BAL (Figure 3E). Th17 and γδ T cells are known to 
produce other cytokines than IL-17, such as GM-CSF (28) and IL-22 (29). We quantified mRNA 
expression levels of these cytokines in the lungs. Strikingly, both Csf2 and Il22 gene expression 
were increased in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized 
Il17raKO mice and Tnfaip3LysM-KO mice (Figure 3F).
In conclusion, lack of IL-17RA-signalling did not alter Th2 cytokines in HDM-sensitized 
mice, while significantly increasing IL-17-production by Th and γδ cells in mice lacking my-
eloid TNFAIP3. Next to IL-17, also GM-CSF and IL-22 levels were increased in lung tissue of 
Tnfaip3LysM-KOIl17raKO mice.
il-17RA-deficiency combined with activated myeloid cells directs local proliferation of 
T cells and γδ T cells in the lungs
As specifically Tnfaip3LysM-KOIl17raKO mice had elevated numbers of pulmonary Th17 and γδ-17 
T cells in response to HDM exposure, we wondered whether these cells are induced by HDM 
or already present in lungs and MLN of naïve mice. Total Th cell numbers were similar between 
lung and MLN of naïve mice of each genotype (Figure 4A). However, pulmonary Th17 cells 
were increased in Il17raKO mice compared to WT mice (Figure 4B). Th17 cell numbers were 
further enhanced in lung and MLN of Tnfaip3LysM-KOIl17raKO mice compared to Tnfaip3LysM-KO and 
Il17raKO mice (Figure 4B). Both total pulmonary γδ T cells and γδ-17 T cells were increased in 
Il17raKO mice and Tnfaip3LysM-KOIl17raKO mice compared to respectively WT and Tnfaip3LysM-KO 
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figure 3: loss of il-17RA-signalling does not affect lung Th2 cytokines in a HDM-sensitized model, but in-
crease il-17 production. Tnfaip3LysMIl17ra mice were analysed after completion of the HDM exposure protocol. 
(A) Flow cytometry data is shown of intracellular cytokine expression within Th cells of representative HDM 
exposed mice. (B) Quantification of BAL Th cell cytokines IL-13, IL-5, IL-17 and IFNγ as determined by flow cytom-
etry. (C) Flow cytometry data is exemplified of BAL γδ T cells intracellular cytokine expression of representative 
HDM exposed mice. (D) Enumeration of IL-17+ γδ T cells in BAL by flow cytometry. (E) Quantification of IL-17+ Th 
cells and γδ T cells in cell suspensions of the MLN by flow cytometry. (F) Plotting Th17 produced cytokine Csf2 
and Il22 mRNA levels within lung homogenates of PBS and HDM challenged Tnfaip3LysMIl17ra mice. Results are 
presented as mean ± SEM of n = 6 per group. *P < 0.05, **P < 0.01.
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controls (Figure 4C-D). Similar to Th17 cells, MLN γδ-17 T cells showed a marked increase in 
Tnfaip3LysM-KOIl17raKO mice compared to Il17raKO mice (Figure 4D).
The increase in pulmonary Th17 cells and γδ T cells could be a consequence of increased 
thymic output, as both T cells and γδ T cells are generated in the thymus (30). Therefore, 
we evaluated thymic T cell development and observed no differences in thymus cell counts, 
proposing normal ab T cell development (Figure S4A). However, only thymic γδ-17 T cells were 
increased in Tnfaip3LysM-WTIl17raKO and Il17raKO mice compared to their respective IL-17RA-
sufficient littermates (Figure S4B-C).
Next, the increased presence of pulmonary T cells and γδ T cells could also be a consequence 
of local proliferation. We thus performed confocal microscopy for CD3 and the proliferation 
marker Ki-67. Tnfaip3LysM-KOIl17raKO mice had cellular infiltrates consisting of CD3+Ki-67+ cells 
present around the bronchi, which was not observed in the lung parenchyma (Figure 4A). In 
the cellular infiltrates of Tnfaip3LysM-KOIl17raKO mice both Ki-67+ T cells (white arrows) and Ki-67+ 
γδ T cells (blue arrows) were present (Figure 4B).
These findings show that Th17 cells and γδ-17 T cells are increased in lungs and MLN of naïve 
mice that harbour both Tnfaip3-deficient myeloid cells and have deficient IL-17RA-signalling, 
due to local proliferation and elevated thymic output of γδ-17 T cells.
Increase in Th17 and γδ-17 T cell-instructive cytokines in the lungs of Tnfaip3LysM-KOIl17ra-
KO mice
Both Th17 and γδ-17 T cell differentiation depend on the cytokine milieu, whereby IL-1β, IL-6, 
and IL-23 play a predominant role (31, 32). And especially activated type 2 conventional DCs 
(cDC2s) and monocyte-derived DCs are a dominant source of these cytokines (31), therefore 
we characterized the number and activation status of DC subsets (Figure 5A). The number of 
migratory cDC1s or migratory cDC2s in the MLN did not alter within the four genotypes after 
HDM provocation (Figure 5B). In contrast, HDM-exposed Tnfaip3LysM-KO mice had significantly 
higher numbers of moDCs compared to WT controls (Figure 5B). The expression level of the 
co-stimulatory molecule CD86 on migratory DCs in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice 
was increased compared to Il17raKO mice (Figure 5C). Especially the migratory cDC2s were re-
sponsible for the enhanced CD86 expression in Tnfaip3LysM-KOIl17raKO mice, as migratory cDC1s 
had unaltered CD86 expression. MoDCs of both Tnfaip3LysM-KO mice and Tnfaip3LysM-KOIl17raKO 
mice exhibited increased CD86 expression compared to their respective littermate controls 
(Figure 5C).
Next, we examined mRNA expression of cytokines implicated in Th17 and γδ-17 T cell dif-
ferentiation and accumulation within lungs of mice after HDM sensitization. HDM-exposed WT 
mice exhibited lower Il1b expression compared to PBS-exposed WT mice (Figure 5D). In con-
trast, HDM-treated Tnfaip3LysM-KO mice and Tnfaip3LysM-KOIl17raKO mice demonstrated elevated 
IL-1β and IL-6 expression in the lungs compared to HDM-treated WT and Il17raKO littermate 
controls (Figure 5D). In contrast, IL-23 expression was markedly increased in HDM-exposed 
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figure 5: increase in Th17 and γδ-17 T cell-instructive cytokines in the lungs of Tnfaip3lysM-koIl17rako mice. 
Mice were analysed after completion of the HDM protocol at an age of 6-8 weeks (A) Flow cytometric gating of 
DC subsets. Example is shown of a MLN derived from a WT mouse. (B) Quantification of MLN migratory cDC1s, 
cDC2s and moDCs using flow cytometry. (C) Enumeration of DC activation in MLN migratory cDC1s, cDC2s and 
moDCs by flow cytometry. (D) Plotting of relative cytokine mRNA levels within lung homogenates of PBS and 
HDM challenged Tnfaip3LysMIL17ra mice. All values were relative to mRNA expression of the household GAPDH 
gene. (E) Representation of cytokines that drive Th17 and γδ-17 T cell development and survival in pie chart 
format. Results are presented as mean ± SEM of n = 4 per group. *P < 0.05, **P < 0.01.
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Tnfaip3LysM-KOIl17raKO mice compared to Tnfaip3LysM-KO controls (Figure 5D). In order to improve 
visualization of the relative contribution to Th17 and γδ-17 T cells differentiating cytokines, 
IL-1β, IL-23 and IL-6 were plotted in pie chart format (Figure 5E). This suggests that an optimal 
cytokine mix with high IL-23, IL-1β and IL-6 was only present in the lungs of Tnfaip3LysM-KOIl17raKO 
mice (Figure 5E).
In conclusion, however cDC numbers and activation states were similar between Tnfai-
p3LysM-KOIl17raKO and Tnfaip3LysM-KO mice, the increase in moDCs in Tnfaip3LysM-KO mice, was not 
observed in Tnfaip3LysM-KOIl17raKO mice. HDM-exposure in Tnfaip3LysM-KOIl17raKO mice induces an 
IL-17 promoting environment with high levels of IL-23, IL-1β and IL-6. This increase in IL-23 
together with the presence of IL-1β and IL-6 could contribute to the differentiation and ac-
cumulation of Th17 cell and γδ-17 T cells in the lungs of Tnfaip3LysM-KOIl17raKO mice.
DisCussioN
IL-17 is implicated in severe and uncontrolled asthma, as patients who suffer from severe 
asthma display increased levels of IL-17 in lung tissue (33). Recently we have shown that the 
presence of intrinsically activated myeloid cells, obtained through TNFAIP3/A20 ablation, 
induces development of Th17 cell associated neutrophilic asthma in contrast to Th2 cell driven 
eosinophilic inflammation induced in control mice (Chapter 4). However, the exact function 
of IL-17 and the influence of IL-17R-signalling on neutrophilic asthma are incompletely under-
stood. To investigate whether neutrophilic inflammation development as observed in HDM 
treatment Tnfaip3LysM mice is dependent on IL-17-signalling in asthma, mice with specific dele-
tion of TNFAIP3 in myeloid cells were crossed to IL-17RA-deficient mice.
Surprisingly, absence of IL-17RA-signalling only had limited effects on neutrophilic or 
eosinophilic inflammation in our HDM-driven airway inflammation mouse models. Th2 cell 
differentiation was not hampered by ablation of IL-17RA-signalling, whereas the presence 
of mucus-producing cells was reduced. Strikingly, ablation of IL-17RA in mice that harbour 
intrinsically activated myeloid cells resulted in a spontaneous accumulation of γδ-17 T cells 
and Th17 cells in the lungs. Furthermore, mice harbouring TNFAIP3-deficient myeloid cells and 
IL-17RA-deficiency displayed enhanced expression of IL-23 in the lungs.
IL-17RA subunit forms a heterodimer with the IL-17RC or IL-17RB subunit. IL-17RA/C het-
erodimer is used by IL-17A, IL-17F, and IL-17A/F and the IL-17RA/B heterodimer is activated 
by IL-17E (also known as IL-25) (17). Ablation of the IL-17RA subunit will therefore affect the 
signalling of IL-17A, IL-17F, IL-17A/F, and IL-25. We observed that neutrophilic inflammation 
persisted in the absence of IL-17RA-signalling, indicating that neutrophilia can develop with-
out the presence of the described IL-17R family members IL-17A, IL-17F, and IL-25. This is in 
contrast to other reports that showed dependency of neutrophil influx on IL-17RA-signalling 
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not only in asthma and COPD, but also in pulmonary bacterial and viral infections (4,9,34-36). 
IL-17RA-signalling in airway epithelial cells induces IL-8 production, a chemoattractant for neu-
trophils (4). However, certain allergens, including HDM can provoke IL-8 secretion by the air-
way epithelium through toll-like receptor (TLR) stimulation (37-39). Furthermore, neutrophils 
are also attracted by the chemokine CXCL13, which is highly expressed by Tnfaip3-deficient 
DCs (Chapter 4). This implicates that neutrophilic inflammation observed in HDM-treated 
Tnfaip3LysM-KOIl17raKO mice is either induced by direct allergen-mediated epithelial activation, 
by CXCL13 from Tnfaip3-deficient DCs, or both mechanisms could be involved.
We found limited effects of defective IL-17RA-signalling on all features observed in 
HDM-mediated allergic airway inflammation including Th2 differentiation and eosinophilic 
inflammation. This incriminates that IL-17A, IL-17A/F, IL-17F and IL-25 are dispensable for Th2-
mediated eosinophilic inflammation upon HDM treatment. Blockade of IL-17A also did not 
influence eosinophilic inflammation and Th2 cytokine secretion upon exposure to the HDM 
Der f allergen (35). In contrast to ovalbumin (OVA)-mediated allergic airway models, where re-
duced eosinophilic inflammation, Th2 cytokines, and airway hyper responsiveness (AHR) were 
observed in either IL-17RA-deficient or IL-17-deficient mice (24, 25). This suggests that the 
importance of IL-17 depends on the allergen/model used. While IL-17-depletion during HDM 
challenges has no effect on eosinophilia and Th2 cytokines, blockage of IL-17 in OVA-mediated 
models attenuates eosinophilic inflammation (24,25). Although IL-17 can be produced by both 
CD4+ T cells and γδ T cells, more recent studies have showed that the regulatory effects of IL-17 
on airway inflammation and remodelling in an OVA-mediated airway inflammation model are 
mediated by IL-17-producing γδ T cells and not by conventional CD4+ T cells (40). Depletion 
of IL-17-producing γδ T cells during the resolution phase of OVA-mediated airway inflamma-
tion model exacerbates eosinophilia, Th2 cytokines and AHR. This implicates that particularly 
γδ-17 T cells are essential for the resolution of OVA-mediated airway inflammation and AHR 
(26). Whether γδ-17 T cells are also involved in the resolution phase of HDM-mediated airway 
inflammation remains to be determined.
In contrast to airway type-2 inflammation, goblet cell hyperplasia was almost completely 
absent in Tnfaip3LysM-KOIl17raKO mice. This suggests that the presence of Th2 cytokines in WT 
mice, and Th17 cytokines in Tnfaip3LysM-KO are essential for goblet cell hyperplasia. Indeed, 
mucus production by goblet cells is induced by Th2 cytokines IL-4, IL-13 (41-44), and Th17 
cytokines IL-17A (7) and IL-17F (45). Furthermore, IL-25 (e.g. IL-17E) is also implicated in goblet 
cell hyperplasia (46,47). Also, the combination of OVA-specific Th2 and Th17 cells induced 
more mucus-producing goblet cells than OVA-specific Th2 cells alone (48). This indicates that 
these IL-17 family cytokines and Th2 cytokines can induce hyperplasia of mucus-producing 
cells separately and can evens take over each other function, as combined absence of Th2 
cytokines and abrogated IL-17RA-signalling in Tnfaip3LysM-KOIl17raKO mice completely hampers 
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the induction of goblet cell hyperplasia. Furthermore, mucus-production by goblet cells in 
Il17raKO mice develops independent of IL-25.
Accumulation of Th17 cells and γδ-17 T cells was observed in the mucosa of the lungs of 
Tnfaip3LysM-KOIl17raKO mice. In our experiment, ablation of IL-17RA-signalling only slightly 
increases the presence of IL-17-expressing T cells, however combined with Tnfaip3-deficient 
myeloid cells, pulmonary Th17 cells and γδ-17 T cells were massively enhanced, both in naïve 
and allergen exposed Tnfaip3LysM-KOIl17raKO mice. Increased pulmonary IL-23-expression, 
high levels of IL-1b and IL-6, and defective negative feedback normally provided by IL-17 in 
Tnfaip3LysM-KOIl17raKO mice, could be responsible for this massive increase. It is known that IL-23 
drives clonal expansion of Th17 cells and γδ-17 T cells (49,50), whereas IL-17 acts as a negative 
feedback to control its own expression (23). Strikingly, only IL-23, but not IL-1b and IL-6 was 
specifically increased in Tnfaip3LysM-KOIl17raKO mice when compared to Tnfaip3LysM-KO mice, sug-
gesting that IL-17RA signalling also controls IL-23 production.
IL-17-secreting potential of γδ T cells is already determined in the thymus by TGF-b and Notch 
signals (27,51), thus they are antigen naïve. This is logical as γδ T cells are innate-like cells, 
preferentially populate mucosal organs and thereby act as the first line of antigen-independent 
defence upon infections (52).
In conclusion, our results indicate that cytokines that signal through IL-17RA reduce but not 
abrogate development of HDM-induced eosinophilic and neutrophilic airway inflammation, 
whereas they are essential for mucus production. Absence of IL-17RA signalling combined with 
Tnfaip3-deficient myeloid cells induces a massive accumulation of both Th17 and γδ-17 T cells 
in the lungs of naïve mice, which was more prominent upon HDM exposure. This spontaneous 
accumulation is likely the result of defective IL-17RA-signalling combined with increased IL-23 
expression and with other IL-17-promoting cytokines, such as IL-1b and IL-6. These findings 
provide new insights into Th17 and γδ-17 T cells biology, and indicate that therapeutic inter-
ventions targeting IL-17 or IL-17RA can induce spontaneous accumulation of Th17 or γδ-17 T 
cells. This provides a new model to study Th17 and γδ-17 T cells pulmonary accumulation and 
survival.
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supplementary figure 1: flow cytometric gating strategy of myeloid cells. An example is shown of a spleen 
derived from a WT mouse.
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supplementary figure 2: Aged myeloid Tnfaip3-deficient mice develop arthritis, regardless of il-17RA-signal-
ling. Mice were analysed at 18 weeks of age when arthritis had spontaneously developed. (A-B) Paws were 
scored biweekly for severity (A) and the derived prevalence graph (B) of spontaneous arthritis is shown. (C) 
Hematoxylin and eosin (H&E) stained paraffin embedded, EDTA decalcified, talo-tibial joints at a magnification 
of 50x is shown. (D) Tolluidine blue stain of the talo-tibial cartilage region is depicted at a magnification of 200x. 
Arrows represent areas of cartilage loss. Scale bars (200μm) are at the lower right corner of the microscopic im-
ages. (E) Histopathologic score of talo-tibial joints as assessed by combining H&E and toluidine blue stain scores. 
Results are presented as mean ± SEM of n = 6-12 per group. **P < 0.01, **P < 0.001, ****P < 0.0001.
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supplementary figure 4: T cell development is normal in the thymus of Tnfaip3-deficient mice, regardless of 
il-17RA-signalling. Naïve mice were analysed at an age of 8 weeks. (A) Quantification of thymic cell numbers. 
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using flow cytometry. Results are presented as mean ± SEM of n = 6 per group. *P < 0.05.
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Table s1: Antibodies used for flowcytometry
Supplementary Table 1: Antibodies used for flow cytometry 
Antibody Conjugate Clone Company 
CD3 APC-eF780 17A2 ebioscience 
CD4 PE-CF594 RM4-5 BD 
CD4 BV711 RM4-5 BD 
CD8 PE-Cy7 53-6.7 ebioscience 
CD11b PerCP-cy5.5 M1/70 BD Bioscience 
CD11c PE Texas Red N418 ebioscience 
CD25 Pe-Cy7 PC61.5 ebioscience 
CD27 Biotin LG.7F9 ebioscience 
CD44 FITC IM7 ebioscience 
CD44 APC-cy7 IM7 BD 
CD45 PE Texas Red I3/2.3 Abcam 
CD64 APC X54-5/7.1 BD 
CD64 PE X54-5/7.1 BD 
CD86 PE Cy7 GL1 BD 
CD103 APC 2E7 ebioscience 
FcƐRI Biotin MAR-1 ebioscience 
GR1 Pe-cy7 1A8 BD 
IFNγ eF450 XMG1.2 ebioscience 
IL-5 PE TRFK-5 BD 
IL-5 APC TRFK-5 BD 
IL-13 AF647 eBio13A ebioscience 
IL-17A AF700 TC11-18H10.1 BD 
MHC-II Alexa Fluor 700 M5/114.15.3 ebioscience 
RORγt PE Q31-378 BD 
Streptavidin PerCP-Cy5.5  BD 
Streptavidin APC-eF 780  ebioscience 
Streptavidin Brilliant Violet 786  BD 
TCRγδ Biotin UC7-13D5 ebioscience 
Ter119 APC TER-119 ebioscience 


6
Tnfaip3-deficient Langerin+ cDC1s 
have increased IL-12 and PD-L1 
expression and abrogate Th2-
mediated airway inflammation
Manuscript in preparation
H Vroman1
IM Bergen1
D van Uden1
JAC van Hulst1
G van Loo2,3
BE Clausen4
L Boon5
BN Lambrecht1,2,6
H Hammad2,6
RW Hendriks1
M Kool1.
1Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.
2VIB Center for Inflammation Research, Ghent, Belgium.
3Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
4Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, 
Mainz, Germany. 
5Bioceros, Utrecht, The Netherlands.
6Department of Respiratory Medicine, Ghent University, Ghent, Belgium
140
Chapter 6
AbsTRACT
background: Conventional type 1 dendritic cells (cDC1s) are critical for antiviral and antitumor 
immunity through the induction of antigen-specific cytotoxic CD8+ T cell responses. Contro-
versy exist concerning cDC1 function in Th2 responses, because both suppressive and support-
ing roles have been reported. DC activation crucially involves transcription factor NF-kB and is 
essential for the activation of naïve T cells and their differentiation into T cell subsets. TNFAIP3, 
a key negative regulator of NF-κB signalling has been shown to control DC activation.
objective: In this study, we investigated whether increased activation of cDC1s, through re-
duced TNFAIP3 expression, would affect Th2-mediated inflammation.
Methods: Mice with conditional deletion of the Tnfaip3 gene, using Langerin-Cre transgenic 
mice (Tnfaip3Langerin-KO) were exposed to Th2-driven airway inflammation models, such as house 
dust mite (HDM) or ovalbumin (OVA)/alum adjuvant.
Results: Ablating Tnfaip3 gene expression in Langerin-expressing cDC1s abrogated Th2-
mediated inflammation in both an HDM and OVA alum-adjuvant model. The frequencies of 
Th2-suppressive Tregs and IL-10 and IFNγ+ CD8+ T cells were increased in Tnfaip3Langerin-KO mice, 
compared to Tnfaip3Langerin-WT mice in both models. Impaired Th2 immunity was associated with 
increased expression of IL-12 and PD-L1 in all pulmonary DC subsets, and not only in Tnfaip3-
deficient cDC1s.
Discussion: We show that increased activation of cDC1s, through reduced TNFAIP3 expres-
sion, abolishes development of Th2-mediated inflammation. This implies that increasing the 
activation status of cDC1s could be a novel pharmacological intervention strategy to treat 
Th2-mediated diseases.
Activated cDC1s suppress Th2 immune responses
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iNTRoDuCTioN
T helper (Th) 2-mediated disease, such as asthma affects people all over the world. Th2 cy-
tokines facilitate the classical allergic response, such as IgE class switching by B cells (IL-4), 
eosinophilic inflammation (IL-5), and goblet cell hyperplasia (IL-13) (1). Dendritic cells (DCs) 
are potent antigen-presenting cells that induce the differentiation of naïve Th cells into ef-
fector cells. Based on surface marker expression, two main conventional DC subsets can be 
identified: cDC1s and cDC2s (2,3). During inflammation, a third population called monocyte-
derived DCs (moDCs) arises (4). cDC2s are considered to be efficient at priming CD4+ T cells 
through MHC class II-restricted antigen (Ag) presentation (5). Upon allergen inhalation, cDC2s 
drive Th2 differentiation, whereas moDCs maintain Th2 inflammation through the secretion of 
chemokines (6). On the other hand, cDC1s have superior Ag-cross-presenting capabilities and 
play pivotal roles in antiviral and antitumor immunity through induction of antigen-specific 
cytotoxic CD8+ T cell responses (7-9). Conflicting data exist concerning cDC1 function in Th2-
mediated diseases, whereby cDC1s were reported to either suppress allergic airway inflamma-
tion (10), be redundant (6) or essential for Th2 immune responses (11). During experimental 
helminth infection, cDC1s control the amplitude of Th2 immune responses through their IL-12 
production (12).
DC activation is needed for proper Th cell differentiation into Th1, Th2, Th17 and regulatory 
T (Treg) cells (13). Activation of DCs in Th2-mediated diseases often occurs through allergen-
mediated triggering of pattern recognition receptors (PRRs) on DCs (14,15). PRR triggering on 
DCs activates the pro-inflammatory transcription factor NF-κB, which initiates transcription 
of pro-inflammatory cytokines. NF-κB activation is negatively regulated by TNFAIP3 (TNFα-
induced protein 3, also known as A20), a ubiquitin-modifying enzyme that deubiquitinates 
several NF-κB signalling molecules (16,17). Thereby TNFAIP3 controls DC activation (18). In this 
study, we investigated whether TNFAIP3 depletion in cDC1s would affect their activation status 
and/or Th2-suppressive capacity. To determine this, we crossed floxed Tnfaip3 mice (19) with a 
transgenic mouse line that expresses Cre under the control of the Langerin promotor (20), and 
performed house dust mite (HDM)-driven and an alum-adjuvant driven allergic airway inflam-
mation experiments. Our data indicate that TNFAIP3 depletion in pulmonary cDC1s inhibits 
Th2-mediated immune responses. This was associated with an increase in the production of 
the Th2-suppressive cytokine IL-12 as well as increased the expression of the co-inhibitory 
molecule PD-L1 on various DC subsets.
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MATERiAls AND METHoDs
Mice
Tnfaip3fl/fl mice (19) were crossed to LangerinCRE/+ mice (20) to generate Tnfaip3Langerin mice. 
Tnfaip3Langerin mice were crossed to ROSA26flEGFP mice. Experiments were performed on mice 
backcrossed to the C57BL/6 genetic background for at least six generations. Mice were housed 
and bred under SPF conditions at the Erasmus MC and analysed at 6-12 weeks of age. All ex-
periments were performed with approval by the animal ethics committee of the Erasmus MC.
HDM-induced allergic airway inflammation
During HDM exposures, mice were anesthetized using isoflurane. Mice were sensitized in-
tranasally (i.n.) with 1 μg/40 μl HDM (Greer) or 40 μl PBS as a control on day 1 (GIBCO Life 
Technologies), and challenged i.n. on days 7-11 with 10 μg/40 μl HDM (6). Mice were sacrificed 
on day 15. Broncho-alveolar lavage (BAL) was obtained by flushing the lungs three times with 
1 mL PBS containing 0.5 mM EDTA (Sigma-Aldrich). Lungs were inflated with PBS/OCT (1:1) 
solution and placed in 4% PFA and embedded in paraffin.
oVA Alum-adjuvant induced Th2 immune responses
Imject alum (Pierce Biochemicals) was mixed with a solution of 20 µg/ml ovalbumine (OVA) an-
tigen (Worthington) (1:20) in saline (OVA-alum) and was stirred for at least 1 hour as described 
previously (21). Mice were immunized intraperitoneally (i.p.) with 500 µl OVA-Alum on day 0 
and on day 6. Blood was taken on day -1 and 5. On day 13 mice were sacrificed and spleens, 
MLN and blood were obtained.
Depletion of Tregs
Mice were treated i.p. with 500 ug of monoclonal anti-CD25 (PC61) or with a monoclonal 
antibody against b-galactosidase (GL113) as isotype control. Mice were injected on day -1, 2, 
7, and 10.
HDM-induced acute immune responses
To study co-stimulatory molecule expression and cytokine production by pulmonary DCs, mice 
were treated with 100 µg/80 µl of HDM extract intra-tracheally (i.t). 24 hours later, single 
cell suspensions were obtained from lungs by digesting the lungs using DNAse (Sigma) and 
Liberase TM (Roche) for 30 minutes at 37°C (6). After digestion, the lungs were homogenized 
through a 100 μm cell strainer (BD Biosciences). Red blood cells were lysed using osmotic lysis 
buffer (8.3% NH4Cl, 1% KHCO3 and 0.04% NA2EDTA in Milli-Q). Cell suspensions were prepared 
and used for flow cytometry procedures.
Activated cDC1s suppress Th2 immune responses
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Antibody treatment of mice
To study the effect of IL-12 and IFNγ on DC activation, mice were treated i.p. with 500 μg anti-
IL-12p40, 500 μg anti-IFNy antibodies, or with monoclonal antibody b-galactosidase (GL113) 
as isotype control, 10, 7, 4, and 1 day prior to 100 µg/80 µl HDM administration on day 0. Mice 
were sacrificed on day 1.
flow cytometry
Single cell suspensions were prepared from broncho-alveolar lavage (BAL) and MLN using 
standard procedures. MLNs were homogenized through a 100 μm cell strainer (BD Biosci-
ences). Flow cytometry surface and intracellular staining procedures have been described 
previously(22). Monoclonal antibodies used for flow cytometric analyses are listed in Table 
S1. For all experiments, dead cells were excluded using Fixable viability dye (eBioscience). To 
measure cytokine production by T cells, cells were stimulated at 37°C using 10 ng/ml PMA 
(Sigma-Aldrich), 250 ng/ml ionomycin (Sigma-Aldrich) and GolgiStop (BD Biosciences), for 4 
hours. To measure cytokine production by DCs, cells were stimulated at 37°C with GolgiPlug 
(BD Biosciences) for 4 hours. Data were acquired using a LSR II flow cytometer (BD Biosciences) 
and FACS software (BD Biosciences) and analysed by FlowJo version 9 (Tree Star Inc software).
lung histology
5 um-thick paraffin embedded lung sections were stained with periodic acid and Schiffs re-
agents to visualize mucus producing cells.
ElisA
Total IgE, HDM-specific IgG1, OVA-specific IgE, IgG1, and IgG2c were measured in serum (Op-
teia, BD Biosciences).
statistical analysis
Mann-Whitney U tests were used for comparison between two groups and a p-value of < 
0.05 was considered statistically significant. Analysis was determined using Prism (GraphPad 
Software, USA).
REsulTs
langerin+ cDC1s comprise only a small proportion of all pulmonary cDC1s
Langerin (CD207) expression has been shown in Langerhans cells in the skin and in a proportion 
of pulmonary cDC1s (20,23). Corresponding to Zahner et al, we also found that Langerin was 
expressed by 15% of cDC1s in the lung, whereas other pulmonary DC subsets did not express 
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Langerin (Figure 1A-B). To determine whether Langerin-Cre targeting of cDC1s parallels CD207 
expression, we crossed Langerin-Cre mice (20) to Rosa26-stopflEGFP mice (Langerin-cre x 
Rosa26-stopflEGFP mice). DC subsets were examined according the gating strategy as shown in 
Supplementary Figure 1. In the lungs and lung-draining mediastinal lymph node (MLN) of naive 
mice at the age of 6-8 weeks, approximately 15% of the cDC1s expressed EGFP, whereas in the 
broncho-alveolar lavage (BAL), 35% of cDC1s expressed EGFP. Expression of EGFP in other DC 
subsets in BAL, lung or MLN was below 3% (Figure 1C-D). TNFAIP3 deletion did not affect EGFP 
expression, because the proportions of EGFP-expressing pulmonary DCs were not different 
between Tnfaip3Langerin-WT and Tnfaip3Langerin-KO Rosa26-stopflEGFP mice (Figure 1E).
Since TNFAIP3 deletion affects the activation status of DCs we determined the expression 
of MHCII, CD86 and PD-L1. Surprisingly, MHCII and CD86 expression were decreased, whereas 
PD-L1 expression was increased on pulmonary cDC1s of Tnfaip3Langerin-KO mice compared to 
Tnfaip3Langerin-WT mice (Figure 1F). As the Langerin promotor targeted only a fraction of pulmo-
nary cDC1s, we compared the expression of PD-L1 in EGFP+ and EGFP- cDC1s of Tnfaip3Langerin x 
Rosa26-stopflEGFP mice. PD-L1 expression was especially increased in EGFP+ cDC1s compared 
to EGFP- cDC1s in Tnfaip3Langerin-KO x Rosa26-stopflEGFP mice and both EGFP- and EGFP+ cDC1s in 
Tnfaip3Langerin-WT x Rosa26-stopflEGFP mice (Figure 1G-H).
In conclusion, these data show that Langerin-expressing cDC1s comprise a small proportion 
of lung cDC1s. Ablation of TNFAIP3 in Langerin+ cDC1s induced EGFP expression in a similar 
proportion of cDC1s as Langerin+ cDC1s, and increased the numbers of pulmonary cDC2s, 
moDCs and pDCs. TNFAIP3 deletion in cDC1s decreased expression of MHCII and CD86, while 
increasing the expression of the co-inhibitory molecule PD-L1.
Depletion of TNfAiP3 in cDC1s increases pulmonary DCs numbers, whereas T cells are 
unaltered
As mice with TNFAIP3 depletion in either DCs using Cd11c-cre, or myeloid cells using the 
LysM-cre developed auto-immune diseases upon aging (18,24), we also analysed whether 
Tnfaip3Langerin mice developed auto-immunity. Tnfaip3Langerin mice were followed until 24 weeks 
of age without developing any signs of auto-immunity or skin inflammation (data not shown). 
We next investigated whether Langerin-Cre-mediated TNFAIP3 deletion in a fraction of pul-
monary cDC1s affected the numbers of pulmonary DC subsets. Numbers of total DCs, and 
specifically cDC2s, moDCs and plasmacytoid (pDCs) were increased in lungs of Tnfaip3Langerin-KO 
mice, compared to WT controls. cDC1 numbers were unaffected in Tnfaip3Langerin-KO mice (Figure 
2A). As activation of DCs can affect T cells (25), we characterized T cells in the lung, mediastinal 
lymph nodes (MLN) and spleen. Both CD4+ as CD8+ T cells numbers were similar between lung, 
MLN and spleen of Tnfaip3Langerin-KO and Tnfaip3Langerin-WT mice (Figure 2B-C).
This indicates that activation of cDC1s increases pulmonary DC subsets, but does not affect 
T cell numbers both locally as systemically.
Acti vated cDC1s suppress Th2 immune responses
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figure 1: langerin+ cDC1s comprise only a small proporti on of all pulmonary cDC1s. (A) Flow cytometric gati ng 
of lung DC subsets in C57BL/6 mice. CD207 expression was evaluated in cDC1s, cDC2s, moDCs, and pDCs. (B) 
Quanti fi cati on of the percentage CD207 expression in diff erent DC subsets by fl ow cytometry. (C) Flow cytomet-
ric gati ng of EGFP expression in lung DC subsets of Langerin-cre x Rosa26-stopfl EGFP mice. (D) Quanti fi cati on 
of the percentage EGFP expression in diff erent DC subsets by fl ow cytometry in BAL, Lung and MLN. (E) EGFP 
expression in cDC1s in BAL, Lung and MLN. (F) Quanti fi cati on of Mean Fluorescent Intensity of MHCII, CD86, and 
PD-L1 in lung cDC1s by fl ow cytometry. (G) PD-L1 expression in EGFP+ and EGFP- pulmonary cDC1s by fl ow cy-
tometry. (H) Quanti fi cati on of PD-L1 in EGFP- and EGFP+ cDC1s in the lung of Tnfaip3Langerin-WT x Rosa26-stopfl EGFP 
and Tnfaip3Langerin-KO x Rosa26-stopfl EGFP mice. Results are presented as mean ± SEM of n = 2-7 per group and 
representati ve of two independent experiments.
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Tnfaip3langerin-ko mice show reduced Th2-mediated inflammation, while Tregs, il-10+ and 
ifNγ+ CD8+ T cell numbers are increased upon HDM treatment
To investigate the effect of cDC1-specific TNAIP3-deficientcy on Th2 differentiation, we ex-
posed Tnfaip3Langerin-KO mice to inhaled HDM to induce allergic airway inflammation (Figure 3A). 
HDM-sensitized and challenged Tnfaip3Langerin-WT mice developed BAL eosinophilic inflamma-
tion, which was severely reduced in Tnfaip3Langerin-KO mice (Figure 3B). The numbers of B and T 
cells were also increased in Tnfaip3Langerin-WT mice upon HDM-sensitization, whereas a minor B 
and T cell infiltration was found in the BAL of HDM-sensitized Tnfaip3Langerin-KO mice (Figure 3B). 
Th2 cytokine secreting CD4+ T cells were increased in HDM-sensitized Tnfaip3Langerin-WT mice 
compared to PBS-sensitized controls. In contrast, the total numbers of IL-5+ and IL-13+ CD4 
T cells in HDM-sensitized Tnfaip3Langerin-KO were not increased compared with PBS-sensitized 
Tnfaip3Langerin-KO mice. In this model, no induction of IL-17+ or IFNγ+ CD4+ T cells was observed 
in HDM-sensitized Tnfaip3Langerin-WT or Tnfaip3Langerin-KO mice (Figure 3C). IgE and HDM-specific 
IgG1 increased upon HDM sensitization in Tnfaip3Langerin-WT mice compared to PBS sensitized 
control mice. No significant differences were found in the concentration of total IgE and HDM-
specific IgG1 in serum of HDM-sensitized Tnfaip3Langerin-WT and Tnfaip3Langerin-KO mice (Figure 3D), 
however, HDM-specific IgG1 in serum of HDM-sensitized Tnfaip3Langerin-KO mice was slightly 
elevated compared to HDM-sensitized Tnfaip3Langerin-WT mice. Complementary, HDM-sensitized 
Tnfaip3Langerin-KO mice showed no lung inflammation and mucus production, which were ob-
served in Tnfaip3Langerin-WT mice (Figure 3F). As Th2-mediated airway inflammation is hampered 
in HDM-sensitized Tnfaip3Langerin-KO mice, we wondered whether Th2-suppressive cells would 
be increased in HDM-treated Tnfaip3Langerin-KO mice. MLNs of both PBS and HDM-sensitized 
Tnfaip3Langerin-KO mice had an increased percentage of Foxp3+CD25+ Tregs compared to both PBS 
and HDM-sensitized Tnfaip3Langerin-WT mice (Figure 3G). HDM-sensitized Tnfaip3Langerin-KO mice 
had similar number of CD8+ T cells in the BAL as compared to HDM-sensitized Tnfaip3Langerin-WT 
mice (Figure 3H). Strikingly, both intracellular IL-10+ and IFNγ+ CD8+ T cells in the BAL of HDM-
sensitized Tnfaip3Langerin-KO mice were increased compared to HDM-sensitized Tnfaip3Langerin-WT 
mice (Figure 3I). Strikingly the increase in Tregs in Tnfaip3Langerin-KO mice was not responsible 
for the reduced Th2-driven immune responses, as Tnfaip3Langerin-KO mice depleted of Tregs by 
an anti-CD25-depleting antibody (PC61), still did not develop Th2-driven inflammation (Figure 
S2A-C).
This implicates that TNFAIP3 deletion in cDC1s and Langerhans cells hampers development 
of Th2 cytokine production and IgE secretion upon HDM exposure, whereas antigen-specific 
IgG1 is not affected. Furthermore, TNFAIP3 deletion in cDC1s induces higher numbers of anti-
inflammatory Tregs and IL-10+ and IFNγ+ CD8+ T cells after inhaled HDM. Intriguingly, depleting 
Tregs in Tnfaip3Langerin-KO mice does not restore Th2-mediated inflammation, indicating that 
Tregs are not essential for the suppression of Th2-mediated inflammation.
Activated cDC1s suppress Th2 immune responses
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systemically induced Th2 inflammation, using oVA-alum is hampered in Tnfaip3langerin-
ko mice
As TNFAIP3 is only depleted in pulmonary cDC1s and Langerhans cells in the skin of Tnfai-
p3Langerin-KO mice, we determined whether Tnfaip3Langerin-KO mice would also mount decreased 
Th2 immune responses that are systemically induced. To induce Th2 immune responses sys-
temically, mice were treated intra-peritoneally with the Th2-inducing adjuvant alum to which 
ovalbumin (OVA) (OVA-alum) was coupled, on days 0 and 6 (Figure 4A). OVA-specific IgE, IgG1 
and IgG2c were induced upon OVA-Alum treatment in Tnfaip3Langerin-WT and Tnfaip3Langerin-KO 
mice, indicative of successful sensitization (Figure 4B). OVA-Alum treated Tnfaip3Langerin-KO mice 
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figure 2: Depletion of TNfAiP3 in cDC1s increases pulmonary DCs numbers, whereas T cells are unaltered. (A) 
Quantification of pulmonary DC subsets by flow cytometry. (B) Enumeration of CD4+ T cells by flow cytometry in 
lung, MLN and spleen by flow cytometry. (C) Quantification of CD8+ T cells by flow cytometry in lung, MLN and 
spleen by flow cytometry. Results are presented as mean ± SEM of n = 3-4 per group and representative of two 
independent experiments.
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had decreased OVA-specific IgE levels as compared to OVA-Alum treated Tnfaip3Langerin-WT mice, 
however OVA-specific IgG1 was unaltered (Figure 4B). Tnfaip3Langerin-KO mice had similar num-
bers of CD4+ T cells both in MLN and spleen as Tnfaip3Langerin-WT mice (Figure 4C), but the propor-
tion of IL-5+/IL-13+ CD4+ T cells in both MLN and spleen were reduced in Tnfaip3Langerin-KO mice 
compared to Tnfaip3Langerin-WT mice (Figure 4D). Intra-peritoneal sensitization with OVA-Alum 
also induced an increased proportion of Tregs in the MLN of OVA-Alum treated Tnfaip3Langerin-KO 
mice compared to Tnfaip3Langerin-WT mice (Figure 4E). No differences were observed in the total 
numbers of CD8+ T cells (Figure 4F), but the frequency of IL-10+/IFNγ+ CD8+ T cells was increased 
in MLN and spleen of Tnfaip3Langerin-KO mice as compared to Tnfaip3Langerin-WT mice (Figure 4G).
These data demonstrate that TNFAIP3 deletion in pulmonary and skin cDC1s even systemi-
cally can inhibit development of Th2 immune responses, and induce anti-inflammatory Tregs 
and IL-10+ and IFNγ+ CD8+ T upon OVA-alum exposure.
Tregs and CD8+ T cells are already increased in naive Tnfaip3langerin-ko mice
As the percentage of effector memory Tregs and numbers of IL-10+ CD8+ T cells was already in-
creased in PBS-sensitized and HDM-challenged mice, we wondered whether these cells would 
be altered in naive Tnfaip3Langerin-KO mice. Indeed, Treg percentages were increased in MLN of 
Tnfaip3Langerin-KO mice as compared to Tnfaip3Langerin-WT mice (Figure 5A-B). We investigated vari-
ous activation markers on the Tregs, of which CD69 is an early activation marker, and CD103 is 
expressed on mucosal Tregs and is associated with a strong suppressive effector function (26). 
The frequency of CD103 and CD103/CD69-expressing Tregs in the MLN of Tnfaip3Langerin-KO mice 
was increased compared to Tnfaip3Langerin-WT mice, at the expense of CD69+ Tregs (Figure 5C-D). 
The numbers of IL-10+, IFNγ+ and IL-10+/IFNγ+ double positive CD8+ T cells in the lungs of naive 
Tnfaip3Langerin-KO mice were augmented compared to naïve Tnfaip3Langerin-WT mice (Figure 5E-F).
In conclusion, these data indicate that Tregs and IL-10/IFNγ-secreting CD8+ T cells are already 
increased in naive Tnfaip3Langerin-KO mice.
TNfAiP3 deletion in cDC1s increases PD-l1 and il-12 expression in all pulmonary DC 
subsets
As Tregs and IL-10 and IFNγ-secreting CD8+ T cells are increased in Tnfaip3Langerin-KO mice, we 
examined DC subsets and changes in co-stimulatory marker expression by DCs either at base-
line or upon HDM stimulation. The number of different DC subsets in the lung was followed 
24 hours after a single intra-tracheal HDM exposure. The total number of DCs, cDC2s, moDCs, 
and pDCs were increased in naïve Tnfaip3Langerin-KO mice compared to controls, whereas strik-
ingly the number of cDC1s was unaltered. After HDM exposure, total DC numbers and moDCs 
increased in Tnfaip3Langerin-WT mice, which was not observed in Tnfaip3Langerin-KO mice (Figure 6A). 
Since activated DCs migrate towards the MLN, we also evaluated DC numbers in the MLN. Total 
DC and cDC2 numbers in PBS-treated Tnfaip3Langerin-KO mice were not different from PBS-treated 
Acti vated cDC1s suppress Th2 immune responses
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figure 3: Tnfaip3langerin-ko mice show reduced Th2-mediated infl ammati on, while Tregs, il-10+ and ifNγ+ CD8+ 
T cell numbers are increased upon HDM treatment. (A) Tnfaip3Langerin mice were sensiti zed i.n. with PBS or 1 
μg HDM on day 0 and challenged i.n. with 10 μg HDM daily between days 7 and 11 to induce allergic asthma. 
Analysis was performed at day 15. (B) Numbers of eosinophils, B cells and T cells determined in BAL by fl ow cyto-
metric analysis. (C) Number of CD4+ T cells in BAL by fl ow cytometric analysis. (D) Number of IL-5+, IL-13+, IL-17+, 
and IFNg+ CD4 T cells in the BAL by fl ow cytometric analysis. (E) Serum total IgE and HDM-specifi c IgG1 levels. 
(F) Histological analysis of mucus producing goblet cells in the airways by periodic acid staining. (G) Percentages 
Tregs of CD4+ T cells by fl ow cytometric analysis in MLN of Tnfaip3Langerin mice that underwent the allergic asthma 
protocol. (H) Number of CD8+ T cells in BAL by fl ow cytometric analysis. (I) Quanti fi cati on of IL-10+ and IFNγ+ CD8+ 
T cells in the BAL by fl ow cytometric analysis. Results are presented as mean ± SEM of n = 2-6 mice per group and 
representati ve of two or more independent experiments. * = p < 0.05, ** = p < 0.01.
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Tnfaip3Langerin-WT mice, whereas cDC1s were increased in PBS-treated Tnfaip3Langerin-KO mice 
compared to PBS-treated Tnfaip3Langerin-WT mice. HDM exposure increased the total numbers of 
DCs, cDC1s, and cDC2s in both Tnfaip3Langerin-KO and Tnfaip3Langerin-WT mice. No diff erences were 
found in DC subset numbers between HDM-treated Tnfaip3Langerin-KO and Tnfaip3Langerin-WT mice 
(Figure 6B).
As co-inhibitory marker expression by DCs is implicated in Treg and IL-10+ inducti on (27), we 
examined PD-L1, PD-L2, ICOSL, and TGF-b on DC subsets aft er HDM exposure. No diff erences 
were observed for PD-L2, ICOSL, and TGF-b expression, as well as the immune suppressive cy-
tokine IL-10 (data not shown). In contrast, we found an increased expression of PD-L1 not only 
in pulmonary cDC1s, but also in cDC2s and moDCs of naïve Tnfaip3Langerin-KO mice, which was 
enhanced aft er HDM exposure (Figure 6C). Everts et al, showed that IL-12 secreti on by cDC1s is 
Figure 5: Langerin-A20 KO mice show increased Tregs and Th2 suppressive cytokine producing CD8+ T cells
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Figure 6: CD103+ DCs display increased PD-L1 and IL-12 expression
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essential for inhibiting Th2 immune responses (12). Alongside the Th2 suppressive properties 
of IL-12, its expression is also essential for the production of IFNγ+ by CD8+ T cells (28). Strik-
ingly, we found increased IL-12 secretion by pulmonary cDC1s of naïve Tnfaip3Langerin-KO mice as 
compared to Tnfaip3Langerin-WT mice. IL-12 production was also increased in cDC2s and moDCs 
of Tnfaip3Langerin-KO mice but to a lesser extent as cDC1s (Figure 6E-F). Besides the increase in 
frequency also the total number of IL-12-expressing DCs in the lungs was increased in naïve 
Tnfaip3Langerin-KO mice compared to Tnfaip3Langerin-WT mice.
This implicates that TNFAIP3 deletion in cDC1s increases the expression of the co-inhibitory 
molecule PD-L1 and Th2-suppressive cytokine IL-12, not only in Tnfaip3-deficient cDC1s, but 
unexpectedly also in all other lung DC subsets.
il-12 and ifNγ are essential for PD-l1 expression on DC subsets in Tnfaip3langerin-ko mice
IL-12 is essential for the induction of IFNγ secretion by CD8+ T cells (28), and IFNγ can induce PD-
L1 expression (29). To determine whether IL-12 and/or IFNγ are responsible for the increased 
PD-L1 expression in all lung DCs in Tnfaip3Langerin-KO mice, we treated mice with anti-IL-12p40 or 
anti-IFNγ antibodies for 10 days prior to a single HDM exposure (Figure 7A). Strikingly, blocking 
IL-12 completely prevents PD-L1 upregulation after HDM exposure in all pulmonary DC subsets 
of Tnfaip3Langerin-KO mice. Anti-IFNγ antibodies also inhibited the upregulation of PD-L1 in DCs 
of Tnfaip3Langerin-KO mice, although less vigorously than anti-IL-12 treatment (Figure 7B-C). CD86 
expression by DC subsets in both Tnfaip3Langerin-WT and Tnfaip3Langerin-KO mice was increased after 
HDM exposure, but unaltered by blocking either IL-12p40 or IFNγ (Figure 7D).
We therefore conclude that, IL-12p40 or IFNγ blockage can separately reduce the increased 
expression of PD-L1 on DCs subsets in Tnfaip3Langerin-KO mice, indicating that IL-12 expression 
by pulmonary cDC1s and IFNγ secretion by CD8+ T cells are essential for the increase in PD-L1 
expression after HDM exposure in Tnfaip3Langerin-KO mice.
figure 6: TNfAiP3 deletion in cDC1s increases PD-l1 and il-12 expression in all pulmonary DC subsets (A) 
Quantification of total DCs, cDC1s, cDC2s and moDCs in lung of PBS or HDM-treated Tnfaip3Langerin mice by flow 
cytometry. (B) Quantification of total migratory DCs, migratory cDC1s and migratory cDC2s in the MLN by flow 
cytometry. (C) Expression level of PD-L1 in different DC subsets of Tnfaip3Langerin mice by flow cytometry. (D) 
Quantification of MFI of PD-L1 in cDC1s, cDC2s, moDCs, and pDCs by flow cytometry. (E) Flow cytometric gat-
ing of pulmonary IL-12-secreting cDC1s. (F) Enumeration of the percentages IL-12 secreting DCs per subsets by 
flow cytometry. (G) Quantification of IL-12-expressing DCs in the lung by flow cytometry. Results are presented 
as mean ± SEM of n = 2-6 mice per group and representative of two or more independent experiments. * = p < 
0.05, ** = p < 0.01.
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DisCussioN
Conventional cDC1s are specialized in CD8+ T cell responses essential for antiviral and anti-
tumor responses; however, there are conflicting data regarding the function of cDC1s in 
Th2-mediated disorders. Recently, it has been shown that cDC1s can suppress Th2-mediated 
inflammation in response to helminth infections via the induction of IL-12 (12). Therefore, we 
hypothesized that activation of cDC1s, mediated via TNFAIP3 depletion, would suppress Th2 
development in response to inhaled HDM.
Our results show that activation of Langerin-expressing cDC1s is sufficient to suppress 
Th2-mediated inflammation in response to inhaled HDM, whereas heterozygous deletion 
of TNFAIP3 in cDC1s did not affect Th2-mediated inflammation. Not only was Th2-mediated 
inflammation attenuated upon locally induced inflammation in Tnfaip3Langerin-KO mice, but 
also systemically induced Th2 inflammation by the strong Th2-promoting adjuvant alum was 
abrogated. Both locally and systemically mediated protocols induced the development of 
highly activated Tregs and IL-10 and IFNγ-secreting CD8+ T cells in the lungs and lung-draining 
lymph nodes. Surprisingly, TNFAIP3 deficiency in cDC1s promoted increased Tregs and CD8+ T 
cell numbers in the steady state. TNFAIP3 deletion in cDC1s increased expression of the Th2-
suppressive co-inhibitory molecule PD-L1 and IL-12, not only on cDC1s but also on all other 
pulmonary DC subsets. Blocking IL-12 and IFNγ both restored PD-L1 expression indicating that 
IL-12 and IFNγ drive PD-L1 expression in mice with Tnfaip3-deficient cDC1s.
Our observation that activated cDC1s can abolish the development of Th2-mediated inflam-
mation agrees with other reports showing that cDC1s suppress Th2-mediated pulmonary 
inflammation upon helminth infections (12), ovalbumin (10), and HDM exposure (6). Further-
more, Helicobacter pylori infection suppresses allergic airway inflammation through cDC1s 
(30). In contrast, others have shown that cDC1s are essential for the induction of Th2-mediated 
differentiation in response to HDM (11,31), and that depleting cDC1s would even hamper Th2-
mediated eosinophilic inflammation (11). This may be a consequence of the use of BXH-2 mice, 
which exhibit a myeloproliferative syndrome and aberrant IL-12p40 production (32) that might 
hamper eosinophilic inflammation. In line, specific depletion of lung cDC1s using Langerin-DTR 
mice did not affect eosinophilic inflammation (6).
cDC1s are a specialized DC subset involved in Treg induction through TGF-ß and retinoic acid 
dependent mechanisms both in vitro (10,33) and in vivo (34). Indeed, activating cDC1s increase 
Treg proportions, and especially the frequency of mucosal associated CD69/CD103 double ex-
pressing Tregs. These Tregs may contribute to dampen the Th2-mediated inflammation, either 
by inhibiting cDC2-mediated Th2 cell differentiation or affecting the effector phase of the Th2-
mediated inflammation. Surprisingly, Treg depletion did not restore eosinophilic inflammation 
in our model, indicating that Tregs are not essential for the suppression of Th2-mediated 
inflammation by activated cDC1s. Furthermore, only PBS-sensitized Tnfaip3Langerin-KO mice dis-
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played increased effector memory Tregs in the HDM-mediated allergic airway inflammation 
model, whereas this was not observed in HDM-sensitized Tnfaip3Langerin-KO mice. Taken together, 
these findings suggest that effector memory Tregs are not maintained during inflammatory 
responses and are therefore not capable of suppressing the Th2-mediated inflammation.
Whereas both cytokine expression by Th2 cells and IgE levels were not induced upon both 
HDM and OVA-alum treatment, surprisingly, we failed to detect any decrease in the Th2-
associated immunoglobulin IgG1 in both protocols. IL-4 expression is essential for IgG1 class 
switching (35). However, follicular T helper (Tfh) cells, and especially IL-21 expression by Tfh 
cells are already sufficient for class switching to IgG1 (36,37). Furthermore, IL-10 expression is 
also known to induce IgG1 class switching (38,39). Hence, IgG1 class switching in Tnfaip3Langerin-KO 
mice may be triggered through other than Th2-associated cytokines.
Ablating TNFAIP3 expression in cDC1s increased the expression of PD-L1 and IL-12 in all 
pulmonary DCs, indicating that DCs in Tnfaip3Langerin-KO mice do not favor Th2 differentiation. 
However, we did not show that PD-L1 or IL-12 directly hamper the development of Th2 im-
mune responses, there are several lines of evidence that suggest that this is plausible. It is well 
known that IL-12 inhibits Th2 (40,41) and promotes Th1 cell development (42), respectively. 
However, we did not observe an increased Th1 cell differentiation, but rather an increase in 
IFNγ-production by CD8+ T cells, which is also dependent on IL-12 (28). The specific increase of 
IFNγ-producing CD8+ T cells and not IFNγ-producing CD4+ T cells may be due to the key feature 
of cDC1s to drive superior CD8+ T cell activation (7-9). Moreover, IL-10-secretion by CD8+ T 
cells can be induced by IL-12, IL-4 or a combined IL-12/IL-4-rich environment (43,44). Tnfaip3-
depletion in cDC1s increased PD-L1 expression not only in cDC1s, but strikingly in all pulmonary 
DC subsets. This is probably mediated by IFNγ produced by CD8+ T cells in Tnfaip3Langerin-KO mice, 
as IFNγ is known to induce PD-L1 expression (29). This may also account for the increased 
PD-L1 expression in all pulmonary DCs, since blocking the upstream instructive cytokine IL-12 
or directly the effector cytokine IFNγ reduced PD-L1 expression. The main source of IL-12 in 
Tnfaip3Langerin-KO mice are most likely Tnfaip3-deficient cDC1s, as those DCs were superior in 
their IL-12 production as compared to other DC subsets in Tnfaip3Langerin-KO mice. Therefore, 
it is conceivable that the suppression of Th2-mediated inflammation in Tnfaip3Langerin-KO mice 
is caused by IFNγ-induced PD-L1 expression on pulmonary DCs in Tnfaip3Langerin-KO mice. Both 
PD-L1 expression on DCs as well as IL-10 and IFNγ-secreting CD8+ T cells are able to suppress 
Th2 cell-driven inflammation and maintain tolerance. In concert with the increased IL-12 
production that favors Th1 differentiation, this creates a Th2 suppressive environment. The 
importance of IL-12 in maintaining the balance between Th1 or Th2 immune responses is 
further supported by the observation that atopic dermatitis exacerbates in psoriasis patients 
treated with ustekinumab (monoclonal antibody to the p40 subunit of IL-12 and IL-23) (45,46).
In conclusion, our data indicate that activating cDC1s increases their Th2-suppressive capac-
ity and abolishes Th2-mediated inflammation in response to HDM. Tnfaip3-depletion in cDC1s 
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increases IL-12 and PD-L1 expression, not only on cDC1s but also on DC subsets indicating 
that the existence of cross-regulation between DC subsets. Activated cDC1s increases Treg 
and CD8+ T cell numbers that secrete Th2-repressing cytokines IL-10 and IFNγ. Thus, implicat-
ing that the specific activation of cDC1s may represent a new pharmacological intervention 
strategy to inhibit Th2-mediated inflammation.
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Supplementary Figure 1: Gating strategy for pulmonary DCs
supplementary figure 1: gating strategy for pulmonary DC subset. Pulmonary DCs were gated according the 
gating strategy.
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supplementary fi gure 2: Tregs depleti on does not restore Th2-mediated infl ammati on in Tnfaip3langerin-ko 
mice. (A) Tregs were depleted in Tnfaip3Langerin mice with i.p. PC61 injecti ons on day -1, 2, 7, and 10. Tnfaip3Langerin 
mice were sensiti zed i.n. with PBS or 1 μg HDM on day 0 and challenged i.n. with 10 μg HDM daily between days 
7 and 11 to induce allergic asthma. Analysis was performed at day 15. (B) Quanti fi cati on of eosinophils, B cells 
and T cells in BAL by fl ow cytometry. (C). Enumerati on of IL-5+, IL-13+, IL-17+, and IFNγ+ CD4+ T cells in the BAL 
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Table s1: Antibodies used for flowcytometryTable	S1	Antibodies	used	for	fl w	cytometry
Antibody Conjugate Clone Company
CD103 eF450 2E7 eBioscience
CD11b PerCP-Cy5.5 M1/70 BD	Biosciences
CD11c PE-TxR N418 eBioscience
CD19 APC-eFluor	780 ID3 eBioscience
CD207 Alexa-fluor	647 929F3.01 Dendritics
CD3 PE-CF594 145-2C11 BD	Biosciences
CD3 APC-eF780 17A2 eBioscience
CD4 BV711 RM4-5 BD	Biosciences
CD4 BV605 L3T4 BD	Biosciences
CD64 BV711 X54-5/7.1 Biolegend
CD69 FITC H1.2F3 eBioscience
CD8 PE-Cy7 53-6.7 eBioscience
CD86 PE-Cy7 GL1 BD	Biosciences
FoxP3 PE-Cy7 FJK-16s eBioscience
GR-1 Pe-Cy7 RB6-8C5 eBioscience
IFNy EF450 XMG1.2 eBioscience
IL-10 PerCP-Cy5.5 JES5-16E3 eBioscience
IL-12 PE C17.8 eBioscience
IL-13 EF660 eBio13A eBioscience
IL-17A AF700 TC11-18H10.1 BD	Biosciences
IL-5 PE TRFK-5 BD	Biosciences
MHCII Alexa	Fluor	700 M5/114.15.2 eBioscience
PD-L1 biotin B7-H1 eBioscience
Siglec	F PE E50-2440 BD	Biosciences
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AbsTRACT
background: Asthma is a heterogeneous respiratory disease that can arise as a consequence 
of different underlying immunological mechanisms. In most asthma patients, the disease can 
be effectively treated with inhaled corticosteroids (ICS). However, a small population of asthma 
patients is unresponsive to this treatment. As these patients display the highest morbidity and 
symptom burden, it is worthwhile to investigate the underlying disease mechanism.
Aims: The aim of this study is to characterize the phenotype of immune cells in peripheral 
blood of asthma patients by automated analyses of flow cytometry measurements and relate 
these to the disease control status.
Methods: Peripheral blood of 37 asthma patients and 22 healthy controls (HC) was drawn, and 
surface expression of CD1c, CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD33, CD86, HLA-DR 
and Siglec-8 was determined using flow cytometry. Cell populations were determined using 
the FlowSOM algorithm, and outcomes of the analyses were confirmed by manual gating.
Results: Our results show that the immune cell composition of asthma patients is very different 
from HC. Asthma patients had higher proportions of blood eosinophils, B cells and monocytes, 
whereas CD8+ T cells and neutrophil proportions were lower than those in HC. Percentages 
of eosinophils and neutrophils were not different between controlled asthma patients and 
uncontrolled asthma patients, but surprisingly, a subset of B cells expressing CD1c+, and HLA-
DR-expressing monocytes correlated with the Asthma Control Questionnaire (ACQ)-score.
Conclusion and Clinical Relevance: In conclusion, HLA-DR+ classical monocytes and CD1c+ B 
cells correlated with disease control status and could thus play a role in asthma patients that 
remain uncontrolled while treated with ICS. We conclude that further studies are required to 
explore the importance of these cell populations in human asthma.
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iNTRoDuCTioN
According to the latest Global Initiative for Asthma (GINA) guidelines, asthma is a heteroge-
neous disease that presents with a broad pallet of respiratory symptoms such as wheezing, 
shortness of breath, chest tightness and cough, in addition to variable airway obstruction (1). 
Clustering and defining characteristics of asthma patients have revealed that asthma is not 
a single disease, but rather a syndrome, that consists of various subtypes that share similar 
clinical characteristics (2). Asthma patients can be categorized based on clinical characteristics 
(phenotypes), or based on the underlying disease mechanism (so-called endotypes) (3,4). To 
date, most asthma patients are grouped into categories that are descriptive and provide infor-
mation regarding one single dimension of the disease, such as factors that triggers the disease 
(e.g. exercise) (5), airway obstruction patterns (e.g. reversible and irreversible) (6), immunol-
ogy (e.g. eosinophilic and non-eosinophilic) (7), or disease control based on corticosteroid 
responsiveness (e.g. well-controlled and uncontrolled) (8). Especially for uncontrolled asthma 
patients it would be beneficial to investigate the underlying disease mechanism, as these pa-
tients display the highest morbidity and symptom burden (8). Improvement of techniques to 
characterize immune cells and molecules enabled characterization of different immunological 
endotypes within asthma. However, current immunological asthma endotypes are often one 
dimensional and frequently based on granulocytic inflammation (eosinophilic, neutrophilic, 
mixed granulocytic, or paucigranulocytic) (9) or on T helper (Th) cell profile (Th2 high vs Th2 
low) (10). It is generally thought that immunophenotyping of asthma patients can contribute 
to therapy management and pave the way for personalized medicine.
Flow cytometry is a powerful tool to identify and characterize immune cell populations, and 
enables high-throughput quantitative analysis of single cells. The possible number of different 
markers characterizing cells simultaneously using flow cytometry increases rapidly (11). Thus, 
flow cytometry is an ideal technology to identify immune cells in different asthma phenotypes. 
The majority of researchers use manual analysis of flow cytometric data. However, this has 
some disadvantages, as manual analysis is a very complex and time-consuming process, and as 
a result, not all combinations of markers are analysed on all cell types. During manual analysis, 
many cells are excluded from used gates, and therefore not analysed, leading to unexamined 
and unnoticed information (12). Furthermore, as this is a manual process, variations between 
researchers result in variability in flow cytometry analyses (13). Recently, advanced machine-
learning algorithm techniques have paved the way for unbiased analysis of flow cytometry 
data (14). Techniques that ease visualisation, such as FlowSOM and SPADE can also be used 
to optimize and control automatic analyses of flow cytometry data (15, 16). Alterations of 
immunological characteristics in different asthma phenotypes (e.g. disease control based on 
Asthma Control Questionnaire (ACQ) are currently unknown. Therefore, here we used the 
machine-learning algorithm FlowSOM to analyse in an unbiased manner 15-colour flow cy-
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tometry measurements of peripheral blood cells of healthy controls and asthma patients that 
differed in disease severity. This approach enabled us to characterize phenotypic differences 
between the immune profiles of healthy controls and asthma patients that are controlled, 
partly-controlled or uncontrolled while treated with ICS.
MATERiAl AND METHoDs
subject characteristics
Patients were diagnosed with asthma by at least one of the following parameters during the 
past 5 years: 1) reversibility to b2-agonists, FEV1 ³12% predicted from baseline and ³ 200 ml 
after 400 mg inhaled salbutamol or equivalent; 2) bronchial hyper-responsiveness to metha-
choline or histamine; 3) peak-flow variability of > 20% over a period of 14 days; 4) fall in FEV1 
> 12% and > 200 ml when tapering treatment. Diagnosed asthma patients were included in 
the study at the Franciscus Gasthuis in Rotterdam, The Netherlands if they met the following 
inclusion criteria: 1) diagnosis of asthma, confirmed; 2) recent (<12 months) metacholine/his-
tamine provocation test; 3) use of ICS and b2-agonist; 4) age between 18 and 50 years old; 5) 
signed informed consent. Asthma patients were excluded from the study if they met one of the 
following exclusion criteria: 1) use of systemic corticosteroid > 7.5 mg three months prior to 
inclusion; 2) treatment with other immunomodulatory medication; 3) concomitant pulmonary 
diseases (including chronic obstructive pulmonary disorders or interstitial lung diseases); 4) 
autoimmune diseases; 5) malignancies; 6) human immunodeficiency virus seropositivity; 7) 
BMI >30; 8) Age >50 years; 9) smoking > 10 pack years; 10) current pregnancy.
Healthy control (HC) subjects were recruited at the Franciscus Gasthuis in Rotterdam and the 
Erasmus MC in Rotterdam, the Netherlands. Healthy subjects were included in this study after 
giving their informed consent and were excluded if they met any of the above listed exclusion 
criteria, or had an FeNO > 50 ppb.
For this study, 37 asthma patients and 22 HC donated peripheral blood. Asthma control was 
evaluated based on two independent ACQ scores in all asthma patients. All asthma patients 
required minimally Global Initiative for Asthma (GINA) treatment step 3 or 4 medication (1).
The Medical Ethical Committee of the Erasmus MC Rotterdam approved this study. Further 
patient and HC characteristics are shown in Additional file 1: Table S1.
flow cytometry staining
Peripheral blood was lysed to remove erythrocytes using osmotic lysis buffer (8.3% NH4Cl, 1% 
KHCO3 and 0.04% NA2EDTA in Milli-Q). Lysed peripheral blood cells were stained for extra-
cellular markers using the following antibodies: CD19-FITC (HIB19, BD biosciences), CD1c-PE 
(AD5-8E7, Milteyni) , CD14-PE-TxR (TuK4, Invitrogen), CD33-PE-Cy7 (VI M505, eBioscience), 
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CD16-PerCP-Cy5.5 (3G8, BD biosciences), Siglec-8-APC (7C9, Biolegend), CD11c-AF700 (B-Ly6, 
BD biosciences), CD3-APC-eFl780 (UCHT1, eBioscience), CD45-V450 (HI30, BD Biosciences), 
CD8-biotin (HIT8a, eBioscience), CD86-BV650 (2331FUN1, BD Biosciences), HLA-DR-BV711 
(G46-6, BD biosciences), CD4-BV785 (SK3, BD Biosciences), Streptavidin-BV605 (BD Biosci-
ences). Fixable Aqua Dead Cell Stain kit for 405 (Invitrogen, Molecular Probes) was used as 
live-dead marker. Cells were measured on a Flow cytometer LSRII (BD Biosciences). Manual 
gating analyses were performed using FlowJo V10 (Treestar). Automatic gating was performed 
in the R environment.
flowsoM based unsupervised analysis and automated cell type detection
Automated analysis was done using the FlowSOM algorithm (15). First, the data were manually 
gated on single live CD45+ cells, including all hematopoietic cells in total blood. Besides the 
analyses performed on all hematopoietic cells in blood, more detailed analyses were per-
formed on CD33- lymphocytes (including B cells, T cells, NK cells and dendritic cells) and CD33+ 
monocytes. CD33- lymphocytes and CD33+ monocytes were selected from single live CD45+ 
mononuclear cells (based on SSC and FSC expression) based on their CD33 expression. Data 
were compensated, transformed with an estimated logical transformation and scaled. Cells 
were subsequently assigned to a Self-Organizing Map with a 6x6 grid (Total blood and CD33- 
lymphocytes) or a 5x5 grid (CD33+ monocytes). Hereby similar cells were grouped, resulting in 
respectively 36, or 25 clusters. Once the data were mapped onto the grid, a Minimal Spanning 
Tree was built to visualize similar clusters in branches. Clusters of cells with similar expression 
markers were clustered within metaclusters (max 10-15). The percentage of selected cells 
within either the cluster or metacluster of interest was computed with respect to percentage 
of CD45+ cells, CD33+ monocytes or CD33- lymphocytes.
statistical analyses
Comparisons between groups were performed using a Mann-Whitney U test. Correlations 
were analysed using Spearman’s rank-order correlation test. P-values were two sided, and 
analyses were performed using R (version 3.3.1) and GraphPad Prism (version 7). P<0.05 was 
considered statistically significant.
REsulTs
unbiased clustering of peripheral blood cells in healthy controls and asthma patients.
To investigate a broad range of immune cells, a flow cytometric staining was designed us-
ing the markers: CD1c, CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD33, CD86, HLA-DR and 
Siglec-8. Combining these markers allowed identification of at least B cells, T cells, dendritic 
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cells, monocytes, eosinophils and neutrophils in peripheral blood. A FlowSOM tree was gener-
ated from an aggregate file that included 4x106 live CD45+ hematopoietic cells of all patients 
and healthy controls (HC) included in the study. In this tree 10 different metaclusters of cells 
with similar marker expression could be observed (Figure 1A). HCs and asthma patients were 
mapped to the FlowSOM tree separately. Significant increases in cell populations between cell 
HC and asthma patients were represented by red coloration of the nodes, whereas significant 
decreases were represented by blue coloration of the nodes (Figure 1B). Comparing frequen-
cies of cells in individual metaclusters revealed significant differences between HCs and 
asthma patients in metaclusters 1, 4, 5 and 6 (Figure 1C). Detailed analysis of each individual 
included in the study showed an increase in metacluster 1, containing eosinophils in asthma 
patients compared to HCs. Moreover, asthma patients displayed decreased frequencies of cells 
in metaclusters 4, 5 and 6, which contained a subset of neutrophils, monocytes, and CD8+ T 
cells, respectively (Figure 1D).
In conclusion, unbiased metaclustering of peripheral blood cells obtained revealed differ-
ences in various cell populations between HCs and asthma patients.
Peripheral blood of asthma patients display altered b and CD8+ T cell frequencies
Significant differences were observed in the lymphocyte population, e.g. T cells in the Flow-
SOM Tree (Figure 1, metacluster 6, 7, 9, 10). Therefore, we next increased the sensitivity of 
our analysis by generating a FlowSOM Tree from an aggregate file containing CD45+, SSClow, 
CD33- lymphocytes of all study individuals. Cells were evaluated for the expression of all mark-
ers except CD33 and Siglec-8, as these markers are either not expressed on lymphocytes, or 
were used to select for lymphocytes. Lymphocytes comprise various cell populations, such as 
B cells, CD4+ T cells, CD8+ T cells, NK cells and DCs, that can be analysed using this analysis. 
From all lymphocytic cells, 15 metaclusters containing cells with similar marker expression 
were identified (Figure 2A). Various significant differences were observed in lymphocyte popu-
lations between HC and asthma patients (Figure 2B-C). We identified a significant increase in 
metacluster 3, 11 and 14, containing respectively CD1c-expressing B cells, CD86-expressing 
CD4+/CD8+ T cells and HLA-DR/CD86-expressing memory CD8+ T cells in asthma patients, 
compared to HCs. Asthma patients displayed decreased frequencies of cells in metacluster 9, 
which contained HLA-DR-expressing CD8+ T cells (Figure 2D). No significant differences where 
observed in CD4+ T cells and NK cell populations between asthma patients and HCs (data not 
shown). DCs could not be identified in a metacluster and this was likely caused by their low 
numbers in pheripheral blood.
In summary, asthma patients showed different frequencies of subpopulations of CD8+ T cells 
and CD1c+ B cells compared with HC, whereas no differences in proportions of CD4+ T cells or 
NK cells were detected.
Flowcytometric profi ling of asthma pati ents
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Asthma pati ents display diff erences in frequencies and acti vati on of CD14+ monocytes
In the FlowSOM Tree generated from all CD45+ cells, signifi cant diff erences were also observed 
in CD33+ monocytes. To improve the visibility of diff erences in monocytes, we generated a 
FlowSOM Tree from an aggregate fi le containing CD33+ monocytes of all individuals included 
in the study. As CD3, CD4, CD8 and CD19 are not expressed on monocytes, only the expres-
sion of CD1c, CD11c, CD14, CD16, CD86 and HLA-DR were evaluated. The FlowSOM Tree build 
from all monocytes was divided into 10 metaclusters, each containing cells with similar marker 
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figure 1: unbiased clustering of peripheral blood cells in healthy controls and asthma pati ents. Cells from 
peripheral blood were stained with the extracellular panel. Single live CD45+ cells for each fi le were exported and 
concatenated. This concatenated fi le was then analysed using FlowSOM and cells were clustered into 36 nodes. 
These nodes were divided over 10 metaclusters (A). Separate FlowSOM trees for healthy controls and asthma 
pati ents (B). P values for the comparison of metaclusters of healthy controls and asthma pati ents (C). Scatt er dot 
plot of the frequency of the cells within the selected metacluster per individual (D). The FlowSOM algorithm was 
run fi ve ti mes to ensure reproducible results. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001.
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expression (Figure 3A). We found that asthma pati ents displayed increased frequencies of 
classical monocytes expressing CD1c, CD86, HLA-DR and CD11c (metacluster 8), and CD1c/
HLA-DR/CD11c-expressing classical monocytes (metacluster 9), compared to HC (Figure 3B-C). 
In contrast, CD86 expressing classical monocytes with lower expression of HLA-DR and absent 
CD1c expression (metacluster 10) were lower in frequency in asthma pati ents, compared to 
HC (Figure 3D).
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figure 2: Asthma pati ents display altered b and CD8+ T cell frequencies. Single live CD45+ and CD33- lympho-
cytes for each fi le were exported and concatenated. This concatenated fi le was then analysed using FlowSOM 
and cells were clustered into 36 nodes. These nodes were divided over 15 metaclusters (A). FlowSOM tree 
for healthy controls and asthma pati ents separately (B). Signifi cant diff erences within between metaclusters 
of healthy controls and asthma pati ents (C). Quanti fi cati on of the frequency of the cells within the selected 
metacluster per individual (D). The FlowSOM algorithm was run fi ve ti mes to ensure reproducible results. * = 
p<0.05, ** = p<0.01.
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These data indicate that asthma patients present with different frequencies and activation 
states of CD14+ classical monocytes, compared to HC, whereas CD16-expressing non-classical 
monocytes are unaltered.
immune profile of asthma patients depends on ACQ-score
Next, we explored whether the differences observed in the metaclusters of total blood, 
lymphocytes and monocytes were correlated with disease control. Metacluster 1 of total 
blood, consisting of eosinophils was significantly increased in all patient groups, compared 
to HC, whereas metacluster 4 of total blood, containing a neutrophil subset was only de-
creased in partly controlled and uncontrolled asthma patients compared to HC (Figure 4A). 
Within the lymphocyte compartment metacluster 3, containing CD1c+ B cells, was specifically 
increased in uncontrolled asthma patients compared to HC. Metaclusters 9 and 11, contain-
ing HLA-DR-expressing CD8+ T cells and CD86-expressing CD4+/CD8+ T cells were decreased 
specifically in partly controlled and uncontrolled asthma patients, whereas metacluster 14, 
which also contained HLA-DR and CD86-expressing CD8+ T cells was specifically decreased in 
well-controlled asthma patients (Figure 4B). Monocyte metacluster 8, containing CD1c/CD86/
HLA-DR/ CD11c- expressing classical monocytes were specifically increased in uncontrolled 
asthma patients, whereas metacluster 9 (containing CD1c/HLA-DR/CD11c-expressing classical 
monocytes) was increased in controlled and uncontrolled asthma patients. CD86-expressing 
classical monocytes with lower HLA-DR and absent CD1c expression (metacluster 10) were 
decreased in asthma patients irrespective of their disease control compared to HC (Figure 4C).
These data indicate that controlled asthma patients are characterized by increased eosino-
phils and CD1c/CD11c/HLA-DR+ classical monocytes and decreased CD86/HLA-DR+ CD8+ T cells 
and CD11c/CD86/HLA-DR+ classical monocytes. In contrast, uncontrolled asthma patients 
display increased eosinophils, CD1c+ B cells, CD1c/CD11c/CD86/HLA-DR+ classical monocytes, 
CD1c/CD11c/HLA-DR+ classical monocytes and decreased neutrophils, HLA-DR+ CD8+ T cells, 
CD86/CD14+ CD4/CD8+ T cells, and CD11c/CD86/HLA-DR+ classical monocytes.
CD1c+ b cells and HlA-DR+ classical monocytes correlate with ACQ score
Flow cytometric analysis using the machine-learning algorithm FlowSOM revealed various dif-
ferences in cell populations. However, it is important to confirm the findings by manual gating 
(Figure S1). In general, FlowSOM clustering resembled the manual gating. However, as ex-
pected automated clustering by FlowSOM gave more metaclusters of distinct cell populations 
as determined by manual gating (Figure S2). Using the FlowSOM algorithm, differences were 
observed in eosinophils and neutrophils in total blood. Using manual gating, similar frequen-
cies of eosinophils were found compared to the FlowSOM analysis, however neutrophils were 
not different in asthma patients as compared to HC (Figure 5A). CD1c+ B cells were also specifi-
cally increased in uncontrolled asthma patients. No differences were observed in CD8+ T cell 
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frequencies between asthma pati ents and HC, whereas HLA-DR+ CD8+ T cells were signifi cantly 
reduced in partly controlled asthma pati ents compared to controlled asthma pati ents and HCs 
(Figure 5B). As FlowSOM revealed diff erences in the expression levels of acti vati on markers on 
cell populati ons, manual gati ng was used to determine the Median Fluorescent Intensity (MFI). 
The MFI of CD86 was also signifi cantly reduced in CD8+ and HLA-DR+ CD8+ T cells of controlled, 
partly controlled and uncontrolled asthma pati ents when compared to HCs (Figure 5C). HLA-
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the selected metacluster per individual (D). The FlowSOM algorithm was run fi ve ti mes to ensure reproducible 
results. * = p<0.05, ** = p<0.01, *** = p<0.001
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DR+ classical monocytes were decreased in controlled and partly controlled asthma patients as 
compared to HC. MFI of CD86 was significantly decreased on classical monocytes of controlled 
and uncontrolled asthma patients compared to HC. MFI of CD1c in classical monocytes was 
only significantly decreased in controlled asthma patients compared to HC (Figure 5D). No 
correlation was found in the frequency of eosinophils, Th2 and Th17 cells and the ACQ-scores, 
as all groups of asthma patients showed increased eosinophil frequencies. In contrast, both 
the frequency of CD1c+ B cells and HLA-DR+ classical monocytes of CD45+ hematopoietic cells 
did correlate with ACQ-scores in asthma patients (Figure 5E).
In conclusion, for various cell populations similar frequencies were determined using manual 
gating as compared to the FlowSOM analysis. Most interestingly, CD1c+ B cells and HLA-DR+ 
classical monocytes correlate with disease severity, and are a better predictor of disease sever-
ity as eosinophil frequency.
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figure 4: immune profile of asthma patients depends on ACQ-score. Enumeration of the frequency of cells 
within metacluster 1 and 4 per individual of total blood (A). Quantification of cell frequencies in lymphocyte 
metacluster 3, 9, 11 and 14 (B). Quantification of cell frequencies in monocyte metacluster 8, 9, and 10 (C). * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001.
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figure 5: CD1c+ b cells and HlA-DR-expressing classical monocytes correlate with ACQ. Quantification of man-
ually gated eosinophils and neutrophils (A). Enumeration of manually gated CD1c+ B cells, CD8+ T cells and HLA-
DR+ CD8+ T cells (B). Quantification of MFI of CD86 in CD8+ T cells and HLA-DR+ CD8+ T cells (C). Quantification 
of HLA-DR+ classical monocytes and MFI of CD86 and CD1c in classical monocytes (D). Correlation between eo-
sinophils, Th2, Th17, CD1c+ B cells and HLA-DR+ classical monocytes (E). * = p<0.05, ** = p<0.01, *** = p<0.001.
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DisCussioN
Our study demonstrates that immune profiling asthma patients and HC by flow cytometry 
over time using FlowSOM is possible and conceives reliable data. Our results show that the 
immune profile of asthma patients is different from healthy controls. Asthma patients had 
increased percentages of blood eosinophils, CD1c+ B cells, and HLA-DR+ classical monocytes, 
whereas HLA-DR+ CD8+ T cells and neutrophil percentages were decreased. We observed 
that eosinophils and neutrophils were not different between controlled asthma patients and 
uncontrolled asthma patients. Surprisingly, we found that a subset of B cells, the CD1c+ B cell, 
was specifically increased in uncontrolled asthma patients, and correlated with the ACQ-score. 
Also, HLA-DR-expressing monocyte proportions correlated with the ACQ-score and were only 
significantly decreased in controlled and partly controlled asthma patients.
Our data revealed that eosinophils are increased in asthma patients irrespectively of their 
disease control status. This is surprising as eosinophils are described to be sensitive to steroid 
treatment. As treatment adherence in asthma patients is also a known complicating factor, 
especially for mild and controlled asthma patients (17). Low steroid adherence could be the 
reason that increased eosinophil percentages are observed in controlled asthma patients.
In our study, we found that percentages of CD1c+ B cells correlated with the ACQ-score. 
CD1c+ B cells were specifically increased in uncontrolled asthma patients. CD1c (BDCA1+) 
expression has been widely described as a marker expressed by dendritic cells (DCs) (18), but 
also for human marginal zone (MZ)-like B cells (19). The function of CD1c on B cells remains 
unknown, however CD1 isoforms are known to present lipids to clonally diverse T cells (20). 
Thus far, CD1c+ B cells have not been described in asthma pathology, but we can speculate that 
this B cell subset could induce CD1c-restricted T cell activation. Surprisingly, no differences 
were observed in the frequencies of CD86+ B cells between asthma patients and HCs, whereas 
a previous study reported increased expression of CD86 on B cells of allergic asthma patients. 
This increase in CD86 was specifically observed in CD23+ B cells, but not in CD23- B cells (21). As 
CD23 was not included in the staining this could cause the discrepancy between the conflicting 
results.
We also observed that the frequency of HLA-DR+ classical monocytes correlated with the 
ACQ-score, whereas others found no differences in HLA-DR expression on monocytes (22). 
Corresponding to our findings, increased expression of HLA-DR was also described in DCs 
cultured from monocytes of atopic asthmatics (23), indicating that the activation status of 
monocytes is likely implicated in asthma pathogenesis.
Our data also implies the potential for automatic analysis of flow cytometric data using 
machine learning algorithm FlowSOM on peripheral immune cells of patients obtained over 
time. Not all differences observed in the automatic analysis were confirmed by manual gat-
ing, however this can be related to fluctuations of marker intensities over time, as differences 
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observed in defined cell populations could most often be confirmed. This is in agreement with 
the FlowCAP consortium where they found lower variability in clearly defined cell subsets as 
compared to dim marker expressions and rare cell populations (24). Measuring peripheral 
blood samples of patients over time faces a lot of challenges as marker intensities can differ 
between patients due to biological factors but also due to technical issues that arise once 
samples are not processed at the same time. Therefore, it is promising to observe that the 
automatic analysis accurately resembled the manual gating.
There are several limitations to our study, as it remains arguable whether peripheral blood 
is representative for a respiratory disease. Furthermore, our data could not be corrected for 
medication adherence as this was not one of the parameters included in the study. Finally, 
this study was designed to provide a general overview of alterations in the immune system of 
asthmatic patients and was not designed to investigate specific differences in T cell activation. 
Our study suggests that the activation status of CD8+ T cells in asthma patients is reduced when 
compared to HCs, whereas CD4+ T cells were unaltered. Based on these observations it would 
be worthwhile to investigate the activation status of CD4 and CD8+ T cells in more detail using 
more extensive activation markers.
Collectively, our data show that automatic analysis of flow cytometric data acquired from 
peripheral blood of asthma patients is feasible and closely resembles manual analysis. This 
unbiased analysis approach revealed that of all immune cells analysed with our study antibod-
ies, HLA-DR+ CD8+ T cells were reduced in all asthma patients, and the percentage of CD1c-
expressing B cells and HLA-DR-expressing classical monocytes showed a significant correlation 
with disease control. No correlation was observed between eosinophils and disease control. 
Therefore, CD8+ T cells, HLA-DR+ classical monocytes and CD1c+ B cells could play an important 
role especially in asthma patients that remain uncontrolled while treated with ICS. These cell 
populations must be carefully characterized and their importance for the pathogenesis for 
asthma be further explored.
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A
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C
figure s2: Comparing manual gati ng to automated clustering by flowsoM. CD45+ blood cells of an individual 
were mapped to the FlowSOM tree. The manual gati ng of the cells was plott ed onto the node, to visualize what 
the origin of these cells was using the manual gati ng (A). CD33- lymphocytes of one individual were mapped to 
the FlowSOM tree and compared to the manual gati ng (B). CD33+ monocytes of one individual were mapped to 
the FlowSOM tree and compared to the manual gati ng (C).
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Table s1: Clinical characteristics of individuals included in the studyTable	S1:	Clini al	Characteristics
HC controlled partly	controlled uncontrolled
n 22 11 10 16
Age 30,2	(22-47) 34,0	(19-48) 27,9	(16-43) 29,2	(18-49)
Sex	(M/F) 5/17 2/9 2/8 1/15
BMI 22,85	(18,9-26,6) 24,2	(19,2-30,6) 24,14	(18,6-29,4) 26,7	(20,6-31,6)
FEV1 100,5	(69-123) 98,4	(83-119) 96,3	(74-119)
ACQ	score 0,4	(0-0,67) 1,08	(0,75-1,41) 2,34	(1,5-3,83)
FeNO 20,2	(6-47) 29,4	(6-70) 33,19	(9-92)
Table s2: Extracellular markers used for flow cytometric stainingTable	S2:	Extracellul 	panel
Marker Clone	 Company
CD3 UCHT1 eBioscience
CD4 SK3 BD	Biosciences
CD8 HIT8a eBioscience
CD11c B-Ly6 BD	Biosciences
CD14 TuK4 Invitrogen
CD16 3G8 BD	Biosciences
CD19 HIB19 BD	Biosciences
CD33 VI	M505 eBioscience
CD45 HI30 BD	Biosciences
CD86 2331FUN1 BD	Biosciences
BDCA1 AD5-8E7 Milteyni
HLA-DR G46-6 BD	Biosciences
Siglec	8 7C9 Biolegend
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In this thesis, we addressed different immunological mechanisms that contribute to the het-
erogeneity observed within asthma. We characterized the role of B cells and B-T cell interaction 
in the development of house dust mite (HDM)-induced Th2-mediated airway inflammation 
and remodelling. We demonstrated that B cells, B-T cell interactions and Tfh cells are dispens-
able for eosinophilic inflammation but necessary for airway remodelling in an asthma model 
using continuous allergen exposure (Chapter 2). By depleting the negative regulator TNFAIP3 
in myeloid cells and dendritic cells (DCs) we found that the activation status of pulmonary DCs 
controls development of eosinophilic and neutrophilic airway inflammation (Chapter 4). Fur-
thermore, we established that IL-17RA-signalling is dispensable for Th2-mediated eosinophilic 
inflammation. Also, neutrophilia can develop in mice with TNFAIP3-deficient myeloid cells and 
defective IL-17RA-signalling (Chapter 5). In Chapter 6, we show that activation of Langerin-
expressing pulmonary cDC1s, by depletion of TNFAIP3, reduces Th2-mediated eosinophilic 
inflammation and instead activates regulatory T cells, as well as IL-10 and IFNg-expressing 
CD8+ T cells. Finally, we characterized various immune cells in the peripheral blood of asthma 
patients with differences in disease control status and demonstrated that eosinophils, Th2 cells 
and Th17 cells are not predictive for disease control status, whereas CD1c-expressing B cells 
and HLA-DR-expressing classical monocytes are (Chapter 7).
In this chapter, we will discuss various different immunological mechanisms that control 
heterogeneity as observed in within animal models and asthma patients.
TH2-MEDiATED EosiNoPHiliC iNflAMMATioN
Type-2 cytokines are secreted by T helper (Th) 2 cells (IL-4, IL-5 and IL-13), type 2 innate lym-
phoid cells (ILC2s) (IL-4, IL-5, and IL-13) (1), and T follicular helper (Tfh) cells (IL-4) (2). These 
cytokines are essential for the pathogenesis of allergic asthma, and drive eosinophilic inflam-
mation (IL-5), IgE class switching by B cells (IL-4) and goblet cell hyperplasia (IL-13) (1, 3). Th2 
differentiation is induced in the lung-draining lymph node by pulmonary DCs that encountered 
allergens in a Th2-instructive cytokine milieu created by the airway epithelium (Chapter 1 and 
3) (4). Recently, the importance of Tfh cells was described for Th2 development, as naïve T 
cells do not directly differentiate into Th2 cells in an HDM-driven asthma model. Th2 cells 
first undergo a IL-4-committed Tfh stage during allergen sensitization before further differen-
tiation into memory Th2 cells during the challenge phase (5). Others also described that Tfh 
cells promote the differentiation of effector Th2 cells and thereby contribute to eosinophilic 
inflammation (6). However, we have shown in Chapter 2 that B cells and B-T cell interaction 
are dispensable for eosinophilic inflammation, but not for airway remodelling after chronic 
exposure to HDM. As final Tfh differentiation is dependent on B cells and interaction between 
B-T cell (7), our data indicates that after chronic exposure to HDM, eosinophilic inflammation 
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can develop in the absence of Tfh cells. Eosinophilic inflammation observed following chronic 
allergen exposure in the absence of B and Tfh cells may be induced or supported by direct 
activation of ILC2s (Chapter 2). As ILC2s can secrete IL-5 in response to pro-inflammatory 
cytokines secreted by the airway epithelium upon allergen recognition (8). Furthermore, Th2 
cytokine-secreting T cells in the broncho-alveolar lavage are not affected by the absence of B 
cells and Tfh cells. This suggests that moDCs can directly induce Th2 differentiation locally in 
the airways upon chronic allergen exposure, leading to eosinophilic inflammation (Chapter 2). 
Our data corresponds to recent work that revealed that B cells are essential for the expansion 
of Th2 cells in the lungs and memory T cells in the lung-draining lymph node only when the 
antigen dose is limiting (9). These data indicate that B cells are dispensable for eosinophilic in-
flammation when allergens are abundantly present. Taken together, the importance of B cells 
and Tfh cells in driving pulmonary inflammation largely depend on the experimental model, 
allergen type, and kinetics of the exposure.
Furthermore, we showed that chronic exposure to allergens provoked inducible bronchus 
associated lymphoid tissues (iBALT) structures (Chapter 2). IBALT structures in asthma patients 
are larger in size and number as compared to healthy controls, however iBALT numbers do not 
correlate with disease severity (10). In contrary, another study found no differences in iBALT 
numbers between asthmatic or non-asthmatic cross-country skiers, arguing the involvement 
of iBALT in asthma pathogenesis (11). In other inflammatory conditions, such as influenza 
infection, the production of viral-specific immunoglobulins in serum is dependent on iBALT 
structures (12). This could indicate that in allergies and asthma, allergen-specific immunoglob-
ulins could also depend on iBALT structures. Therefore, the exact function of iBALT structures 
for asthma pathogenesis remain unknown and should be investigated. To investigate this, 
chronic allergen-driven asthma models should be used, as more acute models consisting only 
a sensitization and challenge phase do not induce iBALT structures.
TH17-MEDiATED NEuTRoPHiliC AiRwAy iNflAMMATioN
In particular, late-onset patients that display more severe forms of asthma have a neutrophilic 
inflammation or a mixed eosinophilic/neutrophilic inflammation that is associated with the 
presence of Th1 and Th17 cytokines (13, 14). These severe asthma patients are often unre-
sponsive to corticosteroid treatment and suffer from severe asthma exaggerations, as both 
Th17 cells and neutrophils are unresponsive to corticosteroid treatment (15-17). In Chapter 4, 
we found that Tnfaip3-deletion in all pulmonary DC subsets induced a neutrophil-associated 
severe asthma phenotype upon HDM treatment. This neutrophilic inflammation was associ-
ated with increased numbers of IL-17 and IFNg-producing CD4+ T cells. HDM treatment in mice 
harboring Tnfaip3-deficient DCs induced Th17 differentiation and hampered Th2 differentia-
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tion, whereas Th1 differentiation was unaltered (Chapter 4). This suggests that DC activation 
controls asthma heterogeneity by directly affecting Th cell differentiation. In Chapter 4 we 
furthermore demonstrated that HDM treatment increased the expression of cytokines that 
promote Th17 cell differentiation, IL-6, and IL-23 especially in Tnfaip3-deficient cDC2s and 
moDCs (figure 1). Simultaneously, cytokines that inhibit Th2 differentiation, such as IL-6 and 
IL-12 were also induced in Tnfaip3-deficient cultured moDCs upon HDM treatment. This sug-
gests that cDC2s and moDCs are the most important DC subsets driving the development of 
either Th2-mediated eosinophilic or Th17-mediated neutrophilic inflammation, which is in line 
with the findings of other (4, 18-20).
cDC1
cDC2
moDC
pDC
CCL22
CCL17
cDC1
cDC2
moDC
pDC
IL-6
IL-23
CXCL3
IL-23
IL-6
OX40L
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the lung and maintain in ammation
RA
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PD-L1
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Increase IFNy expression by CD8+ T cells
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Figure 2: Alterations in DC function upon deletion of Tnfaip3/A20 after HDM exposure 
figure 1: Alterations in HDM-activated DC function upon deletion of TNfAiP3/A20. Activation of cDC1s via 
Tnfaip3-depletion increased IL-12 and PD-L1 expression, not only in cDC1s, but also in other DC subsets, which is 
associated with drastically reduced Type 2 airway inflammation. In contrast, Tnfaip3-deficient cDC2s and moDCs 
express higher levels of IL-6 and IL-23 cytokines, known to drive Th17 differentiation and induce neutrophilic 
inflammation upon HDM treatment.
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IL-17 and IFNg-producing CD4+ T cells are both increased upon chronic HDM exposure, but 
only HDM-specific RORgT+ T cells were induced by Tnfaip3-deficient DCs (Chapter 4). There-
fore, it is uncertain whether these IFNg-producing CD4+ T cells are truly Th1 cells or belong to 
the non-classical Th17 (Th17.1) cell population (21).
Currently it is uncertain whether DC activation is also implicated in the heterogeneity as 
observed in asthma patients. Most DC studies were performed in predominantly Th2 high 
allergic asthma patients and these studies did not compare different types of asthma patients 
(22-25). In Chapter 7, we found increased frequencies of HLA-DR-expressing classical mono-
cytes in uncontrolled asthma patients. The frequency of HLA-DR-expressing classical mono-
cytes even correlated with disease control status. This could indicate that besides alterations 
in DC subsets and activation status, also the activation status of monocytes can contribute to 
asthma severity, not only in mice but also in human. Palikhe et al, showed that intermediate 
monocytes of severe asthma patients display increased levels of protease-activated receptor-2 
(PAR-2), a G-coupled receptor activated by proteases, compared to intermediate monocytes 
of mild/moderate asthma patients (26). PAR-2-mediated activation induces secretion of IL-1b, 
IL-6 and IL-8 (27), cytokines implicated in Th17 differentiation and neutrophilic inflammation. 
This implies that monocytes of severe asthma patients display alterations in activation markers 
that could contribute to asthma heterogeneity and severity.
Furthermore, we found that in asthma patients, the percentage of neutrophils in peripheral 
blood positively correlated to the frequency of RORgT+ Th17 cells in peripheral blood (figure 
2A). Strikingly, the median fluorescent intensity (MFI) of HLA-DR, an activation marker on CD14+ 
classical monocytes was also positively correlated to the frequency of RORgT+ Th17 in the pe-
ripheral blood of asthma patients (figure 2b). In Chapter 4 we showed that the activation status 
of pulmonary DCs in mice, obtained through different TNFAIP3 levels control Th2 versus Th17-
mediated airway inflammation. Therefore, we wondered whether TNFAIP3 levels in human DCs 
would also correlate with Th17 cells. To determine this, mRNA was extracted from MACS-purified 
BDCA1+ cDC2s of asthma patients. Tnfaip3 mRNA levels were not different between healthy 
controls and patients, irrespective of their status of disease control (data not shown).
However, we found that the mRNA expression of Tnip, a protein that enables the function of 
TNFAIP3 (28, 29), was negatively correlated to the frequency of neutrophils (figure 2C), but not 
to the percentage of RORgT+ Th17 in the peripheral blood of asthma patients (figure 2D). This 
suggests that also in human, the TNFAIP3 pathway controls the activation status of DCs and/
or monocytes controls the type of inflammation, being either eosinophilic, or neutrophilic. 
Improving our understanding of factors that drive severe Th17-mediated neutrophilic asthma, 
will likely improve the treatment options for severe uncontrolled asthma patients.
Neutrophilic inflammation is dependent on IL-17 signalling, as IL-17A stimulates airway epi-
thelial IL-8 production, a chemoattractant for neutrophils (30). In Chapter 5, we demonstrated 
that neutrophilic inflammation in Tnfaip3LysM-KO mice is not dependent on IL-17R signalling 
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as neutrophilic inflammation is similar between Tnfaip3LysM-KO mice and Tnfaip3LysM-KOIl17raKO 
mice. Abrogating IL-17RA-signalling in combination with Tnfaip3-depletion in myeloid cells 
increased IL-23 expression, which together with defective IL-17RA-signalling, enhanced 
Th17 differentiation and induced spontaneous accumulation of IL-17+ γδ T cells in the lungs 
(Chapter 5). Whether these IL-17-producing γδ T cells play a detrimental or beneficial role 
in allergic airway inflammation and/or resolution of airway inflammation remains unknown 
and is likely dependent on the allergen type. Depletion of γδ-17 T cells during the resolution 
phase in an OVA-mediated asthma model worsened allergic inflammation (31, 32), indicating 
that upon OVA treatment γδ-17 T cells are beneficial during the resolution phase. However, 
our results indicated that the presence of high amounts of these γδ-17 T cells did not alter 
either eosinophilic or neutrophilic inflammation. This could also be caused by deficiency of 
IL-17RA-signalling which abrogates IL-17. Besides high levels of IL-17, also IL-22 and GM-CSF 
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Figure 3 
figure 2: increased activation of monocytes and DCs in asthmatics are associated with neutrophilia and Th17 
cells. Correlation between proportion of neutrophils and RORgT+ Th17 cells of asthma patients in peripheral 
blood by flow cytometry (A). Correlation between median fluorescent intensity of HLA-DR on CD14+ classical 
monocytes and RORgT+ Th17 cells of asthma patients in peripheral blood by flow cytometry (B). Correlation 
between RORgT+ Th17 cells of asthma patients in peripheral blood by flow cytometry and mRNA expression 
of Tnip in MACS purified BDCA1+ cDC2s of asthma patients (C). Correlation between neutrophils frequency of 
asthma patients in peripheral blood by flow cytometry and mRNA expression of Tnip in MACS purified BDCA1+ 
cDC2s of asthma patients (D).
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were increased in lungs of mice have defective IL-17RA-signalling and harbor activated myeloid 
cells (Chapter 5), implying that upon HDM-mediated asthma models, IL-22 and GM-CSF are 
not beneficial nor detrimental for allergic airway inflammation.
suPPREssioN of AsTHMATiC AiRwAy iNflAMMATioN
Development of asthmatic airway inflammation could also be caused by defective immunologi-
cal suppression, or impaired airway homeostasis. Regulatory T cells (Tregs) are known for their 
immune regulatory functions by secretion of immunosuppressive cytokines IL-10 and expres-
sion of immunomodulatory molecules (33). Depletion of CD4+CD25+ regulatory T (Treg) cells 
increased airway hyper-responsiveness in mice (34). Furthermore, transfer of antigen-specific 
Tregs was able to prevent and suppress Th2-mediated airway inflammation in response to 
OVA (35, 36). These findings indicate that Tregs are essential controllers of asthmatic airway 
inflammation. In vitro studies have also shown that Tregs of non-atopic individuals can sup-
press cytokine secretion by CD4+ T cells upon allergen stimulation, whereas Tregs of atopic 
individuals were unable to suppress this cytokine secretion (37).
The function of cDC1s in T helper responses in asthma remains controversial, as cDC1s 
have been shown to induce Treg differentiation upon allergen exposure (38, 39), but are also 
implicated in Th2 differentiation (40). Pulmonary cDC1s are well appreciated for their superior 
cross-presentation of antigens to CD8+ T cells, essential for the induction of virus-specific CD8+ 
T cells and anti-tumor immune responses (41-43).
In Chapter 6, we showed that increasing the activation status cDC1s by depleting TNFAIP3 
in Langerin-expressing pulmonary cDC1s, inhibited eosinophilic inflammation and Th2 cell 
differentiation upon an HDM-mediated airway inflammation protocol. These activated cDC1s 
rather induced highly activated Tregs and Th2-suppressive IL-10 and IFNγ-secreting CD8+ T cells. 
Activation of cDC1s increased IL-12 and PD-L1 expression, not only on cDC1s but also on other DC 
subsets, implicating interaction between different DC subsets occurs (figure 1). Increased PD-L1 
expression was dependent on IL-12 and IFNγ. Depletion of Tregs in mice harboring Tnfaip3-
deficient Langerin+ cDC1s did not restore Th2-mediated eosinophilic inflammation, suggesting 
that IL-10 and IFNγ-secreting CD8+ T cells but not Tregs suppressed the development of eosino-
philic inflammation. Others have also shown that IL-10-producing cells can suppress cytokine 
secretion by Th2 cells (44). However, in most cases these studies focused on IL-10-producing 
CD4+ T cells but not CD8+ T cells. Our data suggests that IL-10 production by CD8+ T cells could 
be a novel opportunity to suppress Th2-mediated airway inflammation. Furthermore, we also 
found decreased numbers of CD8+ T cells and HLA-DR+ CD8+ T cells in asthma patients (Chapter 
7). Whether cytokine expression would also be different between CD8+ T cells of healthy controls 
and CD8+ T cells of asthma patients remains yet to be determined.
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Whether the activation status of cDC1s, e.g. the expression of co-stimulatory or co-inhibitory 
molecules, is altered in asthmatic patients compared to healthy controls remains unknown 
and should be investigated.
CoNClusioN AND fuTuRE DiRECTioNs
The described heterogeneity of asthma patients is mainly based on clinical characteristics, 
however differences within their immune system driving these clinical characteristics should 
be further explored. In this thesis, we have shown that the activation status of DCs can control 
Th2 and Th17-mediated airway inflammation and can even suppress Th2-mediated airway 
inflammation, dependent on the DC subsets targeted. To achieve this increased activation 
status of DCs, we depleted TNFAIP3 in different DC subsets (Chapter 1). Characterization of 
DC activation and subset distribution both locally and systemically in asthma patients should 
be performed to determine whether DC activation also controls asthmatic heterogeneity in 
asthmatic individuals. Our first preliminary results indicate that there are indeed differences in 
HLA-DR expression of monocytes and TNIP in human cDC2s, suggesting that DC and monocyte 
activation status could control asthma severity in human.
Next, we have shown in this thesis that the type of allergen used in experimental models 
and the exposure timing determine immunological processes and should therefore be chosen 
carefully. Animal models are often used to investigate the mechanisms driving asthmatic 
airway inflammation and to explore new therapeutic strategies for asthma patients. Using 
relevant allergens such as HDM, in physiological concentrations, and treatment schedules re-
sembling exposure in asthma patients will improve our understanding of airway inflammation 
and remodelling in asthmatic subjects (Chapter 2). Animal models that enable investigation 
of heterogeneity in asthmatic airway inflammation are limited and depend on either genetic 
modifications, such as the activation of DCs (described in this thesis) or combined exposure 
with allergens and environmental triggers such as smoke, diesel exhaust particles, or viral 
particles (Chapter 1).
Investigation of the immune system both in peripheral blood and locally in lung in a longi-
tudinal manner is essential to delineate immunological heterogeneity within the asthmatic 
patient population. This will enable the characterization of patients with different immuno-
logical phenotypes and should show whether the type of inflammatory response observed in 
these patients remains stable over time. To achieve this, collaborations are essential between 
clinicians and fundamental researchers, linking these immunological findings to clinical pa-
rameters using bioinformatics. This would improve our understanding of the immunological 
mechanisms driving heterogeneity between asthma patients and should finally result in new 
treatment strategies and therapeutic targets.
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In recent years, new therapies have been established for the treatment of asthma patients. This 
has led to an improved quality of life and lung function for a large number of asthma patients. 
Despite this progress, 10% of the asthma patients suffer from symptoms while treated. These 
patients often present without a classically T helper (Th2)-mediated eosinophilic inflammation 
and rather present with a neutrophilic inflammation or pauci-granulocytic inflammation. To 
generate therapeutic strategies for these patients it is essential to unravel the immunological 
mechanism that underlies these different asthma phenotypes.
Th2 cells are critical regulators of eosinophilic asthma by their secretion of type 2 cytokines 
(IL-4, IL-5 and IL-13). Despite progress in many areas, it is still not completely understood which 
signals are needed for Th2 differentiation. Th2 cell differentiation can involve an intermedi-
ate stage through a follicular T helper (Tfh) cell stadium, as was shown in a house dust mite 
(HDM)-driven asthma model containing a sensitization and challenge phase. This would imply 
that germinal center reactions are important for Th2 differentiation. However, previous studies 
have shown that eosinophilic inflammation can develop in the absence of B cells, and therefore 
in the absence of germinal centers. In Chapter 2 we determined whether eosinophilic inflam-
mation was dependent on the interaction between B and T cells upon chronic HDM exposure. 
We found that in a chronic HDM model, eosinophilic inflammation in broncho-alveolar lavage 
fluid (BALf) and lung tissue can develop in the absence of B-T cell interaction and germinal 
centre reactions. Thus, in contrast to findings in acute HDM models characterized by sensi-
tization and challenge phases, our data in a chronic HDM asthma model demonstrate that 
pulmonary eosinophilic inflammation is independent of B-T cell communication. Nevertheless, 
our chronic HDM model reveals that pulmonary Th2 inflammation and airway remodelling 
requires B cells and B-T cell interaction.
Next to patients with a Th2-mediated eosinophilic inflammation, a subset of asthmatic 
patients suffers from Th17-mediated neutrophilic inflammation. Currently it is unknown 
which mechanism controls this heterogeneity within asthma patients. As dendritic cells (DCs) 
drive differentiation of naïve T cells into both Th2 and Th17 cells, we wondered whether DC 
activation could contribute to asthma heterogeneity. To induce increased DC activation, mouse 
models were used in which TNFAIP3/A20, one of the negative regulators of the pro-inflamma-
tory transcription factor NF-kB, was deleted in different DC subsets, using transgenic mice. In 
Chapter 4, we show that the activation status of DCs controls the development of either eo-
sinophilic or neutrophilic airway inflammation. Highly activated TNFAIP3-deficient DCs induce 
Th17 differentiation and hamper Th2 differentiation upon HDM exposure. TNFAIP3-deficiency 
in specifically type 2 conventional DCs (cDC2s) and monocyte-derived DCs (moDCs) increases 
their potential to produce cytokines implicated in Th17-cell differentiation. Furthermore, 
cytokines that hamper Th2 differentiation were also increased in TNFAIP3-defecient DCs upon 
HDM exposure, indicating that the amount of TNFAIP3 in DCs can control the heterogeneity in 
granulocytic inflammation in asthma.
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IL-17-signalling is implicated in both neutrophilic as eosinophilic airway inflammation, as 
IL-17 activates the airway epithelium to secrete chemokines mediating neutrophil chemotaxis. 
The influence of IL-17-signalling on eosinophilic inflammation differs depending on allergen 
used and time of cytokine exposure. However, whether the neutrophilic inflammation observed 
in chapter IV is dependent on IL-17R-signalling is investigated in Chapter 5. We showed that 
absence of IL-17RA-signalling has only limited effect on neutrophilic or eosinophilic inflamma-
tion in an HDM-driven acute inflammation model. Th2 cell differentiation is not hampered by 
ablation of IL-17RA-signalling, whereas mucus-producing cells are reduced. Defective IL-17RA-
signalling in mice that harbour activated myeloid cells induces spontaneous accumulation of 
RORgt+ γδ T cells and Th17 cells in the lungs. Furthermore, mice harbouring TNFAIP3-deficient 
myeloid cells and IL-17RA-deficiency have elevated levels pulmonary IL-23, needed for Th17 
and RORgt+ γδ T cell maintenance.
In the previous chapters, we showed that especially cDC2s and moDCs are essential for 
the development of Th2 or Th17-associated airway inflammation. However, the function of 
cDC1s in allergic inflammation remains controversial. In Chapter 6 we show that activation of 
cDC1s by deletion of TNFAIP3 in Langerin-expressing pulmonary cDC1s is sufficient to suppress 
Th2-mediated inflammation. Instead of Th2 cells, allergen exposure induces development of 
highly activated Tregs and CD8+ T cells that either express IL-10 or IFNg in the lung in mice 
harbouring activated cDC1s. Intriguingly, TNFAIP3 deletion in cDC1s increases expression of 
the Th2-suppressive co-inhibitory molecule PD-L1 and IL-12. The increased expression of these 
molecules was not only observed in cDC1s, but also in all other pulmonary DC subsets, indicat-
ing cross-regulation between DC subsets.
Also clinically, asthma patients comprise an heterogeneous population, including patients 
that are well controlled by inhaled corticosteroids, whereas other patients remain symptom-
atic under corticosteroid treatment. In Chapter 7, we investigated immunological differences 
in peripheral blood of controlled, partly controlled, and uncontrolled asthma patients and 
healthy controls by flow cytometry. Flow cytometric analysis are often performed manually, 
however during manual analysis cells are often excluded from used gates and not all markers 
are assessed on all cell types. Recently, advanced machine-learning algorithms enable unbi-
ased analysis of flow cytometric data and ease the visualisation of these automated analysis. 
Thereby analysing flow cytometric data in an automated manner using these algorithms im-
proves the interpretation of the data. Using this automated manner of analysing flow cytomet-
ric data, we show that blood eosinophils, CD1c+ B cells and HLA-DR+ classical monocytes are 
increased in asthma patients whereas HLA-DR+ CD8+ T cells and neutrophils are decreased as 
compared to healthy controls. In contrast to eosinophils, Th2, and Th17 cells, CD1c-expressing 
B cells and HLA-DR+ classical monocytes correlate with disease severity, indicating that care-
ful characterization of these cell populations is necessary to determine their implication for 
asthma pathogenesis.
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In conclusion, this thesis shows that asthma is a heterogeneous lung disorder, in which both 
Th2 and Th17 cells can induce asthmatic symptoms. Furthermore, we have shown that the 
activation status of cDC2s and moDCs critically controls Th2 and Th17 differentiation, whereas 
activation of cDC1s abrogates development of Th2-mediated airway inflammation. Targeting 
the activation status of different DC subsets can contribute to asthma heterogeneity and 
asthma severity, or even dampen Th2-mediated immune responses. Further research should 
be performed to investigate whether DC activation and the secretion of cytokines contributes 
to the heterogeneity and severity observed in asthma patients, and whether these factors can 
be used as therapeutic strategy to treat uncontrolled asthma patients.
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NEDERlANDsE sAMENVATTiNg
Astma is een chronische longziekte, die gekarakteriseerd wordt door ontstekingen, verhoogde 
slijmproductie en verbindweefseling in de longen. De incidentie van astma in de Westerse 
wereld is in de laatste tientallen jaren toegenomen. Astma wordt veroorzaakt doordat pati-
enten allergisch zijn voor bijvoorbeeld huisstofmijt of schimmels, wat zogenaamde allergenen 
worden genoemd. Deze allergenen worden in de luchtwegen opgenomen door dendritische 
cellen (DC’s) die hiermee T-cellen activeren, waardoor er een immuunreactie wordt gestart 
wat resulteert in de astmatische symptomen.
In de afgelopen jaren zijn er veel nieuwe therapieën ontwikkeld om astmapatiënten beter te 
kunnen behandelen. Dit heeft gezorgd voor een verbetering van de kwaliteit van leven en een 
verbeterde longfunctie voor veel astmapatiënten. Ondanks deze vooruitgang, blijft 10% van 
de astmapatiënten symptomen vertonen terwijl ze onder behandeling zijn met medicijnen. 
Deze ongecontroleerde astmapatiënten hebben vaak een ander soort ontstekingsreactie in de 
longen, die bestaat uit neutrofielen, in plaats van de eosinofiele ontstekingscellen die in het 
merendeel van de astmapatiënten verhoogd zijn. Om nieuwe therapieën te ontwikkelen voor 
deze patiënten is het essentieel om het immunologische mechanisme wat deze diversiteit aan 
ontstekingsreacties binnen astmapatiënten veroorzaakt te ontrafelen.
Astmatische ontstekingsreacties worden vaak in gang gezet door zogenaamde T-cellen. Deze 
T-cellen herkennen specifieke allergenen en worden geactiveerd wanneer zij deze allergenen 
herkennen als deze aan hun worden gepresenteerd door DC’s. Er verschillende soorten T-
cellen, namelijk Th1, Th2, Th17 cellen, welke verschillende soorten ontstekingsreacties in gang 
brengen, en regulatoire T-cellen (Tregs) die deze verschillende T-cellen afremmen. Th2 cellen 
zijn essentieel voor eosinofiel gedreven astma door het maken van speciale signaalstoffen, 
genaamd cytokines (IL-4, IL-5 en IL-13). Ondanks vooruitgang in vele onderzoeksgebieden, 
is het nog steeds onduidelijk welke signalen er nodig zijn voor de ontwikkeling van Th2 cel-
len. In kortdurende huisstofmijt-gedreven astma modellen die een sensitisatie fase en een 
fase van herhaalde blootstelling bevatten is gevonden dat een T-cel - na activatie door een 
allergeen - een Tfh-stadium doorgaat, voordat de cel uiteindelijk een Th2 cel wordt. Deze Tfh 
cellen bevinden zich in gebieden in de lymfeklieren waar veel interactie plaatsvindt tussen 
B en T-cellen, welke follikels worden genoemd. Verrassend genoeg hebben eerdere studies 
laten zien dat eosinofiele ontstekingsreacties ook kunnen ontstaan in de afwezigheid van B-
cellen en daardoor ook in de afwezigheid van deze follikelgebieden. In Hoofdstuk 2 hebben 
we onderzocht of eosinofiele ontstekingsreacties tijdens langdurig herhaalde blootstelling aan 
huisstofmijt ook afhankelijk zijn van de communicatie tussen B en T-cellen. In tegenstelling tot 
eerdere bevindingen in kortdurende huisstofmijt gedreven modellen, laten onze resultaten 
zien dat in de afwezigheid van B en T-cel communicatie eosinofiele ontsteking kan ontwikkelen 
tijdens langdurige blootstelling aan huisstofmijt. Echter, ophoping van Th2 cellen in de longen 
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en littekenvorming van de longen is wel afhankelijk van B-cellen en communicatie tussen B en 
T-cellen.
Naast patiënten die een Th2-gedreven eosinofiele ontstekingsreactie vertonen, heeft een 
deel van de astmapatiënten een Th17-gedreven neutrofiele ontsteking in de luchtwegen. Op 
dit moment is het nog onduidelijke welke signalen deze diversiteit binnen de astmapatiënten 
veroorzaakt. Omdat geactiveerde DC’s belangrijk zijn voor de ontwikkeling van T-cellen die nog 
geen allergenen hebben gezien tot Th2 of Th17 cellen, vroegen we ons af of de mate van DC 
activatie zou kunnen bepalen welke Th cel ontwikkeling er plaatsvindt. Om dit te onderzoeken 
hebben we gebruik gemaakt van muismodellen waarin de activatiestatus van DC’s artificieel 
verhoogd is doordat het TNFAIP3/A20 gen verwijderd is waardoor er geen functioneel A20 
eiwit gevormd kan worden. TNFAIP3 is een enzym dat de activiteit remt van de transcriptie-
factor NF-kB, die nodig is voor cel activatie. In Hoofdstuk 4 laten we zien dat de activatiestatus 
van DC’s de ontwikkeling van ofwel eosinofiele of neutrofiele luchtwegontsteking controleert. 
Sterk geactiveerde DC’s waarin het TNFAIP3 gen geheel is verwijderd, stimuleren Th17 ont-
wikkeling en remmen de ontwikkeling van Th2 cellen na huisstofmijt blootstelling. Er zijn 
verschillende soorten DC’s met elk hun eigen verschillende functie. Wij hebben gevonden dat 
het gebrek van TNFAIP3 specifiek in type 2 conventionele DC’s (cDC2’s) en DC’s die ontstaan 
uit monocyten (moDCs) zorgt voor een verhoogde productie van cytokines die belangrijk zijn 
voor Th17 cel ontwikkeling. Daarnaast hebben deze geactiveerde cDC2’s en moDCs ook een 
verhoogde hoeveelheid van cytokines die de ontwikkeling van Th2 cellen remmen na huis-
stofmijt behandeling.
IL-17-signalering is betrokken bij zowel neutrofiele as eosinofiele luchtwegontsteking, aan-
gezien IL-17 het luchtwegepitheel stimuleert tot het maken van signaalstoffen die neutrofielen 
aantrekken naar de longen. De invloed van IL-17-signalering op eosinofiele ontstekingsreacties 
is afhankelijk van het allergeen dat gebruikt wordt in het astma model en het moment van 
blootstelling. Of de neutrofiele ontstekingsreactie in hoofdstuk 4 afhankelijk is van IL-17 recep-
tor (IL-17R) signalering is onderzocht in Hoofdstuk 5. Hierin laten we zien dat de afwezigheid 
van IL-17RA-signalering maar een beperkt effect heeft op neutrofiele of eosinofiele ontsteking 
in een kortdurend huisstofmijt gedreven model dat een sensitisatie fase en een fase van 
herhaalde blootstelling bevat. Th2 cel ontwikkeling is niet aangetast door de afwezigheid van 
IL-17RA-signalering, terwijl de slijm-producerende cellen wel verlaagd zijn. IL-17RA-deficiënte 
muizen die geactiveerde monocyten, macrofagen en moDCs bevatten, vertonen ook spontane 
ophopingen van RORgt+ γδ T-cellen en Th17 cellen in de longen. Daarnaast is de hoeveelheid 
van het cytokine IL-23 in de longen van deze muizen verhoogd, wat de instandhouding van 
deze RORgt+ γδ T-cellen en Th17 cellen verzorgt.
In vorige hoofdstukken hebben we laten zien dat met name cDC2’s en moDCs belangrijk zijn 
voor de ontwikkeling van verschillende Th cel ontstekingsreacties die gezien worden in ast-
matische luchtwegen. Echter, de functie van type 1 conventionele DC’s (cDC1’s) in allergische 
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ontstekingsreacties is nog steeds omstreden. In Hoofdstuk 6 hebben we onderzocht of de 
selectieve activatie van cDC1’s in de longen een effect heeft op allergische ontstekingsreacties, 
door het TNFAIP3 gen te verwijderen in cDC1’s die Langerine tot expressie brengen. Hierbij 
hebben we gevonden dat activatie van alleen long cDC1’s voldoende is om de ontwikkeling 
van Th2-gedreven luchtwegontstekingen te remmen. Allergeenblootstelling in muizen waar-
van de cDC1’s in de longen geactiveerd zijn leidt niet tot de ontwikkeling van Th2 cellen. In 
plaats daarvan zagen we Treg en CD8+ T-cellen die IL-10 en IFNg produceren, die beide een 
remmende werking hebben op Th2 cel ontwikkeling en functie. TNFAIP3 deletie in cDC1’s 
verhoogd de expressie van PD-L1 op het celoppervlak en de productie van IL-12, welke beide 
Th2 cel ontwikkeling onderdrukken. Deze factoren zijn niet alleen verhoogd voor cDC1’s maar 
ook voor andere soorten DC’s in de longen, wat suggereert dat er communicatie tussen DC 
subsets plaatsvind.
Op basis van hun klinische karakteristieken zijn astmapatiënten zeer divers. Bij sommige 
patiënten is de ziekte goed behandelbaar is met inhalatiecorticosteroïden, terwijl andere 
patiënten ondanks de behandeling met inhalatiecorticosteroïden klachten blijven houden. 
In Hoofdstuk 7 hebben we onderzocht wat de immunologische verschillen zijn in het bloed 
van patiënten die onder behandeling van inhalatiecorticosteroïden goed gecontroleerd, matig 
gecontroleerd en slecht gecontroleerd zijn. Deze 3 patiëntengroepen zijn vergeleken met ge-
zonde controles. Om de verschillen in het immuunsysteem te bepalen is gebruik gemaakt van 
flow cytometrie. Hierbij werd gebruik gemaakt van geautomatiseerde analyses, waardoor het 
mogelijk werd om alle gemeten markers op alle aanwezige celtypes in bloed en sputum te ana-
lyseren. Met behulp van het automatische analyseprogramma FlowSOM hebben we gevonden 
dat eosinofielen, B-cellen die CD1c tot expressie brengen en HLA-DR+ klassieke monocyten 
verhoogd zijn in het bloed van astmapatiënten, terwijl HLA-DR+ CD8+ T-cellen en neutrofielen 
verlaagd zijn in vergelijking met gezonde controles. In tegenstelling tot eosinofielen, Th2 cellen 
en Th17 cellen, correleren CD1c+ B-cellen en HLA-DR+ klassieke monocyten met de ernst van de 
ziekte. Door verder onderzoek naar deze cel populaties zou het belang van deze celpopulaties 
voor de ontwikkeling van astma bepaald kunnen worden.
Samenvattend, laat dit proefschrift zien dat astma een heterogene longziekte is, waarin 
zowel Th2 als Th17 cellen kunnen zorgen voor astmatische symptomen. Verder hebben we 
aangetoond dat de activatiestatus van cDC2’s en moDCs een belangrijke factor is die bepaald 
of er Th2 of Th17 cellen worden gevormd, terwijl activatie van cDC1’s de ontwikkeling van Th2 
cellen onderdrukt. Verder onderzoek moet uitwijzen of de activatiestatus van DC’s en de cy-
tokines die DC’s produceren bijdragen aan de diversiteit tussen astmapatiënten, de ernst van 
de ziekte, of het onderdrukken van Th2-gedreven astma. Daarnaast zou onderzocht kunnen 
worden of deze factoren kunnen dienen als nieuwe therapie voor astmapatiënten die onder 
behandeling van inhalatiecorticosteroïden klachten blijven houden.
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waren er veel!) naar je toetrok en je eigen maakte was heel knap. De hoeveelheid werk die je 
verzet hebt in je stageperiode is dan ook gigantisch, en hebben mij de gelegenheid gegeven om 
wat meer op het schrijven te focussen. Ik ben dan ook super blij dat je afgelopen september 
bent kunnen starten als PhD-student bij Mirjam.
Ook wil ik graag Prof. dr. Yvan Saeys en Sofie van Gassen bedanken voor alle hulp en onder-
steuning tijdens de periode bij het VIB. Ik heb enorm veel geleerd over bioinformatica en in het 
bijzonder over FlowSOM en de enorme mogelijkheden die hiermee gepaard gaan. Ook wil ik 
graag Martijn Schuijs bedanken voor alle hulp bij de experimenten die we hebben uitgevoerd 
in het VIB. Ondanks dat je zelf altijd een enorme hoeveelheid experimenten lopende had, wist 
je altijd tijd vrij te maken om mij te helpen. Justine en Kim, ook heel erg bedankt voor jullie 
hulp.
Een klinische studie opzetten en draaiende houden is een enorme teamprestatie, en ik wil 
dan ook graag de researchverpleegkundigen van het Erasmus MC en het SFG, Annemarie, 
Marjolein, Bevinda, Simone en Bianca bedanken voor jullie hulp, advies en het includeren van 
alle patiënten. Daarnaast wil ook graag alle betrokken artsen en arts-assistenten bedanken in 
het SFG, en in het bijzonder Dr. Gert-Jan Braunstahl. Zonder patiënten die willen deelnemen 
aan klinische studies zouden klinische studies niet bestaan, dus ik zou ook graag alle astmapa-
tiënten willen bedanken voor het deelnemen aan de studie.
Sandra en Jan Piet, mijn eerste kennismaking binnen het Erasmus MC was als jullie student bij 
de afdeling Reumatologie. Bedankt dat jullie al zo snel tijdens mijn stage mee wilden denken 
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over een baan als PhD-student na mijn afstuderen en mij hebben aanbevolen bij Mirjam en 
Rudi. Zonder jullie was ik nooit op deze promotieplaats terechtgekomen.
Lieve vrienden, bedankt voor alle gezellige feestjes, etentjes en borrels de afgelopen jaren.
Lieve familie, bedankt voor jullie onvoorwaardelijke steun en gezelligheid. Het hebben van 
een hechte familie zo dichtbij is mij heel veel waard. Lieve pap, mam en Moniek, bedankt dat 
jullie altijd voor mij klaar staan, jullie steun betekent heel veel voor mij! Ingrid, bedankt dat 
jij me tijdens de promotie wil bijstaan als paranimf. Ik prijs me gelukkig dat ik een zusje heb 
waarmee ik al die tenniswedstrijden, volleybalwedstrijden, winkelmomenten en city-trips heb 
kunnen beleven.
Lieve Ruud, ik ben jou heel dankbaar voor al je steun. Jij helpt me altijd weer herinneren welke 
dingen er het belangrijkst zijn in het leven. Het leven is mooi samen met jou!
Heleen
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Summary of PhD training and teaching
Name PhD student: H. (Heleen) Vroman
Erasmus MC Department: Pulmonary Medicine
Research School: Molecular Medicine
PhD period: 2012-2017
Promotor: Prof.dr. R.W. Hendriks
Supervisor: Dr.ing. M.Kool
PhD training
General courses, seminars and workshops
2012
– Laboratory Animal Experimentation (4,3 ects)
2013
– Advanced Immunology course (3 ects)
– NVVI Lunteren symposium 2013: ‘The immune system on fire: The intracellular logistics of 
inflammation’ (0,5 ects)
– Workshop on Adobe Photoshop and Illustrator (0,3 ects)
– NRS animal model day (0,3 ects)
– Course on R (2,0 ects)
– Mucosal Immunology (0,5 ects)
2014
– NVVI Lunteren symposium 2014: ‘Mucosal Immunology: crossing borders’ (0,5 ects)
– BROK-course (2,0 ects)
– NRS animal model day (0,3 ects)
2015
– NVVI Lunteren symposium 2015: ‘Immunity and Science Fiction: the next 50 years in Im-
munology’ (0,5 ects)
– Biomedical English writing course (2 ects)
(Inter)national scientific presentations and conferences
17th Molecular Medicine day, Rotterdam (poster) 2013 0,3
NRS Young Investigator, Amsterdam (poster) 2013 0,3
Abcam meeting, Brugge (poster) 2013 0,5
NVVI Winter School, Noordwijkerhout (oral) 2013 0,5
EMDS, Erlangen (oral) 2013 1,0
NRS animal model day (oral) 2014 0,3
Longdagen, Utrecht (poster) 2014 0,5
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18th Molecular Medicine day, Rotterdam (poster) 2014 0,3
13th International Meeting on Dendritic Cells, Tours (poster) 2014 1,0
NVVI Winter School, Noordwijkerhout (poster) 2014 0,5
EAACCI Winter School, Brasov (oral) 2014 1,0
ERS Annual Conference, Estoril (oral) 2014 1,0
ERS Annual Conference, Munchen (oral) 2014 1,0
Longdagen, Utrecht (oral) 2015 0,3
ICMI 2015, Berlin (poster) 2015 1,0
NVVI Winter School, Noordwijkerhout (poster) 2015 0,5
NVVI Winter School, Noordwijkerhout (oral) 2015 0,5
19th Molecular Medicine day, Rotterdam (poster) 2015 0,3
Longdagen, Ermelo (poster) 2016 0,5
20th Molecular Medicine day, Rotterdam (poster) 2016 0,3
International Conference of Immunology (oral) 2016 1,5
Keystone Asthma symposium (oral) 2017 1,5
Teaching
– Winter course, Research Master Infection & Immunity, Erasmus University, Rotterdam.
 Lecture: ‘The immunology of asthma’ (0,5 ects)
– Advanced Immunology Course, Postgraduate School “Molecular Medicine”, Erasmus Uni-
versity, Rotterdam.
 Lecture: ‘Dendritic cell subsets and antigen processing’ (0,5 ects)
Supervising students
– Supervising Master internship 6 months L. Krassenburg, Erasmus University, Rotterdam (10 
ects)
– Supervising Master internship 6 months B. van der Wel, Erasmus University, Rotterdam (10 
ects)
– Supervising Master internship 9 months D. van Uden, Erasmus University, Rotterdam (15 
ects)
Awards
– NRS Young Investigator Travel Grant for EMDS, Erlangen
– NRS Young Investigator Travel Grant for International Conference of Immunology, Mel-
bourne
– ERS Travel Grant for ERS, Estoril
– Long-term research fellowship from the Dutch Lung Foundation (Longfonds) 2016
– Long-term research fellowship from the European Academy of Allergy and Clinical Immu-
nology (EAACI) 2016
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Heleen Vroman was born in Goes on October 17th in 1989. She attended the Buys Ballot Col-
lege in Goes and graduated in 2007 after which she started her studies in Biomedical Sciences 
at Utrecht University. After obtaining her Bachelor of Science degree, Heleen continued with 
a Master in Biology of Disease at Utrecht University and obtained her degree in 2012. During 
this period, she performed a 9 month internship at the department of Pathology at the UMC 
Utrecht in Utrecht and a 6 month internship at the department of Rheumatology at the Eras-
mus MC in Rotterdam. In 2012, she started her PhD project at the department of Pulmonary 
Medicine at the Erasmus MC in Rotterdam. Her PhD project focusses on the effect of dendritic 
cell activation on the development of asthmatic immune responses under the supervision of 
Prof. dr. Rudi W. Hendriks and Dr. Mirjam Kool. During her PhD-project, Heleen obtained two 
long-term research fellowships from the Longfonds and EAACI. These fellowships enabled her 
to visit the VIB in Ghent, Belgium to work with transgene mice harbouring T cells reactive to 
house dust mite and analyse flow cytometry data using the FlowSOM algorithm, under the 
supervision of Prof. dr. Bart N. Lambrecht and Prof. dr. Hamida Hammad. The results of her 
PhD project are described in this thesis and will be defended in June 2017 in Rotterdam. After 
obtaining her PhD, Heleen will work as a Post-Doc at the Tumor Immunology group at the 
department of Pulmonary Medicine of the Erasmus MC.
